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Abstract 
This thesis examines potential applications of advanced MRI-connectivity studies in 
stereotactic functional neurosurgery. Several new analysis methodologies are employed 
to: (1) build predictive models of DBS surgery outcome; (2) refine the surgical target and 
(3) help build a better understanding of the pathogenesis of the treated conditions and the 
mechanism of action of DBS therapy.  
The experimental component is divided into three main parts focusing on the following 
pathologies: (1) Parkinson’s disease (PD), (2) tremor and (3) trigeminal autonomic 
cephalalgias (TAC). 
Section I: In the first experiment (chapter 3), resting state fMRI was used to find 
radiological biomarkers predictive of response to L-DOPA in 19 patients undergoing 
subthalamic nucleus (STN) DBS for PD. A greater improvement in UPDRS-III scores 
following L-DOPA administration was characterized by higher resting state functional 
connectivity (fcMRI) between the prefrontal cortex and the striatum (p=0.001) and lower 
fcMRI between the pallidum (p=0.001), subthalamic nucleus (p=0.003) and the paracentral 
lobule. 
In the second experiment (chapter 4), structural (diffusion) connectivity was used to map 
out the influence of the hyperdirect pathways on outcome and identify the therapeutic 
‘sweet spots’ in twenty PD patients undergoing STN-DBS. Clusters corresponding to 
maximum improvement in symptoms were in the posterior, superior and lateral portion of 
the STN. Greater connectivity to the primary motor area, supplementary motor area and 
prefrontal cortex was predictive of higher improvement in tremor, bradykinesia and rigidity, 
and rigidity respectively. 
The third experiment (chapter 5) examined pyramidal tract (PT) activation in 20 PD patients 
with STN-DBS. Volume of tissue activation (VTA) around DBS contacts were modelled in 
relation to the PT. VTA/ PT overlap predicted EMG activation thresholds.  
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Sections II: Pilot data suggest that probabilistic tractography techniques can be used to 
segment the ventrolateral (VL) and ventroposterior (VP) thalamus based on cortical and 
cerebellar connectivity in nine patients who underwent thalamic DBS for tremor (chapter 
6). The thalamic area, best representing the ventrointermedialis nucleus (VIM), was 
connected to the contralateral dentate cerebellar nucleus. Streamlines corresponding to 
the dentato-rubro-thalamic tract (DRT) connected M1 to the contralateral dentate nucleus 
via the dentato-thalamic area. Good response was seen when the active contact’s VTA 
was in the thalamic area with the highest connectivity to the contralateral dentate nucleus. 
Section III: The efficacy and safety of DBS in the ventral tegmental area (VTa) in the 
treatment of chronic cluster headache (CH) and short lasting unilateral neuralgiform 
headache attacks (SUNA) were examined (chapters 7 and 8). The optimum stimulation site 
within the VTa that best controls symptoms was explored (chapter 9). The average 
responders’ deep brain stimulation activation volume lay on the trigemino-hypothalamic 
tract, connecting the trigeminal system and other nociceptive brainstem nuclei, with the 
hypothalamus, and the prefrontal and mesial temporal areas. 
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Preface 
When my father was twelve, he travelled from Baghdad to London to the National Hospital 
for Neurology and Neurosurgery in Queen’s Square. He was accompanying his disabled 
mother, a 40-year-old woman struck with Parkinson’s disease in her early thirties. He was 
her carer, and would eventually also care for his father who suffered from intractable 
depression. My father used to walk him home from hospital, in his state of post-ictal 
confusion, following electroconvulsive therapy (ECT) sessions. My grandmother developed 
Parkinson’s disease before the advent of L-DOPA, and underwent a pioneering procedure 
in 1962: stereotactic ablative surgery. Unfortunately, the procedure did not have the desired 
effect, most likely a result of inaccurate targeting. My father told me she ‘lost her mind’ in 
the weeks after surgery. I never met my grandfather; he died in hospital of a hypertensive 
intracerebral haemorrhage, a year before I was born. My grandmother I do remember; a 
wheelchair bound woman with snow white silky hair, covered elegantly with a paisley 
pattern headscarf around her head. I recall her embrace and kindness, but I also remember 
that she never smiled. I now recognise this as a classical symptom of her ailment. Without 
the benefit of CT and MRI, my grandmother’s neurosurgeon had no reliable means of 
“seeing” the brain target, whether to plan surgery or confirm the result. Advanced imaging 
techniques have made functional neurosurgery safer, more accurate, and more effective.  
I have been most fortunate to be taken under the wings of Ludvic Zrinzo and Marwan Hariz, 
pioneers and developers of the image guided and image verified approach to stereotactic 
functional neurosurgery. They have helped thousands of patients throughout their careers, 
both directly and indirectly by training others, engaging in research and sharing their 
knowledge. 
This work explores the next frontier in advanced imaging techniques, focusing on the role 
brain connectivity studies can play in advancing the field of stereotactic functional 
neurosurgery; to ultimately help more patients, in memory of Khadija, my grandmother. 
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1. Introduction 
 
 
 
 
 
"In a pitch-black night a blind man is the best guide; he knows 
the roads and paths better than any man who can see. When 
daylight comes, however, it is foolish to use blind old men as 
guides." 
Heinrich Heine (1797 –1856)
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1.1: Background 
Deep brain stimulation (DBS) for central neuromodulation is a well-established therapy for 
a wide range of neurological conditions. This is particularly true in the discipline of 
movement disorders for the treatment of Parkinson’s disease, essential tremor and 
dystonia 1,2. Over 150,000 patients have received DBS worldwide 3. Current research 
explores new brain targets and revisits those formerly used in ablative procedures for the 
treatment of psychiatric illnesses, such as obsessive-compulsive disorders (OCD), Gilles 
de la Tourette’s syndrome (TS), medically refractory depression, and anorexia nervosa. 
DBS has also been used in the treatment of intractable, chronic pain to varying degrees of 
success. Various trials are currently underway for the treatment of a wide range of 
conditions such as dementia, epilepsy, and obesity making the field of DBS and functional 
neurosurgery one of the most rapidly expanding fields in neurosurgery. 4 5,6 
DBS for movement disorders as we know it today was introduced in 1987 for the treatment 
of essential and Parkinsonian tremor 7. High frequency stimulation in the subthalamic 
nucleus (STN) for Parkinson’s disease was first reported in 1993 by Benabid and Pollak in 
Grenoble 8,9. This was followed by the work of Coubes and Krauss et al on pallidal DBS for 
the treatment of dystonia in 1999 10,11. 
A contemporary DBS system comprises DBS lead(s) with a quadripolar electrode 
arrangement, extension cable(s), and a neurostimulator or implantable pulse generator 
(IPG) (Figure 1-1). Novel lead design with segmented contacts allow for directional current 
steering 12,13. The lead is implanted in the brain target area using a precise placement 
technique (e.g. stereotactic frame). This is performed unilaterally or bilaterally depending 
on the symptoms. 
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Figure 1-1: A Medtronic DBS lead (Model 3389) 
 
Medtronic 3389 DBS leads were used throughout this work. Distally, the electrode spacing 
is 0.5 mm, electrode length is 1.5 mm and electrode tip length is 1.5 mm. The diameter of 
the lead is 1.27 mm (Medtronic Inc.) 
1.1.1: A brief history of functional neurosurgery 
Functional neurosurgery involves carrying out an acute anatomical intervention to exact a 
chronic change in function. In line with this statement, functional neurosurgery may well be 
considered to be the oldest surgical discipline in human history 14. Archaeological skull 
findings circa 10,000 BC have demonstrated the practice of trepanation by shamans 15. 
Cave paintings showed that people believed the practice would cure epilepsy, migraine 
and mental disorders 16. The trepanned bone was kept and may have been worn as a 
charm to keep evil spirits away 16. Though one cannot possibly comprehend how this 
procedure would gain any popularity, it survived well into the middle ages and the 
Renaissance despite the likely lack of efficacy 17. Nevertheless, evidence from seven out 
of eight skulls with trepanations from the 6th to 8th centuries found in southwestern 
Germany demonstrated clear evidence of healing, suggesting that many patients did 
survive 17. 
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Figure 1-2: Detail from The Extraction of the Stone of Madness,  
 
 
A painting by Hieronymus Bosch depicting trepanation (c.1488–1516) 
 
The modern practice of functional neurosurgery has somewhat more evidence and rather 
less superstition. This was made possible owing to the emergence and evolution of 
anatomical, physiological and imaging techniques that led to a better understanding of the 
disease process and how it is modulated by surgical intervention. 
Surgical attempts to improve the functional deficit of movement disorders were first focused 
on creating lesions in the pyramidal system, resulting invariably in motor deficits 18-21.  
Though the pathological involvement of the basal ganglia in Parkinson’s disease and 
chorea was demonstrated in the nineteenth century 22-24, the basal ganglia were considered 
a surgical noli me tangere by Dandy, who speculated that the centre of consciousness lies 
therein 25. This did not dissuade others for too long from operating on the basal ganglia. 
Myers resected the head of caudate in one patient with PD in 1939 significantly alleviating 
tremor and rigidity without damage to the pyramidal tract and resulting weakness 26. He 
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later resected the pallidothalamic fibres in the ansa lenticularis which became a popular 
surgical option for movement disorders in the following decade 27-30. 
The pivotal role the basal ganglia had in the surgical treatment of movement disorders was 
further consolidated in 1953 following a report of a surgical accident. Irving Cooper had 
planned to perform a cerebral pedunculotomy on a patient with post-encephalitic 
Parkinsonian syndrome, incidentally referred to him by Walter Freeman, to induce 
weakness and hence improve tremor. Cooper caused damage to the anterior choroidal 
artery during the approach that led him to ligate the artery and abandon the procedure. To 
his delight the patient’s tremor disappeared following surgery without accompanying 
weakness. This outcome was attributed to an ischaemic lesion in the globus pallidus and 
ansa lenticularis 31,32. The following year, Cooper reported a series of 34 patients with PD 
who underwent ligation of the contralateral anterior choroidal artery (6 bilateral) with no 
recurrence of rigidity or tremor one year or longer after surgery 33. He conceded that 
although the procedure was effective, it would never be a routine operation due to the 
variability in the anatomy of the artery and the distribution of its vascular supply leading him 
to adopt chemo-pallidectomy and later cryotherapy as the procedure of choice all through 
the sixties 34. Although Cooper used a probe of his design to perform these procedures and 
his complication rate was relatively low, others adopted a more open approach that carried 
significant morbidity and mortality 35. A less invasive and more accurate approach was 
needed. 
The word “stereotactic” is derived from the Greek for three-dimensional “stereo” and to 
touch “tangere”. Though the term is relatively recent, the basis of stereotaxy have been 
several hundred years in development 14,36. The Cartesian coordinate system attributed to 
René Descartes (c.1596-1650), has allowed for the identification of a point in three-
dimensional space by employing x, y and z coordinates in relation to a fixed point(s) or 
landmark(s). The discovery of X-Rays by Wilhelm-Conrad Röntgen in 1895 allowed for a 
degree of visualization of intracranial structures, which could be used as landmarks, in 
relation to the frame, for stereotactic targeting 37. Sixteen months later, the French 
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photographer Gaston Contremoulins created a stereotactic device that implemented the 
newly discovered x-rays. The device was successfully used in humans to localize and 
extract intracranial bullets by the Parisian surgeon Charles Rémy in 1897 38. However, a 
systematic approach to stereotaxis was first applied in 1906 when Sir Victor Horsley and 
Robert Henry Clarke invented their renowned Horsley-Clarke apparatus, a stereotactic 
frame for animal studies (Figure 1-3) 39. It was not until after the development of air 
ventriculography by Walter Dandy in 1918 that Ernst Spiegel and Henry Wycis developed 
their stereotactic frame to perform ablative procedures in humans in 1947 (Figure 1-4) 40. 
The first operation they carried out was a thalamotomy for depression 40. Spiegel and Wycis 
went on to publish the first human stereotactic atlas in 1952 41. And there it was, “with a 
navigational system and a guiding map, human stereotactic neurosurgery was born” 14. 
Various stereotactic atlases and frames have been developed since, each with their 
inherent advantages and disadvantages 42-44. 
 
Figure 1-3: The Horsley-Clarke apparatus, the Science museum, London 
(left) and Cartesian coordinate grid overlaid on a non-human primate brain 
(right)  
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Figure 1-4: The Spiegel and Wycis stereotactic system 
 
Spiegel and Wycis shifted their attention from the treatment of psychiatric illness to 
movement disorders. They used their frame to create a deep brain lesion by instilling 
alcohol in the globus pallidus interna (GPi) in a patient with Huntington’s chorea 45. They 
then started performing stereotactic pallidoansotomies in PD patients, ablating the same 
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areas that had been lesioned by Meyers, Fenelon, and Guiot via an open non-stereotactic 
approach 46.  
Between 1960 and 1970, more than 40,000 stereotactic procedures were carried out 14,47. 
The rise of functional neurosurgery procedures came to a halt following the discovery of L-
Dopa in 1968. Nevertheless, the emergence late side effects of L-Dopa and its agonists 
became apparent in the mid-1980s. This necessitated a complementary surgical approach 
with medical therapy. The rediscovery of leksell’s stereotactic pallidotomy by Lauri Laitinen 
in 1992 heralded the rebirth of stereotactic functional neurosurgery 48,49. Marwan Hariz, 
Laitinen’s apprentice, has likened this rebirth to “a phoenix rising from the ashes”.  
Ablative stereotactic surgical procedures gained momentum, however, they were not 
without drawbacks. Destructive surgery is irreversible (requiring high targeting accuracy to 
avoid neurological complications) and can carry a stigma. Furthermore, bilateral surgery in 
brain targets used in movement disorders can lead to unacceptable side effects such as 
balance, cognitive, speech and swallowing defects, especially when performed in the 
thalamus and basal ganglia and in a single session 50. 
Deep brain stimulation offered an alternative to ablative surgery. Targeting is relatively 
more forgiving as the stimulation parameters can be adjusted to an extent. Moreover, 
bilateral surgery is better tolerated in the thalamus and basal ganglia. Having said that, it 
comes with the disadvantage of having an expensive implant that is prone to infections, 
device failure and battery depletion requiring further replacement surgery 50. 
The concept of chronic subcortical stimulation was not new. It had been previously trailed 
in the treatment of patients with psychiatric disorders 51 and chronic pain 52. In a famous 
animal experiment, Delgado was able to stop a bull mid-charge by delivering stimulation 
through chronically implanted subcortical leads controlled remotely using radio waves 53. 
Delgado then worked with Sixto Obrador and Jose Martin-Rodriguez to implant bilateral 
electrodes to deliver chronic stimulation in the head of the caudate and septal regions for 
the treatment of brachial-plexus avulsion pain. This is thought to be the first implantation of 
a DBS device in Europe 54. In further work by Carl-Willhelm Sem-Jacobsen, chronically 
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implanted depth electrodes were used to refine prefrontal leucotomy procedures by 
exploring the response to stimulation prior to making incremental, permanent lesions  55. 
More, rather infamous work in the field of chronic deep brain stimulation for psychiatric 
disorders was carried out by the American psychiatrist Robert Heath in Tulane University, 
New Orleans in the 1950s 4. Heath pioneered the concept of ‘self-stimulation’ through 
chronically implanted leads. His work began with a focus on treating schizophrenia, 
epilepsy and pain 56. After some patients reported a sense of ‘euphoria’ when stimulating 
the septal area, Heath began to explore this further in an attempt to identify the pleasure 
centres in the brain 57. Heath’s work has raised considerable ethical concerns 4 and his 
experiments have been deemed “dubious and precarious by yesterday’s standards” 56. 
The list of subcortical structures targeted in DBS is extensive. Considering the role that the 
basal ganglia (BG) play in regulating and modulating internally and externally driven 
behaviours 58, it is no surprise that targeting these structures can have a significant impact 
on brain function. The success of the deep brain stimulation procedure hinges on proper 
patient and target selection and accurate lead placement with stimulation of neurones and 
pathways within a small region, while avoiding current spread to nearby structures causing 
unwanted neurological and/or behavioural side effects. 
Though advancements in imaging techniques in the last century provided a window into 
the brain; targeting deep brain structures, whether for ablation or DBS, continued to pose 
challenges. Direct targeting is not possible using X-Rays because the targets cannot be 
visualised. This led to a reliance on various stereotactic atlases, employing references 
visible on air ventriculography (e.g. the anterior commissure and posterior commissure). 
Indirect targeting requires further intraoperative refinement of targeting variability, which 
can be achieved with electrophysiological mapping (i.e. micro/ macro electrode recording) 
and often intraoperative stimulation and testing 59. CT and early MRI scans did not provide 
the spatial resolution and contrast for direct targeting or target verification. Additionally, MRI 
scans are susceptible to spatial distortion and artifacts, impinging on targeting accuracy 60. 
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Contemporary 1.5 and 3T MRI sequences, when meticulously calibrated and tested, can 
provide a map for direct targeting of many of the subcortical structures commonly used in 
functional neurosurgery (e.g. the STN, the GPi etc.) negating the need for surrogate 
markers required in indirect targeting 61,62. Furthermore, immediate postoperative 
stereotactic MRI offers the ability to verify targeting accuracy by assessing electrode 
placement, guiding relocation of sub-optimally placed electrodes, auditing and ultimately 
improving targeting accuracy and precision, examining the effect of electrode placement 
on long-term therapeutic effects and side-effects and more recently, by utilising it in 
generating volume of tissue activation models around individual contacts to explore the 
anatomical basis to physiological observations and clinical responses 61. 
Nevertheless, access to good quality and reliable MR imaging requires local expertise and 
the ungoverned use of MRI with DBS implants can raise safety concerns. However, when 
appropriate safety precautions are carried out, those risks can be reduced to acceptable 
limits that are far below the risk of other verification techniques commonly used in clinical 
practice 63.  
1.1.2: Targeting neural circuits 
Functionally distinct cortico-subcortical loops, which form elements of the motor, 
associative and emotive systems, pass through the basal ganglia and thalamic nuclei, often 
creating functional sub-regions within these structures with various degrees of overlap 58. 
Localizing these sub-regions (e.g. the sensorimotor STN) is not easily achieved using 
conventional magnetic resonance imaging 58,64. This underlying relationship between 
structure and function suggests that the efficacy of DBS, and avoidance of unwanted side 
effects, may be influenced by the precise stimulation site within the anatomical target. 
Those functional sub regions may show distinct electrophysiological features. This has 
been used as an argument for using MER to refine the final electrode location. However, 
there is a growing body of evidence suggesting that the use of surrogate 
electrophysiological markers is by no means a guarantee for a good long-term outcome. 
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Location of the best MER activity has been shown not to necessarily correlate with the best 
clinical response on macro-electrode testing intraoperatively 65. It has been shown that a 
better predictor of good long-term clinical outcome was the DBS lead position within the 
MRI defined STN 66,67. 
Additionally, using an image guided and verified approach is safer owing to the reduction 
in the number of passes through the brain. A blunt tipped probe is used to create a track to 
the target in contrast to MER, which commonly involves the insertion of two to five sharp 
microelectrodes and their cannulas. This is associated with an increased risk of intracranial 
haemorrhage, which can rarely lead to devastating complications and even death 68 69.  
An additional gain when using an image guided and verified approach is the ability to carry 
out audit that can have a positive impact on future DBS procedures. There is no means to 
replicate an “ideal MER recording” in subsequent procedures. However, MRI verified 
surgery allows for constructing a ‘DBS functional map’ within the targeted structure through 
studying correlations between the contact location, side effects, and efficacy across a 
group. The data can then be replicated in future patients to improve targeting.  
As an example of how audit can help finesse targeting, a recent study found that DBS 
electrodes placed along the medial border of the STN in PD patients led to more long term 
speech deterioration when compared to a slightly more lateral location 70.  
Moreover, an image guided and image verified approach reduces the operative time and 
patient discomfort as surgery can be carried out under general anaesthesia 71, it allows for 
relocation of electrodes when results are suboptimal 72, and anatomical targeting errors 
can be detected and addressed before completing the procedure 73-75. 
Using an image guided and verified approach thus carries significant advantages, however, 
at present, conventional MRI does not provide information on functional mapping within the 
brain target. 
Structural and functional connectivity studies may provide the opportunity to examine the 
concept of “non-invasive” functional mapping against “invasive” mapping with MER. This 
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can provide new ways to define the sub-regions in target nuclei, such as the STN; where 
stimulation in the sensorimotor area gives the optimal results in PD patients 66,76,77. 
In a contemporary, image guided and image verified functional neurosurgery approach, an 
MRI scan is performed with the frame on to calculate the stereotactic coordinates of the 
brain target visible on the scan. In some units, a stereotactic CT scan is performed and 
then co-registered with a preoperative non-stereotactic MRI using linear registration. Once 
the DBS leads are implanted, an intraoperative stereotactic MRI (or CT) is performed to 
confirm the final position of the electrodes. This is the approach used at the National 
Hospital for Neurology and Neurosurgery. Some continue to rely on surrogate 
electrophysiological markers obtained from the neural tissue local field potential using 
microelectrode recording to guide lead implantation. Following lead implantation, extension 
cables are tunnelled under the skin to connect the DBS lead(s) to an 
implantable pulse generator (IPG). The latter is internalised in a pectoral 
or abdominal pocket. The stimulation parameters are programmed and 
adjusted using an external programmer (Figure 1.5) to set up the active 
contacts (single, multiple adjacent, or interleaved), mode of stimulation 
(monopolar or bipolar), stimulation voltage (or amplitude), frequency and pulse width 
depending on stimulation efficacy and side effects. The patient is given a personal 
programmer to switch between different pre-sets of programs (if necessary), increase or 
decrease stimulation intensity (within a pre-set window), or to turn the device on and off. 
The different components of a contemporary DBS system are shown in Figure 1-6. 
 
 
 
 
 
 
 
Figure 1-5:N-
vision 
programmer 
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Figure 1-6: A contemporary DBS system setup showing the different 
components 78  
 
1.1.3: The role of MR connectivity 
Structural and functional connectivity may allow the visualization of targets not readily 
visible on MRI, such as the ventrointermedialis (VIM) nucleus of the thalamus, used in the 
treatment of tremor. Defining white matter tracts using diffusion tractography techniques 
can also help targeting structures such as the medial forebrain bundle, possibly implicated 
in the treatment of depression 79. 
The practice of exploring brain connectivity is not new. The structural connectivity of the 
human brain has been studied for centuries, employing various techniques to define neural 
connections. Gross anatomical studies in the 16th century carried out by the anatomist 
Andreas Vesalius defined various major white matter tracts in the brain. Centuries later, 
the development of the microscope opened the door for the study of the microstructural 
architecture of neural tissue. Tracer studies in non-human primates (NHP) allowed 
scientists to make some inferences about connections in the human brain. Brain lesions 
and tracer studies in humans similarly allowed for mapping brain connections. 
In the context of this work, structural connectivity is used synonymously with diffusion 
connectivity.  
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1.1.4: Functional connectivity 
Functional connectivity refers to correlations in activity between remote regions in the brain. 
The regions might be directly or indirectly (functionally) connected. This is traditionally 
studied using PET and or SPECT techniques. In this thesis, it is pertained to resting state 
fMRI experiments, by examining synchronicity in the haemodynamic response (HDR) on 
BOLD sequences thus determining correlations between different brain regions 80. Further 
description of resting state functional connectivity analysis is provided in chapter 3.  
1.1.5: Structural connectivity 
Structural connectivity refers to direct anatomical connections, via axonal bundles between 
remote brain regions. This can be assessed using MR diffusion connectivity.  
There is no ‘standard’ approach to acquiring and processing diffusion MRI data. This is 
partly due to the mixture of applications of diffusion imaging and the restraints associated 
with acquiring and processing higher quality data. As a result, a plethora of specialised 
software platforms have been developed, each offering different ways of data processing 
and visualization. 
Applications of diffusion MRI can be broadly divided into two categories: (1) the study of 
the scale, density and organisation of brain tissue microstructure e.g. fractional anisotropy 
(FA), mean diffusivity (MD), neurite orientation dispersion and density imaging (NODDI), 
etc.; and (2) the study of macrostructural connectivity by means of tractography. The latter 
can be mostly subdivided into deterministic, probabilistic and global approaches 81. 
1.1.5.1: Introduction to diffusion MRI acquisition 
MRI is highly sensitive to water tissue content. As a result of Brownian motion, water 
molecules are mobile and not static. This motion can be random in isotropic environments 
(e.g. grey matter or CSF) or directional in anisotropic environments (e.g. axonal fibre 
bundles or blood vessels). A directional displacement of sensitised water molecules (phase 
shift) can result in a detectable MRI signal loss. This outlines the basic principle of diffusion 
imaging. In areas of restricted water diffusion, the orientation of white matter tracts can be 
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inferred from the signal loss incurred due to phase shift along the diffusion direction. This 
conventionally involves the use of a pulse-gradient spin echo sequence, were gradient 
pulses are applied on both ends of the 180° refocusing pulse. The signal is then acquired 
using a single-shot rapid image acquisition method such as echo-planar imaging (EPI). The 
strength and duration of the gradient pulse is directly related to signal loss along the 
diffusion direction or to the ‘diffusion effect’. The factor that reflects the strength and timing 
of the gradients is termed the b-value (s/mm2). Each diffusion direction is encoded in x, y 
and z coordinates of the corresponding gradients. Acquiring more diffusion directions 
results in higher angular resolution. This, however; comes at the expense of increased 
scanning time 81. 
Other factors can influence the way diffusion MRI data is acquired. These include the static 
magnetic field strength, spatial resolution (voxel size), number of diffusion shells, number 
of averages acquired, phase encode direction, the quality and number of channels in the 
receive head coil, the use of in-plane acceleration or multi-slice acquisition, etc.  
At the centre of any MRI acquisition there is a central trade-off between signal to noise ratio 
(SNR), image spatial resolution and scanning time. With an increase in the static magnetic 
field comes an increase in the intrinsic SNR (7T > 3T > 1.5T) but not without drawbacks, 
mainly increased inhomogeneity of both the main field (B0) and the RF transmit field (B1), 
resulting in worsening geometrical distortion, in addition to the increased specific 
absorption rate (SAR) resulting in safety implications 82.  
Diffusion sequences are therefore highly customizable. Careful attention to optimising the 
scanning parameters should be sought to ensure that the appropriate sequences are 
acquired. 
1.1.5.2: Modelling diffusion in a voxel 
Several diffusion methods have been developed, each with its strengths and limitations. 
These include diffusion kurtosis imaging (DKI) 83; Q-space imaging such as diffusion 
spectral imaging (DSI) 84 and hybrid diffusion imaging (HYDI) 85; and model based 
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approaches such as the composite hindered and restricted model of diffusion (CHARMED) 
86, NODDI 87 and diffusion basis spectral imaging (DBSI) 88. The most popular diffusion 
models by far are Diffusion Tensor Imaging (DTI) and High Angular Resolution Diffusion 
Imaging (HARDI). 
1.1.5.2.1: Diffusion Tensor Imaging (DTI) 
DTI is one of the simplest models used to describe the anisotropic diffusion phenomenon 
in brain tissue. The use of the term is so ubiquitous, it has become - wrongly - synonymous 
with DWI and with tractography. DTI was first described in 1994 89 as a three-dimensional 
model of Gaussian diffusion displacements in a voxel, depicted in a 3 X 3 covariance 
matrix: 
D = ( 
Dxx Dxy Dxz 
) Dyx Dyy Dyz Dzx Dzy Dzz 
 
In order to visualise the tensor as an ellipsoid (Figure 1-7), the covariance matrix can be 
diagonalized to yield three eigenvalues (l1 > l2 > l3) and their corresponding eigenvectors 
(e1, e2 and e3).   
 
Figure 1-7: The DTI ellipsoid 
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Several scalar matrices, to describe tissue diffusion properties on the microstructural level, 
can be derived from this tensor model such as FA, axial diffusivity, radial diffusivity and 
MD. 
The DTI model has several limitations nonetheless, mainly its inability to resolve multiple 
fibre orientations in a voxel. Furthermore, the assumption of a Gaussian diffusion profile, 
which is at the heart of the DTI model, fails at higher b-values. This has necessitated the 
introduction of more complex models to describe the diffusion signal beyond the simple 
tensor 81. 
1.1.5.2.2: High Angular Resolution Diffusion Imaging (HARDI) 
In this diffusion method, higher b-values (1000 – 3000 s/mm2) and number of diffusion 
directions (in a single shell) are needed when data is acquired. An ensemble of a finite 
number of diffusion tensors is modelled in each voxel 90. This is a more complex model of 
diffusion than DTI and it allows for the resolution of multiple crossing fibres (e.g. in spherical 
deconvolution) 81. This is the diffusion model used in the experiments in this thesis.  
1.1.5.3 MR diffusion tractography 
Tractography is a technique used to study white matter pathways and structural 
connectivity in brain tissue. It runs after diffusion modelling on the voxel level described 
previously. Tractography relies on indirect measurements to create ‘tracts’ through brain 
voxels. Inferences can be made from these tracts to represent white matter pathways 91. 
These pathways have been validated in histological studies, correlating well with known 
anatomy 92. The connectivity profile of a region of interest can be used to segment this 
region according to the maximum probability of connection to the cortex and or to other 
regions in the brain 93,94. This technique has been applied to segment structures within the 
basal ganglia network 95-97. 
Tractography is error prone and has several limitations, however; it remains the only non-
invasive method available to measure the structural connectivity in the human brain tissue 
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in vivo. Tractography algorithms can be local or global, deterministic or probabilistic, model-
based or model free. 
1.1.5.3.1: Deterministic versus probabilistic tractography  
Deterministic tractography is a technique that involves the creation of streamlines starting 
from a seed region of interest in white matter and passing through voxels by following the 
first eigenvector of the diffusion tensor (i.e. the principal direction of diffusion), effectively 
connecting the arrows in each voxel. Streamlines are then terminated when they reach a 
target seed or fall below a set curvature or FA value (e.g. in areas of low anisotropy). 
Deterministic tractography has been very successful in white matter - in vivo - dissection 
98. Since this method usually relies on the DTI model, diffusion data acquisition and 
processing are relatively fast. Despite its success in visualizing large white matter tracts, 
deterministic tractography has significant drawbacks. These include the inability to 
accurately visualize tracts in areas of low anisotropy (e.g. thalamus) or high noise (e.g. 
brainstem); and modelling errors in areas of high anatomical complexity (e.g. crossing or 
kissing fibres). Moreover, errors incurred during streamline visualization can get easily 
propagated resulting in anatomically erroneous connections 99. Concerns regarding 
‘accuracy’ and ‘reproducibility’ have also been recently raised  100. Overall, deterministic 
tractography tends to ‘underestimate’ the number of streamlines in a pathway 101. 
Probabilistic tractography does not utilise ‘streamlining’. Instead, a function of uncertainty 
of the fibre orientation measurement is created in each voxel. This is often referred to as 
the orientation density function or ODF. Once fibre modelling is carried out in each brain 
voxel, tracts can be generated by the propagation of uncertainty over multiple iterations 91. 
In contrast to deterministic tractography, probabilistic tractography can generate tracts in 
areas of low certainty (low anisotropy, high noise, etc.). It can also provide statistical metrics 
of connectivity. This method requires higher quality data (in a single shell i.e. HARDI or in 
a multi-shell form). It is also computationally demanding. These factors translate to 
relatively long acquisition and processing times. Having said that, with advancements in 
MR image acquisition (e.g. multiband acquisition) and processing (e.g. GPU processing), 
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these approaches are becoming more feasible in a clinical setting 102. In a recent 
comparison of different tractography techniques, probabilistic tractography was shown to 
produce results closest to the ground truth, however; it also resulted in more false positives 
than deterministic approaches 101. 
1.1.6: Limitations of MR connectivity techniques 
In order to explore the clinical applications of MR connectivity, it is essential to understand 
the limitations of these techniques. Tractography makes inferences from water diffusion 
direction to produce models of white matter bundles. This is a gross representation of 
neural axons and is highly dependent on voxel size (spatial resolution), number of diffusion 
directions (directional resolution), field strength and many more highly customisable 
parameters from sequence acquisition to pre-processing, post-processing and study 
design, all of which can affect the results. Tractography does not provide information on 
directionality and struggles in regions with crossing or kissing fibres 103. Furthermore, 
tractography has a propensity for favouring short, mesial and straight streamlines over 
long, lateral and tortuous ones 103.  
Resting state functional MR connectivity can be heavily influenced by motion artifact and 
medications. The spatial resolution is considerably poor and single subject studies are 
often meaningless. Both structural and functional MR studies rely on image registration 
which can introduce errors that are unacceptable in stereotactic surgery.  
In the experimental chapters of this thesis we have endeavoured to address the limitations 
of these techniques and we were conscious not to take our results on face value without 
the necessary rigorous appraisal. 
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1.2: Proposed model 
Using structural and functional connectivity, the general aims of this work are to: 
• Sub-segment basal ganglia structures using a non-biased-automated pipeline in 
DBS patients. 
• Assess clinical outcome after DBS surgery using the above models. 
• Generate a symptom-based predictive spatial model based on tractography data 
and electrode parameters, to allow individual based predictions regarding optimal 
electrode configurations. 
• Explore basal ganglia networks, and examine distant brain regions that are 
influenced by DBS activity. 
This work builds on previous work by Lambert et al 96. It has been shown that it is possible 
to generate connectivity based sub-segmentation of multiple regions with no down-
sampling of data within a clinically viable timeframe. The process is highly dependent on 
computing resources. In an example, the brainstem (18,000 voxels) was fully segmented 
and clustered in approximately 24 hours, with the majority of that time spent generating the 
initial tractography 104 105. Utilising this established framework, we provide and validate a 
system of methods to identify, for a given individual, the optimal DBS target location for 
their specific symptoms. We hypothesize that this would help to minimise side effects, 
improve safety, and facilitate the setting of DBS parameters. This also provides a unique 
insight into the mechanisms involved. 
In this work, we employ connectivity analysis combined with spatial DBS information, 
volume of tissue activation and clinical outcome, within a generalized framework to attempt 
to “predict” optimal DBS lead location given the structural and diffusion weighted images. 
This would utilize far more anatomical information; rather than being limited to a certain 
grey-matter structure, it would take advantage of the regional information provided by the 
zone of stimulation or volume of tissue activation (i.e. both grey and white matter). Indeed, 
in vivo optogenetic studies using Parkinsonian rodent models suggest that it is inhibition of 
  
46 
the white matter afferent fibres, rather than the local cell bodies, that are responsible for 
the therapeutic effects of DBS 106, providing a neurophysiological rationale for this 
approach.  
Furthermore, we employ a well-characterized and widely used approach with several 
available techniques 94-96,107 to parcellate the motor thalamus by clustering individual voxel 
tractography information based on cortical and cerebellar connectivity (chapter 6). This is 
yet to be implemented within a neurosurgical framework. We investigate whether this 
information can be used to help map the ventrointermedialis nucleus of the thalamus (VIM), 
a DBS target for tremor. 
Another line of analysis is conducted for predominantly white matter targets, or ill-defined 
targets on structural imaging; such as the dentato-rubro-thalamic (DRT) tract and the 
caudal zona incerta (cZi) [a reticular nucleus] targeted in the treatment of tremor; and the 
ventral tegmental area targeted in the treatment of trigeminal autonomic cephalalgias 
(TAC). For these targets, we use probabilistic tractography to map these tracts and their 
relation to DBS contacts. These approaches help better understand the brain circuitry 
implicated in pathophysiology and DBS mechanism and refine target selection in the future.  
The current project is cautious, taking a retrospective approach, and is done with patient 
safety in mind to allow a robust, well-understood, accurate technique to first be developed 
and thoroughly tested before being used to inform surgical decisions. Clearly there are 
more complicated and advanced models that could be attempted, for example considering 
local tissue impedance, tissue types etc., or performing longitudinal predictions of outcome 
(i.e. clinical stability), but these are secondary projects to the simpler and much more 
achievable primary aims. 
1.3: Literature review 
There are relatively few studies examining the role of connectivity in DBS surgery, and they 
can be broadly divided into three categories:  
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1.3.1: Studies that examine the connectivity of effective DBS targets in healthy subjects 
This is the most common category. These studies examine simple connectivity patterns of 
effective DBS targets in healthy subjects not undergoing surgery 108-114. This approach is 
useful in highlighting the common pathways implicated in DBS therapy but does not 
consider individual variations or differences in connectivity between healthy controls and 
patients. In certain studies, the scans were registered to a standard space e.g. MNI152 
space, a process that readily introduces fusion co-registration errors, which can be 
paramount when studying small structures such as the STN. 
The various reports, in each category, have been sub-grouped under three separate 
headings; movement disorders, pain and psychiatric disorders in the order of how 
established functional neurosurgery is in the treatment of these conditions.   
1.3.1.1: Movement disorders 
In a study that employed functional connectivity to investigate the VIM nucleus of the 
thalamus as a DBS target in the treatment of tremor, Anderson et al used resting state fMRI 
data acquired from 58 healthy subjects to map the functional connectivity between atlas 
defined regions of interest in the thalamus, the motor cortices and the motor activation 
region of the superior cerebellum as identified during a finger moving test. The researchers 
found consistent functional connectivity patterns between those regions of interest. There 
were inter-individual variations in the optimal DBS target in the thalamus 115.  In a similar 
study by Hyam et al, this time using structural connectivity (probabilistic tractography) in 17 
healthy subjects from seeds in the VIM and the ventral oralis posterior (VoP) thalamic 
nuclei. Those regions of interest were identified on a structural MRI scan by an experienced 
neurosurgeon. Distinct connections between the VIM, M1, and the contralateral cerebellum 
were found. The VoP was connected to the SMA. Differences of connectivity between the 
VIM and VoP were identified in keeping with known anatomical data 116. These findings 
support the role probabilistic tractography can play in distinguishing intimate nuclei within 
the thalamus depending on their connectivity patterns thus playing a role in the surgical 
planning. 
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In a study by Horn et al, machine learning techniques were applied to publicly available, 
state of the art diffusion and resting state functional MR data acquired from the human 
connectome project 117. The connectivity profiles of the active contacts in 51 PD patients 
with STN DBS were explored using Lead-DBS toolbox 118. The results were used alongside 
the efficacy profiles for DBS to train a connectivity model. The model was then used to 
predict efficacy in another dataset of 44 patients from a different centre based on 
connectivity. In the training dataset, structural connectivity between the DBS electrode and 
the SMA and functional anti-correlation to M1 correlated with clinical response. This same 
connectivity profile predicted response in the test group with an average error of 15%. The 
authors concluded that STN DBS connectivity in PD can predict clinical outcome across 
independent cohorts 119. The authors submitted that specialized imaging in PD patients 
themselves is not necessary and connectivity data from matched controls is sufficient. This 
remains to be validated. PD patients have been shown to have altered functional and 
structural connectivity and replication of the study using patient specific data may yield 
different connectivity profiles and/ or average prediction error. 
1.3.1.2: Pain 
In a paper by Owen et al, the effective DBS contact location of a patient with cluster 
headache treated successfully with - what the authors term - posterior hypothalamic DBS 
was used as a seed to explore the structural connectivity of the target using probabilistic 
tractography in 13 healthy controls. The authors found consistent connections between the 
so called posterior hypothalamic region with the reticular nucleus and the cerebellum and 
in some patients, connections were also seen with the parietal cortices and the inferior 
medial frontal gyrus 120. These findings shed a light on the possible pathways of action of 
DBS in cluster headache. The role of the so called posterior hypothalamic region in cluster 
headache was first pointed out after a PET study by May et al in 1998 that showed 
activation in what was termed the ipsilateral posterior hypothalamus during attacks 121. A 
year later, another paper showed increased neuronal density in the same area in patients 
with cluster headache using voxel based morphometry analysis 122. This led Franzini et al 
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to successfully treat a patient with refractory CH in 2001 with DBS 123, and report the first 
series of patients in 2003 124. Owen et al’s work is the first to study the in vivo connections 
from the DBS target using probabilistic tractography.   
1.3.1.3: Psychiatric disorders 
Another DBS target, for which several trials are currently being carried out, is the anterior 
cingulate cortex 125-128. Ablative surgery in this region is well established in the treatment 
of medically refractory depression with varied targeting strategies anywhere along the 
dorsal anterior cingulate to the subgenual cingulate cortex, albeit no evidence from blinded 
trials exists to support its efficacy. The practice declined in the last century with the 
development of effective drugs. In general, there was a move away from psychosurgery 
after the 50s and 60s. The poor regulation in the field during the lobotomy era and the lack 
of a consistent multidisciplinary approach gave way to poor surgical and ethical practices 
by some 51,129,130. 
Johansen-Berg et al used the effective contact location from nine patients with medically 
refractory depression treated with cingulate cortex DBS to map the target’s structural 
connectivity using probabilistic tractography in 17 healthy subjects. Using connectivity 
based parcellation of the anterior cingulate cortex, the authors defined two distinct regions: 
a pre-genual region, strongly connected to the medial prefrontal and the anterior mid-
cingulate cortex and a sub-genual region with the strongest connections to the nucleus 
accumbens (NAc), amygdala, hypothalamus, and the orbitofrontal cortex. The location of 
the effective electrode contact points were within the sub-genual region; this finding 
supported the hypothesis that the treatment efficacy is mediated via the effects on a 
distributed network of frontal, emotive, and viscera-motor brain regions 112. This study 
however, did not report on the outcome of DBS in these patients or indeed set out to 
correlate connectivity with outcome. Moreover, patients in the original trial by Mayberg et 
al had a short follow-up period (6 months) and were not blinded to stimulation making it 
difficult to disentangle a real treatment effect from a placebo effect 126.  
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Another study by Gutman et al used diffusion scans from 13 healthy subjects to compare 
the connectivity patterns of two DBS targets used in the treatment of refractory depression, 
the subcallosal cingulate white matter (SCCwm) and the anterior limb of the internal 
capsule (ALIC), in an attempt to explain the mechanisms of action of DBS. Group level 
tract maps were generated and compared for both targets. The authors found areas of 
overlap as expected and areas of distinct connectivity patterns for the two targets. The 
SCCwm had consistent ipsilateral connections to the medial frontal cortex, the anterior and 
posterior cingulate, medial temporal lobe, dorsal medial thalamus, hypothalamus, NAc and 
the dorsal brainstem. The ALIC seed in contrast demonstrated widespread projections to 
the frontal pole, medial temporal lobe, cerebellum, NAc, thalamus, hypothalamus and the 
brainstem. Connections to the frontal pole, medial temporal lobe, NAc, dorsal thalamus and 
the hypothalamus were common to both targets 110. 
The above studies aim to explain the mechanism of action of DBS in the anterior cingulate 
region, whilst a study by Bhatia et al tried to compare targeting techniques using diffusion 
vs. conventional MRI targeting techniques. T1, T2 weighted images and diffusion 
acquisitions were taken in 59 healthy subjects. Targets were selected for both hemispheres 
using the T2 weighted and diffusion sequences. A significant difference was found within 
targets selected using diffusion from those selected using T2 sequences 131. However, it 
must be emphasised that the findings are not coupled with any supporting clinical data or 
evidence of efficacy so no conclusions can be drawn about the role of diffusion connectivity 
in target selection in DBS surgery. 
1.3.2: Studies that use patient specific connectivity data to directly plan surgery or predict 
outcome 
These studies use patient specific connectivity data, either to directly perform targeting in 
DBS surgery or to perform post-hoc analysis, once DBS surgery was done using a 
traditional approach, looking at correlations between DBS lead contact location in relation 
to connectivity maps, and outcome 132. These studies commonly use simple visualisation 
of the first order tensor fields (either directly or through streamline deterministic 
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tractography) to manually identify anatomical regions of interests within structures such as 
the thalamus 133, pedunculopontine nucleus (PPN) 134 or surrounding fibres 135. The manual 
identification employed in these methods introduces observer bias, and does not take full 
advantage of the intrinsic information present in the data to allow these regions to be 
automatically segmented. Moreover, the assumptions made when employing deterministic 
tractography 135 only allow principle fibre bundles to be identified and fail to account for the 
complexity that naturally exists (i.e. multiple fibre tracts and crossing fibres).  
Most of these studies focus on thalamic DBS targeting for tremor, DBS for pain and for 
depression/ OCD. It is imperative to highlight here that unlike DBS for tremor; DBS for pain 
and DBS for depression/ OCD remains experimental and there is no clear evidence to 
support the efficacy of these treatments, or even which target to choose. This “lack of 
evidence for efficacy”, despite seemingly sound mechanistic imaging findings, reminds us 
of the limitations of such a “broad brush” technique when applied to the complex human 
brain affected by disease.  
1.3.2.1: Movement disorders 
Coenen et al published a case report in 2011 describing a patient with medically refractory, 
tremor dominant PD. The patient underwent a preoperative diffusion scan, followed by VIM 
DBS using traditional MRI landmarks for targeting. Intraoperative macrostimulation was 
used to confirm target accuracy. A postoperative CT scan showing the DBS lead was fused 
with the preoperative MRI to confirm lead location. DBS therapy was highly effective and 
preoperative whole brain deterministic tractography (DT) was then performed and the 
dentate-rubro-thalamic (DRT) tract was isolated. The active DBS contact was clearly 
located within the vicinity of the DRT, which has been implicated in the tremor circuit. The 
targets generally used for the treatment of tremor are the VIM, cZi and the posterior 
subthalamic region. This study showed that those targets may indeed form different nodes 
on one neural circuit 136. In the same year the group reported the case of a patient with 
dystonic tremor who underwent bilateral VIM DBS insertion, this time guided by 
deterministic tractography in addition to traditional MRI landmarks, resulting in >90% tremor 
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control 3 months after surgery 137. Although these are reports of single cases, they do 
provide a proof of concept for the use of diffusion connectivity in DBS surgical planning. 
The diffusion imaging parameters used were of poor quality with a limited number of 
diffusion directions and large voxel size. The authors used a deterministic tractography 
technique to model tracts that traverse the thalamus (an area of low anisotropy) where this 
technique has limitations. 
On the same theme, Pouratian et al performed a post hoc analysis of six patients who 
underwent bilateral VIM DBS for tremor. Diffusion scans were performed preoperatively. 
Thalamic segmentation was attained using probabilistic tractography as described by 
Behrens et al 94. Although the study had methodological weaknesses with suboptimal 
diffusion acquisition parameters and the scans were registered to the standard MNI152 
space; the effective DBS contacts were located at the area of the thalamus with the highest 
probability of connection to the premotor and supplementary motor cortices 138. Klein et al 
performed a post hoc connectivity analysis of 12 patients with intractable tremor who 
underwent VIM DBS using traditional MRI landmark targeting. The effective DBS contacts 
were used as seeds for probabilistic tractography using diffusion scans acquired before 
surgery. VIM stimulation resulted in a decrease in tremor magnitude and an improvement 
in the quality of life. Tractography initiated from the effective stimulation site reconstructed 
a highly reproducible network of structural connectivity comprising motor cortical, 
subcortical, cerebellar and brainstem. Connectivity to the primary motor cortex seemed to 
play a key role in successful stimulation 139, in contrast with Pouratian but in keeping with 
the findings by Coenen. 
Groppa et al examined the effective DBS contact locations of seven patients with 
intractable essential tremor with thalamic DBS. The DRT was reconstructed using 
probabilistic tractography in 13 healthy controls using seeds in the cerebellum and the 
brainstem. The effective DBS contacts appeared to lie in the vicinity of the DRT 140. 
Anthofer et al investigated the variability of probabilistic atlas-based VIM targets in relation 
to the surrounding major fibre tracts using deterministic tractography in 10 patients with 
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essential tremor who received VIM DBS. The DRT, pyramidal tract and lemniscus medialis 
where reconstructed by tractography in all 20 hemispheres. The distance from the 
probabilistic atlas-based VIM target to each tract along the x, y and z coordinates was 
measured. Considerable variability of the location of probabilistic atlas-based target points 
of the VIM, in relation to neighbouring major fibre tracts, in individual patients was found. 
These results suggest that individualized targeting to structures not directly visible on 
conventional MRI may be necessary 141. A recent report by Coenen et al presents the 
results of a prospective trial in a group of 11 medically intractable tremor patients who 
underwent post-hoc deterministic tractography analysis after treatment with traditional 
thalamic deep brain stimulation. Tractography was processed postoperatively for 
evaluation, and the DRT was individually tracked. Electrode location was determined with 
helical CT fused to the preoperative MRI. The average follow-up period was 9 months 
(Range 3 - 17 months). The authors used the Essential Tremor Rating Score (ETRS) to 
assess treatment efficacy. This is described as moderate, good and excellent, without 
defining the degree of reduction in ETRS these categories reflect. Tremor was reduced in 
all patients with effective contacts located inside or in proximity to the DRT. The stimulation 
field around the DBS contacts was estimated. Moderate tremor reduction occurred in two 
patients in whom the stimulation field was centred on the anterior border of the DRT. When 
good and excellent tremor reduction was achieved (in nine patients), the stimulation field 
focused on the centre. The authors conclude that tractography can be used to optimize 
targeting in individual patients 132. The authors employed a deterministic tractography 
approach to identify the DRT in each patient. Electrical stimulation field models were 
derived from individual active DBS contact impedance and stimulation amplitude. The 
methodology involved multiple registration steps, increasing the registration error margin. 
Each patient’s postoperative CT scan (showing the DBS contacts) was fused to a 
preoperative MRI scan, which was then normalised to the brain MNI152 space. Each 
modelled DRT was also normalised to the brain MNI152 space to create a probabilistic 
DRT model. Stimulation fields were then simulated on the MNI152 brain. Modelling the 
  
54 
electrical stimulation field or activation volume is notoriously complex and current models 
assume an electrically homogenous and stable local medium, which the brain is certainly 
not 142,143. Nevertheless, this is perhaps the most clinically relevant paper to date 
demonstrating the value of diffusion connectivity in predicting outcome from DBS tremor 
surgery. 
In a study using diffusion connectivity in the operative planning, Schweder et al reported a 
case of a patient with PD who received bilateral pedunculopontine nucleus (PPN) DBS 
surgery. The targeting of the PPN was made using the fractional anisotropy (FA) map. 
Following surgery, the patient had a subjective improvement of 42% on the gait and falls 
questionnaire and 14% on the freezing of gait questionnaire (FOG-Q). Twelve months post-
stimulation the patient underwent a further diffusion acquisition. When the pre-op 
probabilistic tractography pattern from the target seed was compared to the post-operative 
pattern, the authors found differences in the connectivity patterns between the two 
studies144. It is not apparent that any useful conclusions can be drawn from the comparison 
as the study had significant methodological weaknesses. The authors report a single case 
study. The efficacy of the PPN as a target remains contended. An improvement of 14% in 
the FOG-Q is very modest. Imaging parameters were poor with diffusion scans taken on a 
1.5T MRI scanner along 32 directions with substantially large voxels (2.5 mm isotropic) in 
relation to the target in question, i.e. the PPN. The authors also performed post-op diffusion 
imaging in a patient with DBS electrodes implanted in the brainstem, yet they do not 
comment on safety issues or image artifact arising from the implanted leads. The 
differences in the tractography between the pre- and the 12 months post-operative imaging 
may be influenced by lead artifact, seed selection, registration error, various physiological 
factors or simply ageing, yet the authors do not account for those factors. 
1.3.2.2: Pain 
Owen et al performed a post-hoc analysis of diffusion connectivity data using seeds from 
the effective DBS contact location in four patients with medically refractory chronic pain 
who received DBS in the periaqueductal grey (PAG) and the periventricular grey (PVG) 
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areas. Probabilistic tractography was performed using diffusion scans acquired pre-
operatively. The connectivity pattern was consistent with previously reported non-human 
primate (NHP) tracer studies, which used horseradish peroxide to trace connections 
between the PAG and the medio-dorsal thalamus (MD). Other connections to the 
precentral gyrus and central sulcus were also identified. The findings highlight the possible 
network involved in the pain pathway, which may allow for target refinement in the future 
108. The authors acknowledge the restrictions associated with diffusion imaging analysis in 
general, these difficulties become even more pronounced when tractography is performed 
in the brainstem due to the densely packed tracts and nuclei. Brainstem diffusion imaging 
can also be affected by physiological elements, such as the cardiac pulse and the 
respiratory cycle, more than the rest of the brain.  Three sets of diffusion image acquisitions 
were taken on a 1.5T field MRI scanner along 60 diffusion directions. The three sets were 
then averaged to increase the signal to noise ratio (SNR). The voxel size was 2 mm 
isotropic (b=1000), which has limitations when tractography is performed outside the 
brainstem that are accentuated when within it. The authors do not comment on the 
postoperative structural MRI timing or acquisition parameters. Those were the structural 
scans used for registration. It is not clear if there were any registration errors especially that 
the structural and diffusion scans were acquired at different sittings. Brain shift can also 
occur in the immediate period following surgery, which may affect the accuracy of the 
registration. The authors conclude that probabilistic tractography, as a surgical planning 
tool may be a possibility in the future.  
1.3.2.3: Psychiatric disorders 
In a study utilizing functional connectivity to measure the effect of DBS on neural activity in 
OCD, Figee et al wrote a brief communication in Nature Neuroscience in 2013 detailing a 
study of 16 patients who received DBS in the NAc and ALIC for medically refractory OCD, 
and 13 matched controls. Resting state fMRI scans were acquired for the controls, and for 
patients one year after surgery in two states, on and off DBS. Patients completed an 
optimization phase during which they were evaluated every 2 weeks for severity of 
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symptoms and optimal stimulation parameters. The two dorsal contacts were active in all 
patients, implying that the most effective stimulation area was located at the border of the 
NAc core and anterior limb of the internal capsule. The authors state that patients showed 
stable clinical improvements with DBS for at least 1 year. The stimulators were turned off 
for 1 week, which resulted in a 50% increase in OCD symptoms, an 80% increase in anxiety 
symptoms and an 83% increase in depression symptoms The authors found the activity in 
the NAc to be lower in OCD patients in the off state compared to healthy controls, and this 
abnormal activity was normalized once DBS therapy was resumed. The abnormally 
increased functional connectivity between the medial and lateral prefrontal cortex (PFC) 
and the NAc was also normalized with DBS on 145. 
In DBS for depression, Riva-Posse et al acquired preoperative diffusion imaging in 16 
patients with treatment-resistant depression, who received subcallosal cingulate DBS. The 
activation volume around the contacts used for chronic stimulation was modelled for each 
patient retrospectively. Probabilistic tractography was used to delineate the white matter 
tracts traveling through each activation volume. Response was defined as 50% decrease 
in the 17-item Hamilton Depression Rating Scale. DBS responders shared bilateral 
pathways from their activation volumes to the medial frontal cortex via the forceps minor 
and the uncinate fasciculus; the rostral and dorsal cingulate cortex via the cingulum bundle; 
and subcortical nuclei including the NAc, caudate, putamen, and anterior thalamus. Non-
responders did not show these connections. This meant that patient-specific; activation 
volume tractography modelling may identify critical tracts that mediate DBS antidepressant 
response, proposing a novel method for patient-specific target and stimulation parameter 
selection 146. 
Another case report suggested a role that connectivity studies may have in predicting 
outcome from DBS therapy. McNab et al reported a case of a patient with bipolar disorder 
syndrome and medically refractory depression developed following a thalamic stroke. The 
patient was treated with bilateral DBS of the subgenual anterior cingulate cortex (SGCC) 
with no improvement in the depression scores post operatively. The patient died 16 months 
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following surgery. Pre-operative and post-mortem diffusion connectivity studies showed 
evidence of markedly reduced projections from the medial thalamus and the SGCC, to the 
amygdala on the right (stroke affected) side. The authors concluded that reduced 
amygdalo-thalamic and amygdalo-SGCC connections could be a predictor of poor outcome 
following SGCC DBS surgery for depression 147. However, the SGCC is not an established 
DBS target for depression and attempting to infer mechanistic information from connectivity 
studies in this area may be of limited significance. 
1.3.3: Studies that examine networks and connections between cortical and subcortical 
structures 
These studies describe techniques to examine networks and connections between cortical 
and subcortical structures from a purely anatomical prospective, with no special attention 
to DBS targets 93,94,96,148. 
In 2003, Behrens et al published the first report of the use of probabilistic tractography to 
delineate boundaries between different thalamic nuclei based on connectivity patterns 
between the thalamus and the different areas in the cortex. This displayed the role that 
probabilistic tractography could play in parcellating grey matter structures, that traditional 
maximum-likelihood or streamline approaches have failed to produce. The resulting 
thalamic segmentation corresponded well with previous histological findings and tracer 
studies in non-human primates. This has opened up the possibility for the use of this new 
technique to define potential DBS targets not traditionally visualized on structural MR 
imaging, such as the VIM nucleus targeted in the treatment of medically intractable tremor 
94. The technique was also validated by Johansen-Berg et al in 2004 93.  
Another notable report by Lambert et al in 2012 used a similar approach to sub-segment 
and define three major functional regions in the STN based on the maximum probability of 
connectivity between voxels in the STN, and cortical masks in the emotive, associative and 
sensorimotor regions. In vivo differentiation between the sensorimotor STN and the 
emotive and associative parts was only previously possible through invasive 
microelectrode recording techniques 96. A similar technique was used by Chowdhury et al 
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in 2013 to segment the substantia nigra (SN) 97. In 2014, Accola et al used high resolution 
MPM acquisitions to segment the STN based on iron content on magnetization transfer 
(MT) sequences; significant differences in iron contents were found in the emotive and 
motor areas 149. Another study mapped the connectivity between the STN and the cortex 
in what is termed the hyperdirect pathway using both structural and functional connectivity 
studies; Brunenberg et al used high angular resolution diffusion imaging (HARDI) 
probabilistic connectivity and resting state fMRI to study the structural and functional 
connectivity of the STN in 10 healthy subjects. They described the hyperdirect pathway 
connecting the STN and the motor cortex, and they segmented the STN into associative 
(ventrolateral), motor (dorsolateral) and emotive (medial) functional sub-regions based on 
those connectivity patterns. The STN masks were derived from an MNI152 space atlas 
which might have introduced errors in delineating this small, and highly variable nucleus 
150. 
In the previous studies, MRI acquisitions were done with 1.5T or 3T magnetic field 
scanners. Lenglet et al, used ultra-high field MRI acquisitions at 7T to build models of 
connectivity between the basal ganglia and the thalamus using probabilistic tractography 
and resting state fMRI, the findings were in keeping with previously mapped connections 
found in tracer studies in NHPs 148. 
In this work, we use functional and structural MR connectivity imaging acquired in patients 
set to undergo DBS surgery. We present several new analysis methodologies and 
applications: (1) build predictive models of DBS surgery outcome; (2) refine the surgical 
target and (3) help build a better understanding of the pathogenesis of the treated 
conditions and the mechanism of action of DBS therapy.  
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2. General Methods  
2.1: Research questions and hypothesis 
The main research questions are twofold.  
1. Can brain connectivity imaging be used to predict clinical outcome of DBS 
surgery? 
2. Can brain connectivity imaging be used to better target structures in DBS 
surgery? 
2.2: Ethical Considerations 
This protocol was granted ethical approval by West London REC 3 (REC reference 
number: 10/H0706/68). All subjects went through an informed consent process and 
provided signed consent. Participants were assessed to see if they were able to tolerate 
the lengthy imaging paradigm. They were given a copy of the patient information sheet to 
keep (participant consent and patient information sheet samples are included in the 
appendix). Patients were invited to attend the Department of Neuroradiology at the National 
Hospital for Neurology & Neurosurgery, Queen Square to undergo an additional scan within 
the month prior to surgery (and where possible during the surgical admission to reduce 
inconvenience of multiple visits). Any additional travel expenses were reimbursed, as is 
standard practice. 
2.3: Finance and Insurance 
The Brain Research Trust (BRT) provided a grant for £250,000 to finance this project. This 
study was sponsored by UCL. All researchers have medical indemnity insurance. 
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2.4: Data Handling 
All personally identifiable data were kept in a locked filing cabinet in a secure building. The 
neuroimaging and clinical measures were acquired and stored anonymously using code 
numbers. A log of patient identifiers and their code numbers were stored securely and 
separately. Patients were further sub-classified per surgical target and symptom of interest. 
Imaging data were provided only with coded names. All digital data stored on laptops or 
personal computers logged on a local network were stored using code numbers, and are 
password protected with exclusive access only for the research team. 
2.5: Patient selection 
Suitable patients awaiting elective DBS surgery at the National Hospital for Neurology and 
Neurosurgery were contacted and invited to participate. The patients recruited to this study 
were selected per their clinical condition and the planned electrode target site. The primary 
pathologies included were PD treated with the STN as anatomical target, tremor (either in 
the context of PD or not) with the VIM of the thalamus or the cZi as target and CH and 
SUNA with the ventral tegmental area as target.  
2.6: Imaging protocol 
All pre-operative imaging was acquired on a Siemens Magnetom TrioTim Syngo MR B17 
with a 3 Tesla field, at the department of neuroradiology, the National Hospital for 
Neurology and Neurosurgery. Pre-operative stereotactic and Post-operative stereotactic 
MR imaging was acquired as part of the DBS surgical process on a 1.5 Tesla Siemens 
Avanto interventional MRI scanner. This included a 1.5×1.5×2.0 mm3 T2 weighted SPACE 
and a 3D MPRAGE (voxel dimension) sequence showing the implanted DBS electrode(s). 
The pre-operative imaging (non-stereotactic) research protocol included three different 
modalities; DWI acquisitions, followed by whole brain structural, multiparameter mapping 
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(MPM) scans, and a resting state fMRI scan with a total scanning time of 100 min. For 
detailed acquisition parameters, see Appendix 1. 
Taking into consideration that the MRI protocol is relatively lengthy, patient selection was 
paramount. The scan had to be well tolerated, and appropriate counselling needed to be 
given during the consenting process. Whenever patients were not able to tolerate it, the 
scan was abandoned. 
2.6.1: Diffusion Weighted Imaging (DWI) 
Diffusion images were acquired using Siemens’ 511E Advanced Echo Planar Imaging 
Diffusion WIP. In-plane acceleration was used (GRAPPA factor of 2) with partial Fourier 
6/8. In plane resolution was 1.5×1.5 mm2 (Field of view 219×219 mm2, TR = 12200 ms, TE 
= 99.6 ms) and 85 slices were acquired with a 1.5 mm thickness.  Diffusion-weighting with 
b=1500 s/mm2 was applied along 128 directions uniformly distributed on the sphere and 
seven b=0s volumes were also acquired.  To correct for distortions all acquisitions were 
repeated with a reversed phase encoding direction (left to right and right to left phase 
encode) giving a total of 270 volumes acquired ([128 +7] × 2). Total acquisition time was 
62 minutes (Table 2-1).  
2.6.2: Multi Parameter Mapping (MPM) 
A high-resolution quantitative multi-parameter mapping (MPM) approach was developed 
at the Wellcome Trust Centre for Neuroimaging (FIL) and validated and compared for 
reproducibility across both, the FIL and the National Hospital sites using two different 
Siemens Trio Tim scanners. Quantitative anatomical MRI (qMRI) is an MRI technique 
designed to give reproducible, absolute values. This is necessary when comparative 
studies are undertaken longitudinally (over time) or across multiple sites. The approach 
eliminates any deviations in the image values attributable to the scanner and reduces bias 
field artefact thus improving voxel based morphometry (VBM) analysis 151. Using multi-
parameter maps improve the segmentation of subcortical structures owing to the improved 
contrast-to-noise ratio that MT provides over T1w images 152. The maps provided 
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longitudinal relaxation rate (R1 = 1/T1), effective proton density (PD*), magnetisation 
transfer saturation (MT) and effective transverse relaxation rate (R2* = 1/T2) images 152-
154.  
The acquisition consisted of three 3D FLASH acquisitions paired with B1 (transmit field 
mapping data to correct for the effect of inhomogeneous flip angles on the T1 maps) and 
B0 field map acquisitions. Spatial resolution=1×1×1 mm3, repetition time=24.5 ms, multiple 
echo times, field of view=256 mm, flip angle=6 (PD), 21 (T1), 6 (MT) degrees, 
matrix=256×256, partitions=176; total acquisition time of 26 minutes 151. 
 
Table 2-1: DWI acquisit ions with alternating phase encoding 
Acquisition 
number 
Phase encoding 
directions 
Rotation 
degree 
TA 
(min.) 
Diffusion 
directions 
1 R >> L 90.00 04:41 20 
2 L >> R -90.00 04:41 20 
3 R >> L 90.00 05:42 25 
4 L >> R -90.00 05:42 25 
5 R >> L 90.00 04:53 21 
6 L >> R -90.00 04:53 21 
7 R >> L 90.00 05:29 24 
8 L >> R -90.00 05:29 24 
9 R >> L 90.00 05:05 22 
10 L >> R -90.00 05:05 22 
11 R >> L 90.00 05:17 23 
12 L >> R -90.00 05:17 23 
    Total 62:23 270 
 
2.6.3: Resting state fMRI  
Multi-echo Echo Planar Imaging (2D-MEEPI) sequences were obtained in two successive 
acquisitions with a total duration of 15 minutes. Spatial resolution=3×3×2.5 mm3, repetition 
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time=60 ms (/slice), echo time=30 ms, flip angle=90 degrees, field of view=192 mm × 192 
mm, 45 axial slices (2.5 mm thickness), matrix size=64×64 and a total of 512 scans. 
Patients were given instructions to keep their eyes open and gaze fixed on a cross hair. 
2.7: The surgical procedure 
Implantation of the DBS leads was performed using a stereotactic MRI guided and MRI 
verified approach without microelectrode recording (Leksell frame model G, Elekta 
Instrument AB, Stockholm, Sweden). Lead implantation was generally performed under 
general anaesthesia with staged implantation of the Implantable Pulse Generator (IPG) 
(Medtronic, Minneapolis, Minn., USA) except for patients treated for tremor where the target 
could not be directly visualised with structural imaging at 1.5T and intraoperative 
stimulation was necessary to confirm efficacy and avoid side effects. The location of the 
DBS leads was verified with a stereotactic MRI scan on a 1.5T T2-weighted stereotactic 
MR image, and a 3D MPRAGE scan was also acquired to rule out any immediate surgical 
complication e.g. haemorrhage. See Figure 2-1 for STN visualization and target selection 
on MRI. 
2.8: Data Collection: 
The patients underwent all the routine pre-operative checks and screening brain scans 
prior to DBS surgery. Image acquisition was carried out pre-operatively, during the surgical 
admission whenever possible. The patients underwent DBS surgery following the routine 
hospital procedure. As part of this clinical protocol, whilst the patients were still in hospital, 
routine medications were withdrawn to allow the stimulator to be switched on and to 
establish optimal DBS settings (normally 2 days to 1 week after the DBS battery (IPG) is 
implanted). Standardised clinical and psychometric measures were normally taken at this 
point and these were made available for this study. For the STN-DBS group, each electrode 
contact was tested in turn and the clinical response documented, this was repeated in a 
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detailed manner using a screening sheet 6-12 months following surgery. Change in the 
clinical response was quantified using disease specific, standard, validated measures, as 
is routine practice for this surgical procedure. 
 
Figure 2-1: STN visualization and target selection on MRI 
 
Top panel: Preoperative stereotactic T2-weighted axial MRI (1.5T,  2 mm 
thickness, no gap, TR 3500, TE 90.9) at the level of maximal rubral diameter 
(around 5 mm below the AC–PC plane). The subthalamic nucleus (STN) is 
visualised as the hypointense signal lateral to the red nucleus. Bottom left panel: 
The entry and target point are selected to maintain a parenchymal trajectory 
while maximising the length of the trajectory within the visible STN hypointensity 
from the AC–PC to target level. As a result, the final target point (white circle)  is 
located at the target point originally described by Bejjani  et al.  Bottom right 
panel: Post-operative stereotactic T2-weighted axial MRI  at equivalent level 
revealing electrode artefact at intended target 6 1. 
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2.8.1: Perioperative assessment and outcome measures 
A detailed history was taken and a thorough clinical examination performed on every 
patient. Detailed neuropsychological assessment, including validated scales to assess 
mood, anxiety and impulsivity, were performed preoperatively. 
Details of the specific outcome measures for each study are included in the corresponding 
chapters. 
2.9: Statistical Considerations 
2.9.1: Sample Size Calculation 
No previous experience with similar diffusion imaging studies in similar subjects exists. 
Though previous authors have looked at power calculations for simple analysis of major 
tracts (e.g. pyramidal), they acknowledge varying reproducibility across tracts means that 
the numbers here cannot be generalised in a straightforward way to other pathways 155. 
Using DWI data at 2mm isotropic resolutions in 60 directions with a b=1000s/mm2, for 
between group comparisons at a threshold of α = 0.05, a minimum number of participants 
are needed depending on region to ensure 80% power to detect major changes in tract 
volume. Similar studies looking at simple tractography from subcortical regions in deep 
brain stimulation have suggested 20 subjects as adequate 112. The numbers proposed for 
the present study have been shown, through many diffusion imaging publications, to be 
appropriate for this type of research question. 
We have recruited 20 patients with PD treated with STN DBS. For patients with other 
pathologies, a target of 6 – 12 patients was reached. This is due to the smaller number of 
patients with those pathologies who received DBS, which created a recruitment challenge. 
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2.10: Analysis 
Detailed analysis is included in individual chapters. 
2.10.1: Diffusion data pre-processing 
All diffusion weighted imaging (DWI) scans (with accompanying b=0 scans) were converted 
from DICOM (Digital Imaging and Communications in Medicine) files to NIfTI volumes and 
the diffusion gradient direction values and vectors were extracted using Volconv (MJ White, 
NHNN Neuroradiology Department, London UK).   
The diffusion data were acquired with reversed phase-encode blips (left-to-right and right-
to-left), resulting in pairs of images with distortions going in opposite directions. From these 
pairs, the susceptibility-induced off-resonance field was estimated using a method 
described by Andersson et al 156 as implemented in FSL 157 and the two images were 
combined into a single corrected one using Topup (FSL v5.0), a tool for estimating and 
correcting susceptibility induced distortions prevalent in SSEPI DWI. The output from 
Topup was then fed into Eddy (FSL v5.0) for correction of eddy current distortions and 
subject movement 158. 
The final step in diffusion pre-processing was registration. Patient averaged distortion 
corrected b=0 volume was registered to brain extracted structural image in native patient 
space (pre-implantation MPRAGE) with Flirt (FSL v5.0) using linear registration with six 
degrees of freedom, normal search and correlation ratio cost function. The resultant 
transformations were then composed with the transformations previously generated using 
non-linear registration between the structural in native patient space and the standard 
MNI152-1mm space producing diffusion-to-standard space transformations and their 
corresponding inversions. 
The pre-processed data were fed into BedpostX (FSL v5.0) to estimate fibre orientations. 
Up to three crossing fibres were estimated in each brain voxel using model 2 and graphics 
processing unit (GPU) parallelization 159,160. Probtrackx was then used on these estimates 
to obtain global connectivity (i.e. the probability of the existence of a path through the 
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diffusion field between any two distant points, a surrogate measure of anatomical 
connectivity) 103. Using the obtained transformations to and from standard space, 
tractography protocols and masks were defined in MNI space.  
2.10.2: Multi Parameter Mapping (MPM) pre-processing 
This was carried out in the MPM toolbox (SPM12). MT, PD and T1 weighted imaging MR 
sequences were processed with paired B1 images; the resultant maps were quantitative 
MT, PD*, R1 (1/T1) and R2* (1/T2*) maps. The MT map was used for segmentation 
(SPM12). The resultant grey matter map was later used to create cortical masks for regions 
of interest (RoI). The grey matter, white matter and CSF maps were combined and 
binarised to form a brain mask to be used for brain extraction. The R1 map was then used 
for registration with the subject’s diffusion space using FDT (FSL5.0 FMRIB) 151.  
2.10.3: Resting State FMRI pre-processing 
This section is described in Chapter 3. 
2.10.4: DBS Volume of Tissue Activation (VTA)  
In order to examine the effects of DBS on the surrounding brain tissue, there is a need to 
generate realistic, patient specific computational models of tissue activation around DBS 
electrodes. To date, there is no standardised method for producing these models. The 
models can therefore vary from simple, single cable models (generally assuming a 
surrounding axon diameter of 2.5 µm and a homogeneous medium) resulting in spherical 
volumes that can be quickly and easily produced; to overly complicated, pathway activation 
models that take into consideration local tissue conductivity and diffusivity (assuming larger 
diameter axons that require multiple stimuli to generate an action potential) 161.  
In this work, we used SureTune® (Medtronic Inc. Minnesota), a DBS therapy planning 
platform to model VTAs around individual contacts (chapters 4, 5, 6 and 9) and to manually 
delineate STN volume meshes (chapters 4 and 5).  The VTAs were created based on 
homogeneous finite element simulations of the distribution of the electric potential together 
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with coupled axon cable models. Axon models were composed of 21 nodes, with a 
diameter of 2.5 µm and oriented in the vicinity of the lead in a perpendicular orientation. 
Specific VTA thresholds were calculated for every electrical setting, taking into 
consideration the specific stimulation configuration, amplitude and pulse width as described 
by Åström and colleagues, in order to generate DBS therapy VTA 162. Patient-specific tissue 
conductivity and patient-specific axon orientations were not considered. 
This is a simplified linear model that does not account for local impedance inhomogeneity 
163. While it is important efforts are put into improving DBS models to resemble reality, it 
may not help to add details to a rough model when the basic knowledge of the DBS 
mechanisms of actions are still debated. Indeed, various models over- or under-estimate 
the VTA 142. The presence of axons of different diameters and cell bodies, with variable 
action-potential thresholds, in the DBS region, complicates matters further. Our other 
justification for not using a more complex model is the fact that minute variations in VTAs 
are unlikely to have a large effect on statistical analysis and tractography results, due to 
the relatively larger spatial resolution of our structural and diffusion MRI data.  
2.10.5: Sweet Spot Analysis 
In order to generate statistically significant, probabilistic clusters predictive of efficacy and 
side-effects of DBS therapy, a novel analysis method was developed. This method was 
used in chapters 4 and 9. 
In chapter 4, VTAs were generated around all individual DBS contacts at four different 
stimulation voltages (1,2,3 and 4 V) producing 32 different VTAs. In chapter 9, only VTAs 
corresponding to the active DBS contacts at the optimised stimulation amplitudes were 
generated. The VTAs were transformed from subject space to MNI space and a group 
average VTA region of interest was then generated from all individual VTAs. 
A general linear model (GLM) was created with efficacy (chapters 4 and 9) and side-effects 
variables (chapter 4) that are associated with each VTA to test against each voxel in that 
VTA. A single-group average design was used. The variables were demeaned and single 
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group t-test with threshold-free cluster enhancement (TFCE) was used as test statistic 164. 
Nonparametric permutation inference approach, similar to that commonly used for VBM 
and fMRI time series analysis, was carried out for each voxel (within the overall group 
average VTA region and not the entire brain) using Randomise (FSL5.0) with 5000 
permutations to build up the null distribution to test against as previously described 165. Raw 
t-stat (t statistic) images were then masked by the significant voxels from thresholded 
(α=0.05) t-stat images, also corrected for multiple comparisons. 
2.10.6: Computational Resources 
One of the obstacles when seeking to employ probabilistic tractography clinically is the 
computational resources needed to process the raw data in a feasible, timely fashion. 
Parallel processing, or general processing over GPU (GPGPU) techniques have been 
developed to use GPU cores instead of using the CPU when processing big datasets. This 
has shown very promising results when used in processing diffusion data 160. For this 
reason, we decided to build a GPU cluster for the sole use in processing the diffusion data. 
The system has four CUDA enabled NVIDIA GeForce GTX TITAN GPU cards, with a 
combined sum of 11,520 cores (Figure 2-2).  
2.11: Post-processing 
Details of the specific post-processing for each study are included in the corresponding 
chapters. 
2.12: Recruitment into the study 
Table 2-2 gives a summary of the different conditions and number of patients recruited 
and needed in each category. 
Figure 2-2: Gilgamesh, the high performance computer built  for general 
processing over GPU (GPGPU). 
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Table 2-2: Shows the various patient groups recruited with DBS target and 
number of patients recruited.  
Patient group DBS target Recruited 
Parkinson’s disease (PD) STN 21 
Cluster headache VTa 19* 
SUNA VTa 11** 
Tremor dominant PD VIM 4 
Essential tremor VIM 5 
 Total 60 
 
* 7 patients with CH underwent connectivity studies 
** Only 3 patients with SUNA underwent connectivity studies, therefore,  only 
clinical analysis of efficacy and side-effects was carried out 
STN = subthalamic nucleus, VTa = ventral tegmental area,  VIM = 
ventrointermedialis of the thalamus.  
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Section I: 
 
Connectivity in Parkinson’s 
Disease 
 
“The pathological physiology of the Parkinsonian syndrome is the study of an 
organized chaos, a chaos induced in the first instance by destruction of 
important integrations and reorganized on an unstable basis in the process of 
rehabilitation” 166. 
Ivy Mackenzie (1877-1959).
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3. Functional connectivity: L-DOPA Responsiveness in 
Patients with Advanced Parkinson’s Disease 
3.1: Abstract 
Neuronal loss and dopamine depletion alter motor signal processing between cortical 
motor areas, basal ganglia and thalamus, resulting in the motor manifestations of 
Parkinson’s disease.  Dopamine replacement therapy can reverse these manifestations 
with varying degrees of improvement. To evaluate functional connectivity in patients with 
advanced Parkinson’s disease and changes in functional connectivity in relation to the 
degree of response to L-DOPA, nineteen patients with advanced Parkinson’s disease 
underwent resting state functional magnetic resonance imaging in the ON medication state. 
Scans were obtained on a 3 Tesla scanner in 3×3×2.5 mm3 voxels. Seed based bivariate 
regression analyses were carried out with atlas-defined basal ganglia regions as seeds, to 
explore relationships between functional connectivity and improvement in the motor section 
of the Unified Parkinson’s Disease Rating Scale (UPDRS-III) following L-DOPA challenge. 
False discovery rate (FDR)-corrected p-value was set at <0.05 for two-tailed t-test. A 
greater improvement in UPDRS-III scores following L-DOPA administration was 
characterized by higher resting state functional connectivity between the prefrontal cortex 
and the striatum (p=0.001) and lower resting state functional connectivity between the 
pallidum (p=0.001), subthalamic nucleus (p=0.003) and the paracentral lobule 
(supplementary motor area, mesial primary motor and primary sensory areas). Our findings 
show characteristic basal ganglia resting state functional connectivity patterns associated 
with different degrees of L-DOPA responsiveness in patients with advanced Parkinson’s 
disease. L-DOPA exerts a graduated influence on remapping connectivity in distinct motor 
control networks, potentially explaining some of the variance in treatment response. 
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3.2: Introduction 
Parkinson’s disease is a neurodegenerative disorder that affects multiple systems in the 
brain in a progressive and, to some extent, a predictable fashion 167. Considerable 
degeneration of dopaminergic neurons in the substantia nigra pars compacta leads to 
dopamine depletion in the striatum. This depletion causes dysfunction within the basal 
ganglia-thalamo-cortical ‘motor’ circuit, resulting in the hallmark motor triad of resting 
tremor, rigidity and bradykinesia. 168,169. 
Numerous animal and human studies have demonstrated structurally and functionally 
segregated parallel circuits or loops that connect the cortex to the basal ganglia and 
thalamus 170-172. This segregation is essential for motor processing and learning. Dopamine 
deficiency results in loss of this segregation and emergence of synchronized oscillations 
between basal ganglia structures and cortical areas. 173. A correlation between motor 
deficits in Parkinson’ and abnormal synchronized oscillatory activity, especially in the ‘beta’ 
band width (15-35hz) 174-176, has been shown at multiple levels in the motor circuit, which 
is also suppressed by dopaminergic therapies 177-179. Alterations of basal ganglia 
physiology in Parkinson’s disease, therefore, broadly consist of two elements: an increase 
in the neuronal discharge rate in the STN and globus pallidus internus (GPi) and the 
appearance of synchronized neuronal oscillations 180. A new, dynamic ‘center-surround 
model’ has been proposed with excitatory input from the motor cortex directly influencing 
the STN through the ‘hyper-direct’ pathway and affecting the globus pallidus without 
passing through the striatum 181-184. 
Functional connectivity of the brain can be explored using resting state fMRI. This offers a 
relatively simple and fast approach to map brain functional connectivity and pathological 
neural network changes. The technique does not rely on an experimental task design, 
making data analysis streamlined and less vulnerable to experimental bias 185. 
The time course of low frequency (<0.1 Hz) fluctuations in blood oxygen level-dependent 
(BOLD) signal has a high degree of temporal correlation in functionally connected brain 
areas or ‘nodes’ 186. Multiple statistical modeling techniques, such as seed-based 
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correlation mapping and independent component analysis (ICA), can then be used to 
examine this functional connectivity 185,187. Resting state functional connectivity (fcMRI) has 
been used in various clinical applications 188. For example, selective changes were found 
in individuals at risk of Alzheimer’s disease 189 and also documented in patients with major 
depression 190. Statistically significant positive correlations have been found between fcMRI 
and structural connectivity 191-194. 
Resting state fMRI connectivity changes may relate to the abnormal synchronized 
oscillations in Parkinson’s disease. Evidence for this relation has been demonstrated in 
numerous human and non-human primate studies. Correlation between the slow frequency 
(<0.1 Hz) of the BOLD signal in resting state fMRI and neural electrophysiological activity 
at higher frequencies 195, in the alpha band range 196, the gamma band range 197 and in the 
beta band range 198, provides inference between networks identified using fcMRI and their 
underlying neurophysiological correlates. This relation can be very useful in studying and 
understanding Parkinson’s disease neurophysiology. 
To date, several fcMRI studies have examined the connectivity profile in patients with 
Parkinson’s disease compared to healthy controls and the effect L-DOPA therapy has on 
the connectivity pattern 199-207. The majority of these studies, with the exception of one 206, 
were on patients in the early stages of Parkinson’s disease. Limited information is available 
about the functional connectivity changes that occur later on in the course of the disease 
when complications of chronic L-DOPA therapy, such as levodopa induced dyskinesias 
(LID) and motor fluctuations, emerge. 
Furthermore, patients can have varying degrees of response to L-DOPA in advanced 
Parkinson’s disease. The emergence and progression of L-Dopa refractory signs 
represents one of the most challenging aspects of treating the disease. Furthermore, the 
degree of L-Dopa responsiveness is an important factor in patient selection for STN DBS. 
Greater than 25%–50% improvement in motor  UPDRS (UPDRS III) following ‘L-DOPA 
challenge’ is generally considered a good outcome predictor for STN DBS in Parkinson’s 
disease 208. 
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In this study, a seed-based approach to resting state functional MRI is used to examine 
differences in functional connectivity of the basal ganglia with cortical and subcortical areas 
in relation to the degree of clinical response to L-DOPA challenge in 19 patients with 
advanced Parkinson’s disease and motor fluctuations. Our aim is to identify the fcMRI 
correlates associated with differences in treatment response to better understand the 
underlying neural network activity in advanced Parkinson’s disease. 
3.3: Materials and methods 
3.3.1: Patients 
Nineteen patients who met UK brain bank criteria for idiopathic Parkinson’s disease were 
included (Table 3-1). Patients were recruited from the surgical waiting list for bilateral STN 
DBS after selection by a multidisciplinary team of specialized movement disorders 
neurologists and functional neurosurgeons. All patients underwent a neuropsychological 
assessment and a structural brain MRI to rule out dementia and significant brain atrophy, 
respectively. A formal L-DOPA challenge test was conducted, whereby the motor section 
of the unified Parkinson’s disease rating scale (UPDRS III), was assessed in the OFF state 
at least 12 hours after omitting Parkinson’s disease medications and repeated 30-60 
minutes (or when clinically ON) after administration of the patient’s regular medications 
supplemented with an additional dose of 50mg/12.5mg dispersible Madopar. Inclusion in 
the present study was limited to L-DOPA responsive patients with advanced Parkinson’s 
disease with at least 25% improvement of UPDRS III between off and on medication states 
and who could tolerate lying flat for the duration of the scan. 
3.3.2: Magnetic resonance imaging data acquisition 
Imaging was acquired during admission before DBS surgery. Medications were optimised 
by a specialist neurologist to ensure patients were in the ON- state, with no concurrent 
head tremor or LID at the time of MRI. 3T Siemens Magnetom Trio Tim Syngo MR B17 
was used with a well-padded 32 channel receive head coil to reduce discomfort and head 
motion during the scan. 
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3.3.3: Resting state functional MRI  
Multi-echo Echo Planar Imaging (2D-MEEPI) sequences were obtained in two successive 
acquisitions with a total duration of 15 minutes. Spatial resolution=3×3×2.5 mm3, repetition 
time=60 ms (x 45 slices = 2700 ms), echo time=30 ms, flip angle=90 degrees, field of 
view=192 mm × 192 mm, 45 axial slices (2.5 mm thickness), matrix size=64×64 and a total 
of 512 scans. Patients were given instructions to keep their eyes open and gaze fixed on a 
cross hair  
3.3.4: Structural MRI 
Multiple Parameter Mapping (MPM) sequences 151 were acquired for structural imaging just 
before the functional MRI scan. In brief, the whole protocol consisted of three 3D FLASH 
acquisitions performed with T1, Proton Density (PD), and Magnetization Transfer (MT) 
weighting; these were paired with B1 (transmit field mapping data to correct for the effect 
of inhomogeneous flip angles on the T1 maps) and B0 field map acquisitions. Spatial 
resolution=1×1×1 mm3, repetition time=24.5 ms, multiple echo times, field of view=256 mm, 
flip angle=6 (PD), 21 (T1), 6 (MT) degrees, matrix=256×256, partitions=176; total 
acquisition time of 26 minutes. 
3.3.5: Preprocessing 
The structural scans were processed using the voxel based quantification (VBQ) toolbox 
in SPM12 to generate quantitative maps of multiple tissue properties (MT, PD*, R1 (1/T1) 
and R2* (1/T2*)) 151.  The MT maps, which provide high contrast to noise ratio, were 
segmented to generate white matter, grey matter and cerebrospinal fluid (CSF) maps using 
the ‘Segment’ toolbox in SPM12 152,209. 
The first three scans of each resting state session were discarded. The two sessions were 
concatenated to produce a single 506 scan time-series. Functional volumes underwent 
realignment, unwarping and slice-timing correction. The functional scans of each subject 
were rigidly registered to the anatomical (R1) scans and the corresponding CSF and white 
matter maps. Anatomical scans were then spatially normalized to MNI space (spatial 
  
77 
resolution=2×2×2 mm3); the resultant transformation was further used to normalize the 
functional data. Functional outlier detection was carried out using Artifact Detection Tools 
(ART)-based scrubbing (www.nitrc.org/projects/artifact_detect/). The functional volumes 
were then inspected and smoothing was applied to reduce potential spatial and temporal 
artifacts using an 8 mm full width at half maximum Gaussian kernel.  
In order to reduce spurious sources of variance in the functional data; denoising was carried 
out using component-based noise correction method (CompCor) 210. The temporal time 
series with estimated subject motion (three rotation and three translation parameters, plus 
another six parameters representing their first-order temporal derivatives), as well as the 
BOLD time series within the subject-specific white matter mask (three principal component 
analysis parameters) and CSF mask (three principal component analysis parameters), 
were used as temporal covariates and removed from the BOLD data using linear 
regression. Ultra-low frequency fluctuations in the resulting residual BOLD time series were 
removed using a high-pass filter (1/128s, ≈0.0078 Hz). All processing steps were 
undertaken in MATLAB-based CONN toolbox 211. 
With tremor and dyskinesias as potential sources of motion, the framewise displacement 
(FD) was calculated in order to precisely quantify the degree of motion correction performed 
for each volume of each subject 212.  In order to assess the possibility of movement 
confounding fcMRI analysis, a Pearson correlation was performed between the mean of 
each patient’s FD values and the fcMRI of interest. 
3.3.6: Analysis 
Seed based analysis was performed. Regions of interest (ROI) were defined on the FSL 
Harvard-Oxford cortical structural atlas, the ATAG subthalamic nucleus atlas 213, and the 
ATAG MNI04 basal ganglia atlas. The right and left caudate, putamen, pallidum, STN, and 
thalamus were defined as ROIs for seed-to-voxel and ROI-to-ROI analysis.  Those nodes 
largely incorporate the subcortical elements of the cortical-basal ganglia-thalamic loop 
implicated in motor control 214,215. The paracentral lobules were used in the ROI-to-ROI 
analysis to further explore the strong fcMRI shown in the seed-to-voxel analysis. 
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Bivariate regression coefficients of the ROIs BOLD time series were measured before 
being entered into second-order between subject analysis. The connectivity of each of 
these network nodes to the rest of the brain was individually explored using seed-to-voxel 
analysis.  FcMRI within cortico-basal ganglia-thalamic circuits was also explored using 
ROI-to-ROI analysis. Only the BOLD signal within each subject-specific gray matter mask 
was included in these calculations; normalizing each subject to the aforementioned atlases 
permitted second order analysis. 
General linear models were generated to assess the relationship between the degree of 
improvement after L-DOPA (% improvement UPDRS-III) and connectivity. Thresholds for 
voxel-level height and cluster-level extent were set to a false discovery rate (FDR)-
corrected P-value of <0.05. Seed-level correction was used to apply FDR separately for 
each seed ROI by implementing both a voxel-level height threshold and a cluster level 
extent threshold. Given the changes that occur in fcMRI with age (Ferreira, 2015), the 
primary effect of change in UPDRS III score with medication on functional connectivity was 
investigated while controlling for patient age in the GLM. In order to account for any effects 
related to differences in disease severity at the time of testing, the primary effect of L-dopa 
related change in UPDRS III score on cortico-basal ganglia-thalamic networks was 
investigated while controlling for UPDRS III OFF-medication score. 
 
3.4: Results 
3.4.1: Patients 
Scanning proceeded with no adverse effects. The mean improvement in UPDRS III 
following L-DOPA administration was 26.3 points (60%, SD=20%) [95% confidence interval 
(CI): 21.5–31.1, P<0.0001]. There was no significant difference between the left and right 
UPDRS III OFF hemi-body scores [mean difference 2.4 points, P=0.12]. One patient had 
L-DOPA responsive tremor-dominant Parkinson’s disease (UPDRS III OFF=33, ON=10). 
Mean Mini Mental State Examination Score (MMSE)=29.5/30 (SD=0.6). Modified Hoehn 
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and Yahr Staging was 3-4 for all patients. Mean levodopa equivalent dose (LED) was 1330 
mg (SD=484.5). No significant correlation was found between daily LED and UPDRS-III 
OFF scores (r=0.16, P=0.5) or UPDRS-III improvement during L-DOPA challenge (r=0.32, 
P=0.18 and r=0.25, P=0.31 for raw and percentage change respectively). Detailed patient 
information can be found in Table 3-1.  
 
Table 3-1: Patient information and L-DOPA challenge 
  Range Mean ± Std. Deviation 
Age (yr.) - 41-70 55.5 ± 9.9 
Gender 15M, 4F - - 
Hand dominance 19 RHD   
Disease duration (yr.) - 4-22 11.2 ± 4.4 
Duration of motor fluctuations (yr.) - 1-9 3.4 ± 1.8 
UPDRS III OFF (p) - 20-73 43.8 ± 12.9 
UPDRS III ON (p) - 4-42 17.5 ± 9.9 
Left hemibody UPDRS III OFF (p)  - 4-23 14.2 ± 6 
Right hemibody UPDRS III OFF (p) - 4-20 11.8 ± 4.7 
 
RHD=right hand dominant, M=male, F=female, yr.=year, p=points  
 
3.4.2: Quantification of Motion Correction 
Mean framewise displacement (FD) values ranged from 0.3 mm to 2.8 mm (1.6 ± 0.7 mm). 
No volumes were discarded in preprocessing. There was no statistically significant 
correlation between FD measures and fcMRI calculations. (Table 3-2) 
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Table 3-2: Analysis of potential effects of motion correction (framewise 
displacement, FD) on resting state functional connectivity (fcMRI)* 
 
 
GP-
PL 
Thal
-PL 
STN-
PL 
Put-
PL 
GP-
M1 
Thal
-M1 
STN-
M1 
Put-
M1 
Caud-
MFPC 
Caud-
LPFC 
Put-LPFC 
R 0.05 0.44 0.37 0.01 0.16 0.27 -0.01 0.04 0.13 0.34 0.39 
p-value 0.88 0.18 0.27 0.98 0.64 0.43 0.99 0.90 0.71 0.31 0.24 
 
* For each ROI-to-ROI analysis, a Pearson correlation was performed between 
mean FD values for each patient and the calculated fcMRI values.  
GP = globus pallidus; Thal  = thalamus; STN = subthalamic nucleus; Put = putamen; 
Caud = caudate; PL = paracentral  lobule; M1 = motor cortex; MFPC = medial 
prefrontal  cortex; LPFC = lateral prefrontal  cortex 
 
3.4.3: Basal ganglia and thalamic functional connectivity 
Greater improvement in UPDRS III scores following L-DOPA administration was 
associated with higher fcMRI between the caudate and dorsolateral and medial prefrontal 
cortices and between the putamen and the inferior part of the left dorsolateral prefrontal 
cortex (DLPFC), centered on the inferior frontal gyrus. Greater improvement in UPDRS III 
scores was also associated with lower fcMRI between the basal ganglia and thalamus and 
the sensorimotor cortex, specifically, in the mesial areas with the portions of M1, SMA, and 
S1 residing in the paracentral lobule and superior portion of the cortical convexity. This was 
particularly notable for the pallidum and thalamus, and less prominent for the caudate and 
putamen. (Table 3-3) 
The cluster for STN negative correlations with M1 and S1 was more diffuse. Greater 
improvement in UPDRS III scores was also associated with lower fcMRI between the 
thalamus and the posterior parietal cortex (PPC), between pallidum and PPC, between 
pallidum and lingual and fusiform gyri (visual association area), between STN and right 
PPC, between STN and left superior temporal gyrus, between STN and lingual gyrus, 
cuneus and precuneus (left) and between STN and posterior and caudal anterior cingulate 
cortices. (Figure 3-1) 
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Table 3-3: Functional connectivity of basal ganglia and thalamus with 
paracentral lobule in correlation with UPDRS III reduction following L-DOPA 
administration 
  
Paracentral lobule 
t-score 
FDR corrected P-
value MNI coordinates Cluster Size 
x y z    
STN +32 -16 +56 9445 -3.46 0.0032 
Pallidum +24 -48 +58 10407 -4.03 0.0010 
Caudate +14 -52 +62 2672 -3.72 0.0018 
Putamen -02 -12 +74 2123 -3.36 0.0040 
Thalamus +32 -30 +74 8093 -3.77 0.0017 
 
MNI coordinates represent the centre of gravity of the cortical cluster 
FDR=false discovery rate  
 
Figure 3-1: Functional connectivity changes between cortical areas and 
subthalamic nucleus (A), globus pallidus (B), caudate (C), putamen (D) and 
thalamus (E) in relation to percentage improvement in UPDRS III with L-
DOPA administration using a seed-to-voxel analysis  
 
Colour scale represents t score values 
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Figure 3-2: Connectivity graph showing ROI-to-ROI analysis (t-score) 
against improvement in UPDRS III following L-DOPA administration 
 
 
Line colors and width reflect the strength and polarity of connectivity as 
designated in the heat bar (correlations represented in orange and red; and anti-
correlations represented in blue).   The nodes on the perimeter of the 
connectivity circle are labeled and their colors correspond to those il lustrated 
on the adjacent brain images. 
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ROI-to-ROI analysis showed that UPDRS III improvement with L-DOPA was positively 
associated with higher fcMRI between the caudate and the thalamus [t=3.27, corrected-
p=0.03] and the caudate and the pallidum (t=3.38, corrected-p=0.01), on the left. A similar 
trend was also seen on the right side between the caudate and the thalamus but did not 
reach statistical significance after correcting for multiple comparisons (t=2.60, corrected-
p=0.07. (Figure 3-2). 
3.5: Discussion 
In In this work, resting state functional MRI was used to examine basal ganglia and thalamic 
functional connectivity in patients with advanced Parkinson’s disease. Employing seed-to-
voxel and ROI-to-ROI approaches, associations with the degree of response to L-DOPA 
were demonstrated. After adjusting for age and disease severity (baseline UPDRS III), 
significant associations were evident between L-dopa responsiveness and fcMRI between 
basal ganglia and cortex, and within basal ganglia and thalamus. The degree of response 
to L-DOPA, as measured by improvement of UPDRS III scores, was associated with 
increased fcMRI between the striatum and thalamus (caudate-pallidum and caudate-
thalamus) and between the striatum and the PFC. The degree of response to L-DOPA was 
inversely associated with increased fcMRI between the thalamus, pallidum and STN and 
the paracentral lobule and parieto-occipito-temporal association areas.  As there was no 
significant correlation between movement correction measures and fcMRI, it is more likely 
that these findings are the result of inherent differences in the basal ganglia-thalamic-
cortical networks than the result of differences in patient movement. 
Daily LED did not appear to correlate significantly with the degree of UPDRS-III response 
during the L-DOPA challenge or with the baseline UPDRS-III scores. This is likely due to 
the unpredictable bioavailability of dopamine in the brain following oral administration of 
levodopa mediated by erratic intestinal absorption, metabolism and transport across the 
blood brain barrier 216-218.  Levodopa dose was therefore discounted from the analysis. 
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A consistent pattern of change in metabolic activity in Parkinson’s disease has been 
described previously in PET studies. Disease progression is often associated with 
increasing metabolism in the STN, GPi and thalamus as well as in the dorsal pons and M1, 
which progresses to declining metabolism in the PFC, SMA and inferior parietal regions. 
This pattern is shown to be reproducible and is referred to as a Parkinson’s disease related 
covariance pattern (PDRP) 219-221. Studies that used task-based fMRI to examine the 
activation patterns of the motor network in Parkinson’s disease patients showed cortical 
activation abnormalities centered on a fronto-parietal cortical network comprising the pre-
SMA, M1, and posterior parietal cortex, partially reversed with L-DOPA. Inconsistent 
results, potentially a consequence of disparities in selection and timing of the applied tasks, 
were found in those studies. 222. 
Other studies have looked at group changes in activation in early or advanced PD patients 
in the presence and absence of L-dopa therapy, but none have sought to directly analyze 
the relationship between functional connectivity and degree of L-dopa response. 
In a study that examined fcMRI changes in Parkinson’s disease, a reduction in connectivity 
between the SMA, left dorsolateral PFC and left putamen was demonstrated. This 
connectivity pattern correlated with UPDRS III and was relatively normalized following L-
DOPA administration 199. Decreased connectivity between the PFC and the left putamen, 
right insula, right PMA, and left inferior parietal lobule was also demonstrated in another 
study of 18 Parkinson’s disease patients and matched controls 202. We showed in the 
present study that an increase in resting functional connectivity between the PFC, mostly 
in the inferior frontal gyrus (IFG), and the striatum was associated with a better response 
to L-DOPA. The IFG role is well described in the behavioral (proactive) inhibition network 
223-229. It has also been implicated in the pathogenesis of L-DOPA-induced dyskinesias 
(LID), possibly a reflection of motor inhibition network failure. Transcranial magnetic 
stimulation (TMS) over the right IFG reduces the extent of dyskinesia induced by a supra-
maximal single dose of L-DOPA 206. 
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Changes in fcMRI between the STN, M1, SMA and PMA have been previously described 
in Parkinson’s disease compared to controls. In a study of fcMRI of the STN in 31 
Parkinson’s disease patients with early stage disease during the medication-off state 
compared to 44 healthy controls, connectivity was increased to M1, SMA and PMA. A 
tremor-dominant subgroup showed localized increase in connectivity between the STN and 
hand area of M1 and the primary sensory cortex. In a non-tremor subgroup, increased 
connectivity was found between the STN and mesial cortical motor areas including the 
SMA 201. 
The pattern of fcMRI changes shown in our study is supported by findings from a recent 
study that looked at differences in ‘networks’ identified on independent components 
analysis (ICA) in 27 Parkinson’s disease patients and 16 controls. Significant functional 
connectivity increase in patients, between the sensorimotor network and the spatial 
attention network in the parietal cortex, was found and was correlated with UPDRS III 207. 
Furthermore, L-DOPA has been shown to restore fcMRI in the sensorimotor network, 
especially in the SMA, when administered to drug-naïve patients 204. 
Our analysis did not show a statistically significant correlation between improvement in 
UPDRS III and change in fcMRI between the putamen and the inferior parietal cortex. 
However, changes in fcMRI between these areas have been shown in Parkinson’s disease 
patients when compared to controls 200. 
We have shown that reduced resting functional connectivity between the striatum, pallidum 
and the thalamus is associated with a worse response to L-DOPA. It is conceivable that 
this finding is a result of the breakdown of segregation within the basal ganglia and the 
emergence of oscillatory activity within the sensorimotor network with dopamine depletion 
173. This pattern of fcMRI abnormality was also demonstrated in a study that focused on 
the functional connectivity between the striatum, thalamus and the brainstem. In that study, 
13 patients with advanced Parkinson’s disease compared with 19 controls showed lower 
functional connectivity patterns with the thalamus, midbrain, pons and cerebellum. A 
progressive ‘gradient’ of altered connectivity (posterior putamen > anterior putamen > 
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caudate) was observed in keeping with the pattern of dopaminergic loss in the 
pathogenesis of PD 203. 
The shared findings of studies that investigated the way fcMRI is influenced by L-DOPA in 
Parkinson’s disease 199-205,207, point towards an abnormal fcMRI pattern which is relatively 
restored following L-DOPA administration. We propose that the contrasting patterns of 
functional connectivity that we have observed in association with L-DOPA responsiveness 
are a reflection of the relative degrees of normalization of functional connectivity with 
dopamine therapy. On the one hand, improvement of motor symptoms with L-Dopa was 
associated with increased resting functional connectivity between the striatum and the 
DLPFC and IFC; and on the other hand with decreased resting functional connectivity of 
the STN and pallidum with the paracentral lobule and parieto-occipito-temporal association 
areas. It has been previously shown that PD patients can suppress involuntary movements 
albeit for short periods of time 230. Given that we examined functional connectivity in the 
resting state, when patients were instructed to remain at rest and refrain from making any 
movements, the observed pattern of increased caudate-DLPFC/IFC functional connectivity 
with greater L-Dopa responsiveness may potentially reflect engagement of a goal-directed 
proactive inhibition network to withhold voluntary movement 229,231.  By contrast, the 
negative association between L-Dopa responsiveness and functional connectivity of the 
STN and pallidum with the M1 and posterior association areas may reflect engagement of 
a more ‘reactive’ inhibition pathway via the hyperdirect pathway 229,231 for withholding 
movements during the resting MRI in those with a worse response to levodopa medication. 
However, further work is needed to support this proposition.  
Increased functional connectivity between the thalamus and the sensorimotor cortex has 
been previously demonstrated in fcMRI studies comparing PD patients to healthy controls 
232. This is consistent with primate models of PD where there is increased activity in the 
ventrolateral thalamus 215. In our study, we demonstrated a negative correlation between 
thalamic-sensorimotor fcMRI and the response to L-DOPA. This once again supports the 
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hypothesis that in poor responders there is reduced fcMRI normalisation to dopamine than 
in good responders. 
The validity of negative correlations, or anticorrelations, as neurophysiological findings in 
fMRI data has been a subject of debate. Analytic artifacts may arise from carrying out global 
signal regression to remove confounds due to noise in the BOLD time series, leading to 
anticorrelations even when they are not truly present 233-235, 236. This had led to a widely 
accepted consensus not to interpret those findings when using global signal regression 
233,237. In our analysis, however, we applied the CompCor method of noise reductions, 
which does not rely on global signal regression and which has been shown to have higher 
sensitivity and specificity 238. It is believed that the use of the ComCor method can generate 
valid anticorrelations between brain networks in fMRI 211. We consider that the findings of 
negative correlations between subcortical and cortical areas in relation to the degree of 
response to L-DOPA here may have sound neurophysiological basis. 
3.5.1: Limitations 
All our patients were on optimal L-DOPA medication at the time of the MRI scan. For this 
reason, we cannot make any inferences on the acute effects of L-DOPA on the underlying 
pathophysiology as was demonstrated in other reports that compared changes in fcMRI 
before and after L-DOPA administration. 199-207. In contrast with the majority of these reports 
our patients had advanced Parkinson’s disease with severe motor fluctuations and, not 
infrequently, freezing of gait. We opted to only scan the patients in the ON state with their 
usual treatment regime firstly to reduce patient discomfort during the MRI scan and 
secondly to reduce motion artefact, which may degrade the quality of the resulting fMRI 
scans. 
Another limitation associated with fcMRI techniques is that the technique is largely limited 
to group-level analysis. While this is useful in exploring group-wise changes, inferences on 
the individual level cannot be readily made, especially on a diagnostic/predictive capacity. 
This may limit the clinical application of the technique in individual patients. 
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Our analysis focused on fcMRI changes between cortico-subcortical structures in 
Parkinson’s disease. We employed prior knowledge to define basal ganglia structures as 
ROIs for connectivity analysis. We have not explored cortico-cortical fcMRI changes and 
our findings, therefore, are limited to networks that include those predefined ROIs. 
3.6: Conclusion 
Differences in functional connectivity patterns of the basal ganglia, as mapped using resting 
state fMRI, are associated with different degrees of response to L-DOPA therapy in patients 
with advanced Parkinson’s disease, at the group level. This is consistent with the 
hypothesis that the clinical effects of dopamine are a result of remapping of functional 
connectivity. Networks linked to cognitive (proactive) motor inhibition show relatively higher 
connectivity whilst networks linked to reactive motor inhibition show lower connectivity with 
better dopamine response. Furthermore, connectivity is relatively stronger in between 
basal ganglia structures with better dopamine response. Future studies may be able to 
validate these results and explore markers at the ‘individual level’ by employing machine 
learning algorithms to build predictive models of response to treatment, thus validating, or 
even corroborating the L-DOPA challenge test. The next step will be to explore the 
functional connectivity correlates predictive of response to STN DBS in this group once 
data become available. This could potentially aid with patient selection and help with 
understanding the mechanism of action of DBS. 
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4. Subthalamic deep brain stimulation sweet spots and 
hyperdirect cortical connectivity in Parkinson’s disease 
4.1: Abstract 
The optimal stimulation site for subthalamic nucleus deep brain stimulation remains ill-
defined. Previous studies disagree on whether contacts within the nucleus, or superior to 
it, give best improvement in motor symptoms. Furthermore, the role cortical connectivity 
has with respect to predicting the success of deep brain stimulation is yet to be established. 
Here, we aimed to identify subthalamic region stimulation clusters that predict maximum 
improvement in rigidity, bradykinesia and tremor, or emergence of side-effects; and 
secondly, to map-out the cortical fingerprint, mediated by the hyperdirect pathways that 
predict maximum efficacy. 
High angular resolution diffusion imaging in 20 patients with advanced Parkinson’s disease 
was acquired prior to bilateral subthalamic nucleus deep brain stimulation. All contacts 
were screened one-year from surgery for efficacy and side-effects at different amplitudes. 
Voxel-based statistical analysis of volumes of tissue activated models was used to identify 
significant treatment clusters. Probabilistic tractography was employed to identify cortical 
connectivity patterns associated with treatment efficacy. 
All patients responded well to treatment (46% mean improvement off medication UPDRS-
III [p<0.0001]) without significant adverse events. Cluster corresponding to maximum 
improvement in tremor was in the posterior, superior and lateral portion of the nucleus. 
Clusters corresponding to improvement in bradykinesia and rigidity were nearer the 
superior border in a further medial and posterior location. The rigidity cluster extended 
beyond the superior border to the area of the zona incerta and Forel-H2 field. When the 
clusters where averaged, the coordinates of the area with maximum overall efficacy was 
X=-10(-9.5), Y=-13(-1) and Z=-7(-3) in MNI (AC-PC) space. Cortical connectivity to primary 
motor area was predictive of higher improvement in tremor; whilst that to supplementary 
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motor area was predictive of improvement in bradykinesia and rigidity; and connectivity to 
prefrontal cortex was predictive of improvement in rigidity. 
These findings support the presence of overlapping stimulation sites within the subthalamic 
nucleus and its superior border, with different cortical connectivity patterns, associated with 
maximum improvement in tremor, rigidity and bradykinesia. 
4.2: Introduction 
Subthalamic nucleus (STN) high frequency stimulation is an established treatment in 
selected patients with advanced Parkinson’s disease (PD) 8,239,240. The STN is thought to 
comprise functional subdivisions implicated in motor, associative and limbic functions with 
degrees of overlap 241-246. The motor subdivision occupies the so-called ‘dorsolateral’ 
aspect; nevertheless, the most effective target location has been contended. Authors have 
argued that contacts within the ‘dorsolateral-STN’ give the biggest improvement in UPDRS-
III66,76,77; others have maintained that contacts ‘dorsal’ to the STN, in the zona incerta (ZI) 
area and Forel-H2 field, have superior efficacy 142,247-253. A third group found both locations, 
or border contacts to be equally effective 246,254-258. 
This discrepancy is attributed to several factors. One is reliance on surrogate markers such 
as microelectrode recording 76,142,248,249,252,254,256-258 and non-specific atlas coordinates or 
deformable atlases 142,246,248,249,251,254,256,257 to identify the STN borders, not readily 
discernible on low or intermediate field MRI 259. Another is using postoperative CT instead 
of stereotactic-MRI to confirm contact location within the target, overlooking errors 
introduced by brain shift or image co-registration 60,260. Complicating matters further, is the 
STN’s peculiar contour, double-oblique orientation and position within a junctional area 
where anatomical terms of location change, rendering localization description within the 
STN ambiguous 64,261,262. The term “dorsal”, used when referring to the STN, is 
synonymous with “posterior” in the pons and “superior” in the thalamus 263. Here we use 
unambiguous anatomical terms (superior/ inferior) to describe location within the STN. 
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Lastly, overlooking the volume of tissue activated (VTA) and only examining centre of 
active contacts location ignores the effect contacts adjacent to the nucleus might have on 
nuclear cell bodies dendrites, as well as axons within the white matter outside the nucleus 
264-269 and limiting the comparison to the most effective contacts that landed in the chosen, 
predetermined target. 
A proposed mechanism of action of STN-DBS is through interrupting synchronised 
oscillations between STN and cortex 173-180 possibly through modulation of hyperdirect 
pathways 172,181-184,215,242,243,270-272. The objectives of this study were to identify the optimal 
STN stimulation site separately for improvement in rigidity, bradykinesia and tremor; 
identify stimulation sites accountable for common side-effects encountered with STN-DBS 
one-year after surgery; and explore the cortical connectivity or fingerprint of stimulation 
volumes, through these hyperdirect pathways, in a bottom-up fashion, by proceeding 
stepwise through the following aims: 
 
1. To create a group specific STN template by manually delineating, co-registering and 
averaging individual subthalamic nuclei 
2. To screen all DBS contacts at amplitudes of 1,2,3 and 4 Volts for contralateral 
improvement in rigidity, bradykinesia and tremor; and emergence of side-effects 
3. To generate VTA models for all DBS contacts at these amplitudes 
4. To carry out a voxel based morphometry (VBM) style regression analysis of modelled 
VTAs and their associated efficacy and side-effect profiles 
5. To use probabilistic tractography from modelled VTAs of all DBS contacts to predefined 
cortical areas excluding tracts passing through the thalamus and striatum and only 
including tracts passing through the internal capsule (hyperdirect pathway) 
6. To generate a DBS-cortical connectivity matrix, using the output from the previous step, 
to test the predictive significance of cortical connectivity 
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4.3: Materials and methods 
4.3.1: Patients 
Twenty patients (four female), who met UK Brain Bank criteria for idiopathic Parkinson’s 
disease 273, were included (Table 4-1). Patients on the surgical waiting list for bilateral STN-
DBS were recruited after selection by a multidisciplinary team of specialized movement 
disorders neurologists and functional neurosurgeons. All patients underwent formal 
neuropsychological assessment and structural brain MRI to rule out dementia and 
significant brain atrophy, respectively. Patients underwent L-DOPA challenge test during 
the routine selection process. Those with an improvement <25% on the UPDRS-III were 
excluded.  Inclusion in the present study was limited to patients who could tolerate and had 
no contraindications to a prolonged 3T-MRI scan. 
4.3.2: Preoperative magnetic resonance imaging data acquisition 
Imaging was acquired with patients in the ON-medication state, with no concurrent head 
tremor or dyskinesia. Imaging was performed on a 3T Siemens Magnetom Trio Tim Syngo 
MR B17 using a 32 channel receive head coil. Padding was used inside the head coil to 
reduce discomfort and head motion during the scan. 
4.3.3: Diffusion weighted MRI 
Details of diffusion weighted MRI acquisition and preprocessing are described in the 
general methods sections.  
4.3.4: Surgical procedure and intraoperative magnetic resonance imaging data 
acquisition 
Bilateral DBS (3389 Medtronic lead) implantation was performed under GA using a 
stereotactic MRI-guided and MRI-verified approach without microelectrode recording 
(Leksell frame G, Elekta) as detailed in previous publications  274,275. Two stereotactic, pre-
implantation scans were acquired, as part of the surgical procedure, to guide lead 
implantation; a T2-weighted axial scan (partial brain coverage around the STN) with voxel 
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size of 1.0×1.0 mm2 (slice thickness=2 mm) and a T1-weighted 3D-MPRAGE scan with a 
(1.5 mm)3 voxel size on a 1.5T Siemens Espree interventional MRI scanner. Three-
dimensional distortion correction was carried out using the scanner’s built-in module. 
Target for the deepest contact was selected at the level of maximal rubral diameter (~5 mm 
below the AC-PC line). To maximise DBS trace within the STN, the target was often chosen 
1.5 - 2 mm posterolateral to that described by Bejjani 276. Stereotactic imaging was 
repeated following lead implantation to confirm placement. A dual channel implantable 
pulse generator (IPG) (Activa PC, Medtronic, Minneapolis, Minn., USA) was then implanted 
in the infra-clavicular region on the same day of lead implantation or within a week, as a 
staged procedure. 
4.3.5: Outcome measures 
4.3.5.1: DBS contact efficacy and side-effect profile screening 
DBS efficacy and side-effects screening was performed one-year from surgery. 
Medications were withdrawn for twelve-hours before assessment. DBS was switched off 
and after a five to ten-minute washout period, hemi-body (upper limb) rigidity, bradykinesia 
and tremor scores were assessed and rated from 0-4 (0=normal, 1=slight, 2=mild, 
3=moderate and 4=severe). Once baseline scores were documented, all contacts were 
screened one at a time using monopolar stimulation in four stimulation sessions with 
amplitudes of 1, 2, 3 and 4 volts, frequency of 130 Hz and pulse width of 60 µs until the 
effect was established. A washout period was allowed between stimulation sessions until 
baseline was reached. Scores were reassessed for every session whilst evaluating the 
emergence and progression of stimulation-related side-effects (i.e. facial pulling, 
dysarthria, diplopia and paraesthesia). An example screening sheet is provided in 
Appendix 2.  
4.3.5.2: DBS contacts volume of tissue activated (VTA) modelling 
Specific VTA thresholds were calculated for every electrical setting, taking into 
consideration the specific stimulation configuration, amplitude and pulse width as described 
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by Åström and colleagues, in order to generate DBS therapy VTA 162. Intraoperative (pre- 
and post-implantation) stereotactic scans were co-registered. Scans were first manually 
aligned to a pre-implantation MPRAGE scan, before running automated co-registration with 
a restricted volume of fusion centred around the diencephalon/ mesencephalon. This was 
carried out to minimise registration error resulting from eventual brain shift incurred during 
surgery, despite minimal brain shift with our surgical technique 260. Registration accuracy 
was carefully inspected and the process iterated if necessary. 
Pre-implantation T2-weighted stereotactic scans were used to generate STN meshes. Two 
experienced practitioners (HA a functional neurosurgeon and PM a movement disorders 
neurologist) carried out the process independently with <15% interrater variability in 
identifying the boundaries of the STN across patients. The post-implantation MPRAGE was 
used to fit the DBS lead model within the MRI artefact produced by the leads. Individual 
VTAs were then generated around each DBS contact with voltages of 1, 2, 3 and 4 volts 
resulting in 32 VTAs per patient. 
4.3.6: Image Pre-processing 
Pre-implantation MPRAGE scans were brain extracted using BET (Brain Extraction Tool, 
FSL v5.0) 277. A two-step procedure was used to register native scans to the MNI152 
standard-space T1-weighted average structural template image (1mm resolution) 278. The 
first step employed a linear (affine) transformation using FLIRT (FMRIB's Linear Image 
Registration Tool) using 12 degrees of freedom 279,280. The output from this step was used 
to execute non-linear registration (second step) using FNIRT (FMRIB's Non-Linear Image 
Registration Tool) 281. This process produced individual native-to-standard (MNI space) 
non-linear warp fields which were then applied to the STN and VTA volumetric meshes 
acquired from SureTune to transform all volumes to standard space. 
4.3.7: Analysis 
4.3.7.1: Model of VTAs and efficacy scores 
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Group-average, bilateral STN templates and total VTA areas were generated from 
standardised (MNI space) individual STN volumes and DBS contacts VTAs using Fslmaths 
(FSL5.0) (Figure 4-1 and Figure 4-2). 
Right sided individual contact VTAs were lateralised to the left by flipping the images along 
the x axis (x, y, z > -x, y, z) using Fslswapdim (FSL5.0). All VTAs were then merged using 
Fslmerge (FSL5.0) into a 4D data file. In each voxel, each of the VTAs (one for each of the 
32 different stimulation conditions) was modelled as a linear combination of efficacy scores, 
and side-effects (0=absent, 1=transient or 2=persistent) within subject. A general linear 
model (GLM) was created with efficacy and side-effects variables to test against each voxel 
in corresponding VTAs in a single-group average design (each variable was tested 
individually). This analysis was carried out for each subject independently. The variables 
were demeaned and single group t-test with threshold-free cluster enhancement (TFCE) 
was used as test statistic 164. Nonparametric permutation inference approach, similar to 
that commonly used for VBM and fMRI time series analysis, was carried out for each voxel 
using Randomise (FSL5.0) with 5000 permutations to build up the null distribution to test 
against as previously described 165. Raw t-stat (t statistic) images were then masked by the 
significant voxels from thresholded (α=0.05) t-stat images, also corrected for multiple 
comparisons. The resultant images from each subject were combined to form a group 
average. Cluster-based inference using Cluster (FSL5.0) was carried out to extract the 
clusters and local maxima in outputs. 
4.3.7.2: Tractography 
Probabilistic tractography was generated in ProbtrackX2 GPU version (Behrens 2007) 282 
(FSL5.0) (number of samples=5,000, curvature threshold=0.2, step length=0.5 mm 
subsidiary fibre volume fraction threshold=0.01) 283. 
The combined (total) VTA areas were used to generate tractography (in MNI space) for the 
left and right hemispheres; additionally, tracts were generated from combined efficacy 
clusters instigating improvement in bradykinesia, tremor and rigidity as generated from the 
voxel-based morphometry (VBM) style DBS-contact VTA analysis in Randomise (FSL5.0). 
  
96 
Waypoints were used in the internal capsule to isolate the streamlines to three cortical 
target areas; (1) primary motor cortex (M1 [Brodmann’s area 4]), (2) supplementary motor 
area (SMA) [Brodmann’s area 6] and (3) prefrontal cortex (PFC). CSF termination and mid-
sagittal exclusion masks were applied to exclude false positive streamlines and 
commissural tracts respectively. To improve connectional contrast between the three 
targets, each of them was used as a target, while the other two were used as exclusion 
masks. For instance, to track the STN-M1 pathway, M1 was used as target, while SMA and 
PFC were used as exclusion masks. This ensured that the tracked connection contained 
paths connecting STN to M1, and at the same time not connecting STN to any of the other 
two targets. Similarly, for the other two target regions. 
4.3.7.3: DBS-Cortical connectivity 
A connectivity matrix was generated between all seed points in the combined (total) VTA 
area mask and all points in the cortical target masks (i.e. M1, SMA and PFC) using the 
output from tractography. The streamline counts for each voxel were normalised by the 
total number of streamlines reaching all targets to acquire a proportional measure. A t-
statistic was used to calculate the connectivity within the individual DBS-contact VTAs 
(inside) versus the connectivity outside the contact VTAs but within the combined (total) 
group average VTA and this value was used in subsequent regressions (denoted as CON). 
This value effectively reflected connectivity of voxels activated in a certain stimulation 
condition, using connectivity in inactive STN voxels as a baseline. An in-house MATLAB 
(MathWorks Inc.) script was used to test the relationship between the cortical connectivity 
of individual DBS-contact VTA voxels and the improvement in efficacy associated with each 
DBS-contact VTA. To account for the effect of VTA volume and stimulation amplitude on 
efficacy, these factors were used as nuisance covariates in the regression analysis. 
Efficacy for alleviation of a particular symptom was then modelled as a linear combination 
of the connectivity values to each of the three target areas, VTA volume and stimulation 
voltage, as shown below. Alleviation of three symptoms was individually explored (tremor, 
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bradykinesia and rigidity). All the explanatory variables (EVs) were normalised (demeaned 
and standard deviation made equal to 1), so that: 
 
Efficacy = b0 + b1×CONVTA →M1 + b2×CONVTA→ SMA + b3×CONVTA→PFC + 
b4×VOLTAGE + b5×VTA_VOLUME 
 
CON: connectivity; VTA: volume of tissue activated; M1: primary motor area; PFC: 
prefrontal  cortex; SMA: supplementary motor area,  b0-b5: unknown model  
parameters. 
 
4.4: Results 
4.4.1: Patients 
Scanning proceeded with no adverse effects. The mean pre-operative mini-mental score 
(MMS) was 29.6 (SD=0.6, Range=2). One patient had tremor-dominant PD without motor 
fluctuations. Six patients had no significant tremor and were therefore excluded from the 
tremor VTA efficacy and cortical connectivity analysis, but included in the rigidity and 
bradykinesia analyses. There was no surgical morbidity or mortality and all DBS leads 
landed within a mean (SD) of 0.8 (0.4) mm from the planned target. Patient demographics, 
improvement in UPDRS-III following L-DOPA administration (L-DOPA challenge, 
preoperatively), improvement in UPDRS-III one-year from surgery with DBS ON and OFF 
medications and change in L-DOPA equivalent daily dose are shown in Table 4-1. 
4.4.2: VTA Modelling 
Group average, statistically significant clusters correlated to stimulation efficacy and side-
effect EVs within and around the STN are shown in Figure 4-2 and Figure 4-3. 
Improvement in bradykinesia, rigidity and tremor with DBS was associated with VTA 
clusters in the posterior, superior and lateral STN with the bradykinesia and rigidity areas 
extending to the superior border and being more medial and posterior than that of tremor. 
The three clusters were averaged into a single area in the superior and lateral STN with 
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maximum intensity at X=-10(-9.5) Y=-13(-1) and Z=-7(-3) in MNI (AC-PC) space. Facial 
pulling was associated with VTA cluster in the region of the corticobulbar fibres. Acute 
dysarthria was associated with VTA cluster in the internal capsule. Diplopia was associated 
with the VTA cluster in the region of the mesencephalic oculomotor nerve fibres in the 
tegmentum. Paraesthesia was associated with the VTA cluster in the mid-portion and 
inferior STN. See Table 4-2 for cluster volumes and MNI coordinates. 
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Table 4-1: Patient demographics, preoperative L-DOPA challenge, 
postoperative change in UPDRS III and medication requirement 
 Mean SD SE Minimum Maximum Range 
Age* 56.3 10.2 2.3 41 71 30 
Disease duration* 11.2 4.3 1.0 4 22 18 
Duration of motor fluctuations* 3.1 2.0 0.4 0 9 9 
UPDRS III OFF (LC) 43.8 13.0 3.0 20 73 53 
UPDRS III ON (LC) 17.4 9.9 2.3 4 42 38 
UPDRS III Improvement (LC) 
95% CI:21.6-31.3, t:11.4, df:18, 
p<0.0001ϯ 
26.5 
(61%) 
10.1 
(15.8%) 
2.3 
(3.6%) 
7 
(33%) 
47 
(91%) 
40 
(58%) 
UPDRS III (OFF Med. OFF DBS) ** 50.5 17.2 3.9 24 96 72 
UPDRS III (OFF Med. ON DBS) ** 27.1 12.5 3.0 14 51 37 
UPDRS III Improvement** 
95% CI:16.8-29.4, t:7.5, df:16, 
p<0.0001ϯ 
23.4 
(46%) 
12.8 
(17.4%) 
3.1 
(4.2%) 
8 
(22%) 
45 
(73%) 
37 
(51%) 
UPDRS III ON Med. OFF DBS** 27.6 14.1 3.2 10 62 52 
UPDRS III ON Med. ON DBS** 13.3 9.1 2.2 3 34 31 
UPDRS III Improvement** 
95% CI:10.4-18.3, t:7.6, df:17, 
p<0.0001ϯ 
14.3 
(52%) 
8.0 
(17.4%) 
1.9 
(4.1%) 
41 
(9%) 
28 
(81%) 
24 
(62%) 
LEDD (Preoperative) 1365.6 509.8 114 540 2550 2010 
LEDD (Postoperative) 770.6 306.6 68.6 320 1266 946 
LEDD Reduction with DBS 
95% CI: 386.3-803.8, t:6, df:19, 
p<0.0001ϯ 
595 
(44%) 
203.2 
(39.9%) 
45.4 
(39.8%) 
220 
(40.7%) 
1284 
(50.4%) 
1064 
(52.9%) 
 
*: At surgery; **: At 12 months; ϯ:  2-tailed paired-t test; CI: Confidence Interval;  
Med: Medications; SD: Standard deviation; SE: Standard error; df: degrees of 
freedom; LC: L-DOPA Challenge (preoperative); LEDD: L-DOPA equivalent daily 
dose 
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Figure 4-1: STN and VTA modelling, co-registration and analysis pathways 
 
The graph on the left shows examples of STN, DBS lead and VTA modelling in SureTune package. Transformation from native space to  
MNI space is  shown for STN and VTA models. Tractography to M1 is shown in red,  to SMA in blue and to PFC in green.  The graph on the 
right shows group average STN in green and total VTA area in red-yellow (IC: internal capsule; PFC: prefrontal cortex; SMA: supplementary 
motor area; M1: primary motor area; VTA: volume of tissue activated)
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Figure 4-2: Volume of t issue activated significant clusters for maximum 
efficacy and emergence of side effects of subthalamic nucleus deep brain 
stimulation (z coordinate is in MNI space) 
 
 
Group average STN is shown in green
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Table 4-2: Volume of t issue activated significant clusters with maximum 
effect and centre of gravity coordinates in MNI and corresponding AC-PC 
space 
 
VTA: Volume of tissue activation; VOL: Volume; P-VAL: p-value; AC: anterior 
commissure; PC: posterior commissure 
 
 
Table 4-3. Model parameters that significantly contribute to the efficacy 
prediction 
 Con STN-M1 
(b1>0) 
Con STN-SMA 
(b2>0) 
Con STN-PFC 
(b3>0) 
Voltage 
(b4>0) 
VTA-Volume 
(b5>0) 
Rigidity p=0.035 p=0.0006 p=0.005 p=10-6 p=0.02 
Bradykinesia p>0.05 p=0.005 p>0.05 p=0.001 p>0.05 
Tremor p=0.04 p>0.05 p>0.05 p=10-7 p>0.05 
 
P values correspond to testing each parameter being different from zero.  
Con: connectivity
 
VTA Cluster 
VOL 
(mm3) 
P-VAL 
Maximum effect coordinates 
MNI (AC-PC) 
Centre of gravity coordinates 
MNI (AC-PC) 
X Y Z X Y Z 
Rigidity 62 0.006 -9 (-8.5) -13 (-1) -7 (-3) -11 (-10.5) -15 (-3) -7 (-3) 
Bradykinesia 6 0.037 -11 (-10.5) -14 (-2) -7 (-3) -11 (-10.5) -14 (-2) -7 (-3) 
Tremor 11 0.014 -11 (-10.5) -12 (0) -6 (-2) -12 (-11.5) -12 (0) -6 (-2) 
Combined 26 - -10 (-9.5) -13 (-1) -7 (-3) -11 (-10.5) -14 (-2) -7 (-3) 
Facial pulling 77 0.012 -11 (-10.5) -19 (-7) -1 (3) -12 (-11.5) -18 (-6) -2 (2) 
Dysarthria 149 0.002 -17 (-16.5) -12 (0) -5 (-1) -15 (-14.5) -11 (1) -2 (2) 
Diplopia 185 0.002 -7 (-6.5) -12 (0) -15 (-11) -7 (-6.5) -16 (-4) -12 (-8) 
Paraesthesia 475 0.002 -10 (-9.5) -20 (-8) -18 (-14) -11 (-10.5) -15 (-3) -12 (-8) 
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Figure 4-3: Volume of t issue activated significant clusters of subthalamic 
nucleus deep brain stimulation (MNI–Z = -7mm) * 
 
* Group average STN is shown in green. All clusters were corrected for multiple 
comparisons using non-parametric (gold-standard) approaches 
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4.4.3: Tractography 
4.4.3.1: Tractography from combined, group average, entire VTA area 
Six tracts were generated for each patient starting from the entire average VTA seed mask 
and ending in one of the predefined cortical targets in both hemispheres. Tracts to M1 
ended mostly medially extending to the hand area. Group averages were produced for 
each tract class. The resulting six group average tracts are shown in Figure 4-4. 
4.4.3.2: Tractography from bradykinesia, rigidity and tremor efficacy clusters 
Eighteen tracts ([3 efficacy seed clusters × 3 cortical targets] × 2 hemispheres) for each 
patient were generated using seed masks corresponding to efficacy clusters in the STN as 
shown in Figure3. Tract group averages were again produced for each tract class (i.e. 
individual efficacy clusters to M1, SMA and PFC). Only tracts ending in the medial aspect 
(superior frontal gyrus) of M1, SMA and PFC survived. This is shown in Figure 4.4. 
 
 Figure 4-4: Group average tractography: from the combined overall 
average VTA mask– left and from the combined efficacy clusters - right to 
M1 (red), SMA (blue) and PFC (green) 
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4.4.4: DBS-Cortical connectivity analysis 
Rigidity, bradykinesia and tremor had different VTA-cortical connectivity predictive profiles. 
Table 4-3 shows which model parameters significantly contribute to predicting efficacy for 
each symptom.  In the case of rigidity, connectivity to SMA (b2~32 [p=0.0006]) and PFC 
(b3~26 [p=0.005]) were highly significant. The effect was about half of that explained by 
voltage (b4~53 [p<0.0001]). For bradykinesia only connectivity to SMA was highly 
significant (b2~23 [p=0.005]). The effect was about two-thirds of that explained by voltage 
(b4~34 [p=0.001]). In the case of tremor, connectivity to the primary motor area was 
significant (b1~27 [p=0.04]). The effect was about a third of that explained by voltage (b4~80 
[p<0.0001]). 
Figure 4-5 shows the relationship between connectivity and efficacy for different 
stimulation amplitudes. Even if stimulation amplitude is a strong predictor of efficacy in all 
cases, the effect of connectivity can be also seen, particularly for rigidity and bradykinesia. 
For rigidity we can observe an upward trend for the efficacy as a function of the median 
connectivity to SMA. Particularly for intermediate voltages (2 and 3 Volts), being at an STN 
sub-region with higher connectivity to SMA leads to higher efficacy in alleviating rigidity. 
For bradykinesia, there is not a clear trend for high voltages (3 and 4 volts), but low/medium 
stimulation (1 and 2 volts) seems to benefit from being at a location with a high SMA 
connectivity. Thus, when voltage is low, exact contact location within the STN really 
matters. The profiles for tremor are much noisier and voltage amplitude clearly determines 
efficacy in this case. 
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Figure 4-5: Plots showing relationship between percentage improvement in 
efficacy and VTA-cortical connectivity with stimulation amplitude (right) for 
rigidity, bradykinesia and tremor 
 
The connectivity of  al l voxels belonging to the respective VTA vs eff icacy is i llustrated with the 
scatter plots on the left.  The median of these connectivity values is plotted vs efficacy on the 
right. Connectivity is defined as a t-score between the normalized streamline count of the 
activated STN region and the streamline count of  the non-activated STN region,  i.e. the latter is 
used as a “basel ine” connectivity in each case.
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4.5: Discussion 
Voxel based statistical analysis of volumes of tissue activated, at increasing amplitudes, 
around individual DBS contacts, one year after STN DBS was used in 20 patients with 
Parkinson’s disease (14 patients in the case of tremor) to (1) map out statistically significant 
clusters in the STN area, reflecting efficacy and side effects zones; (2) generate 
probabilistic tractography streamlines (hyperdirect pathways) from said volumes to 
predefined cortical areas [M1, SMA and PFC] and (3) identify the pattern of cortical 
connectivity that predicts response to treatment. 
Appropriately selected patients responded well to DBS with reduction in LEDD and 
improvement in UPDRS-III both ON and OFF medications one-year post op (Table 4-1). 
4.5.1: Efficacy and side-effects clusters in the STN region 
Using a statistical analysis approach akin to that used in voxel based morphometry, distinct 
clusters in the STN corresponding to improvement in rigidity, bradykinesia and tremor are 
demonstrated (Figure 4-2 and Figure 4-3). All clusters are in the supero-lateral (motor) 
STN with overlapping bradykinesia and rigidity clusters. The tremor cluster is central within 
the supero-lateral STN whilst rigidity and bradykinesia appear to be more medial, posterior 
and superior. The rigidity cluster is the largest of the three and extends beyond the STN 
into the subthalamic region in the area of rostral ZI and Forel-H2 field (pallido-thalamic 
fibres) whilst the bradykinesia cluster does not extend beyond the STN border 262. The 
average cluster with overall maximum improvement in all motor symptoms lies in the 
superior-lateral portion of the STN. 
This pattern could partly explain the disparity in the findings of previous reports exploring 
the best stimulation site. It is now apparent that improvement in different motor symptoms 
might be associated with stimulation of different sites in and around the STN. This is not a 
novel notion, Cintas and colleagues showed that improvement in tremor, rigidity and 
bradykinesia can follow stimulation in different contacts 252.  Clusters corresponding to 
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familiar side effects encountered with stimulation in well-established anatomical locations 
validate our findings (Figure 4-2). 
It is paramount to highlight that the stimulation effect presented (for efficacy and side-
effects) is a response to acute stimulation (during screening) and not long-term stimulation. 
This is an especially important point with regard to delayed emergence of side-effects 
resulting from chronic stimulation, particularly deterioration in speech intelligibility. The 
optimal DBS target may eventually vary according to emergence of such side-effects 284,285. 
There are two main problems of carrying out a group analysis examining efficacy of 
individual DBS contacts. The first is the variability in the STN between individuals (and 
hemispheres in the same individual) and the method to describe contact locations. Using 
categorical, arbitrary division within the nucleus reduces sensitivity and specificity of the 
analysis. It also introduces observer bias. We overcame this problem by using a unique 
probabilistic STN template generated from our patient group, in order to visualise the 
resulting clusters, and co-registering volumes of tissue activation to MNI space. We tested 
voxels independently in the analysis across all contacts/ voltages for each individual, 
increasing the sensitivity and specificity of our approach. 
The second problem is adjusting for baseline inhomogeneity. This is often overlooked and 
can produce statistical anomalies (e.g. a 5-point improvement from a baseline of 10 gives 
the same percentage of improvement of 30 from a baseline of 60) 286,287. In order to 
overcome this, we examined efficacy clusters in each patient individually. The resultant 
clusters were then averaged across the entire group. 
4.5.2: Tractography and cortical connectivity fingerprint 
In vivo tractography studies in the region of the STN carry significant challenges. Motion 
artefacts, as a result of the highly pulsatile nature of the brainstem region, can degrade the 
MRI signal during diffusion image acquisition, reducing the signal-to-noise ratio (SNR). This 
is complicated by the presence of myriad criss-crossing axons and reticular brain regions 
104,105. One way of dealing with this is by using pulse-gating and respiratory rate monitoring 
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during diffusion imaging. Likewise, by acquiring multiple diffusion scans, at a high angular 
resolution (increasing acquisition time), SNR is improved 91,103. 
Several studies have indeed used tractography to examine STN connectivity to cortical and 
subcortical areas but most used diffusion MR acquisition parameters more suited for 
conventional clinical application, such as mapping major white matter tracts prior to surgical 
intervention with low angular resolution (number of diffusion directions ≤ 64), low spatial 
resolution (voxel size ≥ 2mm) and low angular contrast (b-value=1000s/mm2) 288-290. 
Choosing the appropriate diffusion imaging parameters is of particular importance in the 
STN. This is in part due to its relatively small dimensions (12 mm in the longest axis and 4 
mm in maximal thickness) 262 requiring small voxel dimensions; and low fractional 
anisotropy (grey matter) requiring higher diffusion sensitisation (b-value).  
We acquired 270 diffusion scans per patient (in 2×128 directions sets) over 62 minutes. 
We meticulously and systematically corrected artefacts and examined the processed 
imaging data for quality control. We modelled three crossing fibres per voxel and used 
probabilistic tractography to ameliorate the crossing fibre problem.  
Recently, there has been a tendency to use tractography in an exploratory fashion. Though 
there is a place for this in delineating large white matter bundles, the results should always 
be scrutinised for false positives. Tunnel effect, crossing and kissing fibres pose particular 
difficulties 92,103. In order to keep the analysis focused, a set of tractography rules based on 
knowledge from neurophysiological and NHP tracer studies was used, without being too 
restrictive. The effect of STN-cortical connectivity was examined rather than simply 
described. The precise role of the cortico-STN hyperdirect pathway remains to be fully 
understood. It has been proposed that, through this pathway, direct cortical information 
reaches the STN before indirect cortical output via the cortico-basal ganglia route. This 
potentially allows for direct cortical modulation of STN output 291. 
Our working hypothesis was that STN DBS exerted an effect through the hyperdirect 
pathway. The results suggest that three hyperdirect pathways connect the combined 
electrode stimulation area in and around the STN. Furthermore, distinct connectivity 
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patterns predict response to DBS. Connectivity to M1 appears to predict improvement in 
tremor; to SMA predicts improvement in bradykinesia; and to both SMA and PFC for 
improvement in rigidity. Purely visualising the tractography results from the subthalamic 
region to the distinct cortical areas is not informative by itself, however; the GLM analysis, 
examining the relationship with efficacy, illustrates that connectivity is indeed relevant to a 
degree that is comparable to that of DBS voltage.  
This model fits with functional and anatomical expectations. A non-human primate tracer 
study examining the hyperdirect pathway shows that M1 STN terminals occupy the 
dorsolateral portion of the STN; whilst SMA and PFC terminals are more medially located, 
with areas of overlap between M1 and SMA; and SMA and PFC 241. 
From a functional perspective; the primary motor area, SMA and PFC command sub-
specialised roles in motor control. PET and SPECT studies have shown reduced 
metabolism in the PFC and SMA with Parkinson’s disease progression 219-221. The SMA is 
typically concerned with motor encoding and planning, whereas M1 is implicated with motor 
execution and the PFC plays a role in cognitive/ behavioural motor response selection and 
proactive motor inhibition 229,292,293. DBS of the STN, by impacting on different fronto-basal 
ganglia pathways, has been shown to produce differential effects on reactive and proactive 
inhibition and on conflict resolution 294. 
Resting tremor in Parkinson’s disease is thought to be pathologically separate from 
bradykinesia and rigidity. The severity and magnitude of tremor is not related to the amount 
of dopamine deficiency in the substantia nigra and response to dopamine replacement can 
be poor in comparison to response in other motor symptoms 295-298. Pathological 
oscillations in a cerebello-thalamo-cortical network, possibly triggered by pallidal 
dysfunction in Parkinson’s disease, is thought to be culpable 299. The cortical focus in this 
tremor network is in the primary motor cortex and not the SMA. This is supported by 
evidence from a transcranial magnetic stimulation (TMS) study that demonstrated tremor 
suppression following stimulation of the primary motor cortex 296. 
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A resting state functional MRI study has also shown increase in connectivity between the 
STN and hand area of M1 and the primary sensory cortex tremor-dominant subgroup; 
conversely, in a non-tremor subgroup, increased connectivity was found between the STN 
and wider cortical areas including the SMA as well as M1 201. Another study that used 
resting state fMRI showed that STN DBS modulates the hyperdirect M1-STN projections 
300. 
Two confounding factors are present when testing cortical connectivity of the volumes of 
tissue activated around each contact. The increase in tissue volume leads to an increase 
in the number of tractography voxel seeds. This, in turn, increases the number of 
streamlines from the VTA to the cortex in a non-linear fashion. The second confounding 
factor arises from the inexact relationship between stimulation amplitudes and increasing 
efficacy. Especially because the local population of neurons may have different action-
potential thresholds. For this reason, voltage and seed volume effects were made 
covariates to study their effect on efficacy as well as that of the connectivity profile. 
In the case of rigidity, an upward trend for all voltages was noted, particularly for 
low/medium voltages (e.g. 2 and 3 Volts) with higher connectivity to PFC and SMA, 
resulting in higher efficacy. For bradykinesia, the plot shows no clear trend for high voltages 
(3 and 4) but an upward trend for low voltages (1 and 2 Volts). In other words, when voltage 
is low, it matters most where the STN is stimulated. The tremor plot shows that voltage 
clearly determines efficacy in this case with a slight upward trend for voltages 1 and 3. 
We focused the tractography analysis on hyperdirect pathways to three cortical areas 
known to be involved in tone control, motor initiation, planning and execution. We cannot 
rule out the existence of other cortical-STN pathways that may also influence outcome from 
DBS. Our analysis did not explore the influence of STN-subcortical connectivity (e.g. 
thalamic/ striatal). The reason for this is two-fold: the strength of tractography diminishes 
with distance rendering DBS-subcortical connectivity artificially stronger than DBS-cortical 
connectivity; and the combined VTA area clearly encroaches on the thalamic border as 
shown in Figure 4-1. It is, therefore, hardly surprising to find an increase in connectivity 
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between volumes of tissue activated and the thalamus, as was demonstrated in a recent 
study 289. 
The efficacy cluster analysis we carried out does not address potential covariance within 
symptoms per se. We therefore cannot assert that the three areas are independent of each 
other based on the VBM analysis alone (especially in the case of rigidity and bradykinesia 
clusters), however; there is a clear difference in cortical connectivity pattern predictive of 
improvement in individual symptoms. This difference is supported by anatomical and 
functional studies as described in the discussion. We show that the average cluster lies in 
the dorsal-lateral portion of the STN in keeping with existing wisdom. We opted not to 
explore this relationship between the individual clusters further as this has little significance 
in clinical practice, as a well-placed DBS electrode can easily straddle the three areas. 
Nevertheless, carrying out the VBM analysis separately has produced convergent efficacy 
clusters in close proximity. This substantiates the novel technique used here. 
4.5.3: Limitations 
The limitations of the VTA model used in this study and the rationale behind using this 
model have been described in chapter 2 (2.10.4). Although the number of patients was 
relatively small (20 for the analysis of bradykinesia and rigidity analysis and 14 for the 
tremor analysis), we analysed two cerebral hemispheres independently by investigating 
hemi-body effects of stimulation doubling up the overall number in the analysis. 
Furthermore, testing the effect of stimulation for each individual contact at different voltages 
provided more data points per hemisphere. The main reason for the relatively small number 
of subjects stems from the difficulty in recruiting patients with advanced Parkinson’s 
disease who are successfully selected for STN-DBS and can also tolerate having a lengthy 
MRI scan. We assessed stimulation efficacy in the upper limbs and not the lower limbs. We 
judged that this would give a more quantifiable and reproducible measure of improvement. 
Furthermore, patients with significant lower limb symptoms are seldom good candidates 
for STN-DBS. This does however mean that our results concerning the efficacy spots 
cannot directly be transferrable to patients with lower limb symptoms. 
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Another limitation is the inherent diffusion MRI imperfections as detailed in the discussion. 
Further improvements in diffusion imaging, with higher spatial and angular resolution and 
improved MRI gradients will add to the value of this modality 102,283. 
Multiple registration steps introduce error to the system. Nonetheless; we meticulously 
confirmed registration accuracy at each step to alleviate the impact of this issue. Manual 
STN delineation introduces observer bias; however, using two experienced clinicians to 
perform this independently reduced inaccuracy. Furthermore, by using a group average 
imprecisions were minimized. Prior to carrying out the VTA cluster analysis, we lateralized 
the right sided DBS contacts and STN to the left. This approach is commonly used in 
imaging studies; however, it assumes no functional differences between the left and right 
STN. Given that the lateralised structures differ in size in our right hand dominant cohort, 
we must acknowledge the possible existence of different connectivity and efficacy 
relationships according to STN laterality. However, although reports have pointed to the 
existence of lateralised differences in emotional processing, no such differences have been 
established in motor processing 301. 
Another limitation in the efficacy and side effect cluster analysis is the autocorrelation in 
the data. The VTAs, by definition, have a degree of overlap which increases the power but 
theoretically also increases the risk of false positives. This is certainly a weakness of the 
analysis. Having said that, spatial autocorrelation is a well-known phenomenon in VBM and 
fMRI analysis and permutation tests do not easily accommodate correlated datasets, as 
such dependence violates null-hypothesis exchangeability, however; it is suggested that 
non-parametric permutation testing is less amenable to false positives than parametric 
permutations 302. We have also carried out the analysis for each subject separately to 
reduce the effect of inter-individual variability. 
Lastly, the relatively long scan duration is a drawback. This was accepted to achieve the 
required SNR and resolution. However, novel MRI acquisition techniques (Simultaneous 
Multi-Slice Imaging and Multi-Band Imaging) 303 have been developed that will allow future 
studies to run similar protocols within half the time without compromising the SNR. 
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4.6: Conclusion 
The optimal DBS site for patients with Parkinson’s disease for tremor, bradykinesia and 
rigidity appears to correspond to different areas in the motor STN.  Stimulation in the central 
portion of the superior STN is most effective for tremor, whilst stimulation in further medial 
and posterior areas, within the superior portion, gives highest improvements in 
bradykinesia and rigidity. DBS-cortical connectivity, along the hyperdirect pathways, to M1 
is predictive of maximum improvement in tremor, to SMA is predictive of maximum 
improvement in bradykinesia and to both SMA and PFC is predictive of maximum 
improvement in rigidity. 
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5. Pyramidal tract activation due to subthalamic deep brain 
stimulation in Parkinson’s disease 
 
5.1: Abstract 
Subthalamic deep brain stimulation (STN-DBS) is an effective treatment for Parkinson's 
disease (PD), but can have side effects caused by stimulus spread to structures outside 
the target volume such as the pyramidal tract. In this paper, we set out to assess the 
relevance of pyramidal tract activation with STN-DBS in PD. 
In a multimodal, blinded study in 20 STN-DBS patients, we measured stimulation 
thresholds for evoking electro-myographic activity in orbicularis oris and first dorsal 
interosseous muscles at each of 150 electrode sites. We also modelled the electric field 
spread and calculated its overlap with the estimated anatomical location of corticospinal 
and corticobulbar tracts from primary motor cortex using 3 Tesla MRI probabilistic 
tractography. 
Mean resting motor thresholds were significantly lower for the contralateral orbicularis oris 
(3.5 ± 1.0 mA) compared with ipsilaterally (4.1 ± 1.1 mA) and with the contralateral first 
dorsal interosseous (4.0 ± 1.2 mA). The modelled volumes of corticobulbar and 
corticospinal tract activated correlated inversely with the resting motor threshold of the 
contralateral orbicularis oris and first dorsal interosseous, respectively. Active motor 
thresholds were significantly lower compared with resting motor thresholds by around 30% 
to 35% and correlated with the clinically used stimulation amplitude. Backward multiple 
regression in 12 individuals with a “lateral-type” speech showed that stimulation amplitude, 
levodopa equivalent dose reduction post-surgery, preoperative speech intelligibility, and 
first dorsal interosseous resting motor thresholds explained 79.9% of the variance in 
postoperative speech intelligibility. 
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In conclusion, direct pyramidal tract activation can occur at stimulation thresholds that are 
within the range used in clinical routine. This spread of current compromises increase in 
stimulation strengths and is related to the development of side effects such as speech 
disturbances with chronic stimulation. 
5.2: Introduction 
Subthalamic deep brain stimulation (STN-DBS) is an established treatment for motor 
fluctuations in patients with Parkinson's disease (PD) 304-306. Although most eligible patients 
benefit from this therapy, there is still a large variability in the outcome. Spread of electrical 
field to surrounding structures is one of the main causes of side effects, and therefore 
precise position of the electrodes in the subthalamic area is a crucial factor in the size of 
the eventual benefit. An important structure in terms of side effect is the pyramidal tract, 
including the corticospinal tract (CST) and the corticobulbar tract (CBT), running through 
the posterior limb of the internal capsule and the cerebral peduncle (crus cerebri), 
surrounding the lateral aspects of the STN 307-309. The distance between a DBS electrode 
in the STN and the cerebral peduncle carrying these fibres is in the range of a few 
millimetres and pyramidal side effects of stimulation are often observed, particularly at 
higher strengths of stimulation 310,311. However, it can be clinically tricky to distinguish 
pyramidal from other side effects, for example, muscle spasms from dystonia related to 
DBS 312, pain 313, or speech disturbances, which may arise from either pyramidal tract 
stimulation or stimulation of the medial zona incerta, the prelemniscal radiations, or the 
fasciculus cerebellothalamicus 314,315. 
Several studies have examined the spread of current from single stimuli through DBS 
electrodes placed in the STN to the adjacent pyramidal tract 310,316-318 These studies found 
motor-evoked potentials (MEP) in facial muscles and strictly contralateral arm and hand 
muscles by applying bipolar, high-amplitude stimulation through adjacent contacts. So far, 
however, a systematic assessment of the potential of electromyography (EMG) as an aid 
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in electrode localization in relation to the pyramidal tract and its relevance for clinical 
outcome has not been carried out. 
Therefore, we explored the relationship between stimulation amplitude thresholds of the 
CBT and CST attributed to STN-DBS in a multimodal approach. We recorded MEPs elicited 
by single stimuli through all DBS electrodes using monopolar stimulation and amplitudes 
up to 6.0 mA. As a proof of concept, we created models of the volume of tissue activated 
(VTA) corresponding to each stimulus. Areas of overlap between said volumes and CST 
and CBT as generated by probabilistic tractography were calculated and correlated with 
EMG data. Finally, associations between MEPs and clinical effects and side effects were 
assessed to identify the potential for EMG in troubleshooting in PD patients treated with 
STN-DBS. 
5.3: Methods 
5.3.1: Participants and DBS implantation 
Twenty-one patients with advanced PD who underwent STN-DBS were assessed post 
operatively. The surgical procedure has been previously described 61,63,67. In brief, 
implantation of bilateral quadripolar DBS electrodes (3389 Medtronic, Minneapolis, MN) 
was performed without microelectrode recording and under general anaesthesia between 
May 2013 and July 2014 71. All patients had electrodes of 1.27 mm in width, with contacts 
of 1.5 mm in length, separated by 0.5 mm, and numbered from 0 to 3 (lowest to highest) in 
the left hemisphere and 8 to 11 in the right hemisphere. The STN was visualized and 
accurate lead placement verified on intraoperative, stereotactic T2-weighted MRI 
sequences on a 1.5 Tesla (T) Siemens Avanto interventional MRI scanner (Siemens 
Healthcare, Erlangen, Germany). 
5.3.2: Experimental design 
Patients were assessed approximately 1 year after STN-DBS implantation. Four different 
authors independently evaluated neurophysiological (PM, neurologist), clinical (DG, 
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neurologist), speech (ET, speech therapist), and imaging (HA, neurosurgeon) 
assessments; each blinded to the other three assessments.  
5.3.3: Clinical assessments 
A standardized neurological examination including the UPDRS motor section (UPDRS-III) 
and the Dyskinesia Rating Scale was carried out off medication/on stimulation and on 
medication/on stimulation. Off-medication UPDRS-III scores, recorded preoperatively, 
were used as comparators to determine the motor benefit of STN-DBS. A repeat formal 
clinical screening of contacts was performed for each contact at 60 μs and 130 Hz in steps 
of 0.5 V every 10 seconds up to 4.0 V or until the patients experienced discomfort. 
Pyramidal side effects, defined as motor contractions of facial muscles, pharyngeal and/or 
laryngeal muscles, and the upper and lower limbs that are time-locked to stimulation, 
reproducible, appearing, and disappearing at the same thresholds 311, were systematically 
recorded. 
5.3.4: EMG Recordings 
EMG activity of the orbicularis oris muscle (OOr) and the first dorsal interosseous muscle 
(FDI) was recorded using 9-mm Ag-AgCl surface cup electrodes with the same equipment 
in a standardized fashion in an on-medication condition. We used a signal amplification 
gain of 2,000, recording frequencies at 10 kHz, and a band-pass frequency filter of 20 to 
1,000 Hz. The signal was digitized and saved for offline analysis blinded to the conditions 
tested using Signal V4.08 (CED, Cambridge, UK). For the OOr, the active electrode was 
placed 1 cm lateral to the mouth corner, and the reference 2 cm lateral, for the FDI the 
muscle belly and the tendon of the same muscle, was used, respectively 318. 
First, MEP were assessed while patients were sitting in a comfortable armchair and 
instructed not to speak and to relax, but not to sleep. Stimuli were elicited by the impulse 
generator on each of four contacts on each electrode in a monopolar stimulation mode. 
Stimulation at a low frequency of 3 Hz (allowing enough time for MEP recordings before 
subsequent stimuli) and at 60-μs pulse width (PW) was increased in 0.5-mA steps up to 
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6.0 mA or until bothersome side effects appeared. A PW of 60 μs was chosen because it 
is most widely used in clinical practice and has, in fact, been used in all our patients, 
allowing comparisons of EMG results with the clinically obtained data. Thirty sweeps of 
EMG triggered by the stimulation artifact were averaged per condition to detect the resting 
motor threshold (RMT) of pyramidal tract activation. RMTs were determined as the lowest 
stimulus intensity inducing MEPs clearly recognizable above background activity upon 
visual inspection (in most instances, this was the case when MEPs reached >10 μV in 
amplitude). 
Second, active motor thresholds (AMTs) were assessed in 13 patients during sustained 
muscle contraction of approximately 25% of maximum voluntary force production (provided 
to the participants as visual feedback with a line on the EMG screen, which they were asked 
to match); first, of the FDI by squeezing a roll of tape, and second, of the OOr by forming a 
smiling mouth. For this condition, stimuli were only elicited by the clinically used contacts 
on each side. AMT was determined as the lowest stimulus intensity inducing MEPs clearly 
recognizable above background activity upon visual inspection. 
Third, 7 patients underwent recordings of the same muscles with step-wise increasing 
pulse width (60, 120, 180, 240, and 450 µs) in order to calculate the chronaxies of the 
stimulated pyramidal fibres. Figure 5-3. 
5.3.5: Speech assessments 
Speech assessment was done in an on-medication condition preoperatively and 
postoperatively (on stimulation). It consisted of a standardized assessment of speech 
intelligibility 319 and 1-minute monologue on the topic of the patient's choice as described 
previously 70,314. Analysis of speech intelligibility consisted of extracting percentage of 
words understood. Additionally, speech was perceptually classified into two groups 
according to our clinical experience and the literature: the “medial” speech type with 
strained-tight and continuous phonation, inaccurate articulation, and what sounds like 
breathing insufficiency 70,315 and the “lateral” speech type characterized by monotone-flat 
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intonation, fast rate of speech, and reduced movement of lips and tongue. Analysis was 
performed separately for these two groups. 
5.3.6: MRI acquisition and processing 
5.3.6.1: DBS contacts volume of tissue activated (VTA) modelling 
DBS contacts volume of tissue activated (VTA) modelling was done on scans obtained 
intraoperatively on a 1.5 T Siemens Avanto interventional MRI scanner. Intraoperative MRI 
scans were uploaded and the post-implantation MPRAGE was used to fit the DBS lead 
model within the MRI artefact produced by the leads. Individual VTAs were then generated 
around each DBS contact with voltages of 0.5 to 6.0 mA in 0.5 mA steps. Binary image 
files of VTAs along with corresponding transformation matrices were exported and 
processed in MATLAB (MathWorks Inc.) using in-house software to generate 
Neuroimaging Informatics Technology Initiative (NIfTI) volumes for further analysis. 
5.3.6.2: Diffusion weighted MRI and probabilistic tractography 
Seventeen patients had undergone high angular resolution diffusion imaging in the week 
prior to STN DBS implantation on a 3T Siemens Magnetom using a padded 32-channel 
receive head coil to reduce discomfort and head motion. Details of diffusion weighted MRI 
acquisition and pre-processing are described in the general methods sections.  
Two separate cortical seed masks were used to generate tractography for each 
hemisphere; the hand area in the primary motor cortex for the CST and the face area for 
the CBT as published previously 308,320. Waypoints were used in the internal capsule and 
the crus cerebri to direct the streamlines. CSF termination and mid-sagittal exclusion masks 
were applied to exclude false positive streamlines and commissural tracts respectively. The 
generated tracks were visually inspected and group averages were created to improve the 
quality of the resulting templates. These were then transformed back to patients’ native 
space using non-linear registration and the non-linear standard-patient space transforms. 
This allowed inclusion of the three patients with no preoperative diffusion data. Overlap 
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between The VTAs and the CST and CBT was then quantified using fslmaths (FSL V5.0) 
to generate overlap volumes and then fslstats (FSL V5.0) to measure those volumes.  
5.3.7: Statistical analysis 
Because data were largely non-normally distributed, as shown by the Shapiro–Wilk test, 
we used nonparametric tests for comparative statistics. Variables are given in medians 
(25th–75th percentiles), unless specified otherwise. The main neurophysiological outcome 
measure was defined as the threshold of stimulation strength in mA eliciting clear visually 
perceptible MEPs. As a proof of principle, motor thresholds of the OOr and the FDI were 
then correlated to MRI modelled volumes of CBT and CST activated, respectively. As 
volumes of overlap increased linearly with increasing stimulation strength (data not shown), 
we used volumes of overlap modelled at the maximum applied stimulation strength of 6.0 
mA for correlations with motor thresholds. Linear regression analyses were additionally 
performed to assess the influence of volumes of CBT and CST activated on motor threshold 
of respective muscles as well as factors determining postoperative speech intelligibility. 
SPSS software (version 22.0; IBM Corp., Armonk, NY) was used for all statistical analyses. 
The local significance level was set at two-sided P < 0.05. 
5.4: Results  
5.4.1: Patient characteristics and clinical assessments 
One patient could not tolerate withdrawal from high-frequency stimulation for EMG 
measurements and was excluded. The remaining 20 patients (3 females, aged 60.6 [52.6-
67.9] years; disease duration: 11.3 [7.2-13.8] years; stimulation duration: 1.0 [0.9-1.4] 
years) were eligible for analyses. UPDRS-III scores off-medication were 45.0 (35.5-51.5) 
preoperatively and 27.0 (17.0-35.0) postoperatively (P < 0.001). Levodopa equivalent 
doses were 1,446 (1,177-1,978) preoperatively and 650 (500-953) postoperatively 
(P < 0.001). Settings for chronic stimulation were as follows: 2.0 (1.5-2.1) mA amplitude; 
130 (125-130) Hz frequency; and 60 µs PW in all patients. Table 5-1. 
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5.4.2: Muscle evoked potentials 
A total of 150 contacts could be assessed at rest (in two patients only a unilateral 
assessment on the electrodes contralateral to the less affected side was possible, and two 
contacts of two other patients were dysfunctional as indicated by high impedance and were 
therefore not tested). Out of these, in 148 (98.7%) contacts it was possible to elicit MEPs 
in the contralateral OOr, in 138 (92.0%) in the ipsilateral OOr, and in 144 (96.0%) in the 
contralateral FDI using stimulation strengths up to 6 mA (for example see Figure 5-1). 
Table 5-2 illustrates the RMTs, which were significantly lower in the OOr contralateral to 
the side of stimulation compared with the ipsilateral one and compared with the FDI. 
At the maximum applied stimulation strength of 6 mA, MEPs reached mean amplitudes of 
107.7±115.4µV in the contralateral OOr, compared with 36.4±41.1µV in the ipsilateral OOr 
(Z=-8.4, p<0.0001) and with 344.2±637.4µV in the FDI (Z=-3.2, p=0.0027). MEPs were 
elicited after a mean of 7.8±0.9ms in the contralateral, 7.8±0.9 ms in the ipsilateral OOr 
(Z=-0.3, p=0.732), and after 20.9ms±1.6ms in the FDI (Z=-7.8, p<0.0001). The latency was 
inversely correlated with the amplitude of the MEPs (r=-0.369, p=0.0004 for the 
contralateral OOr; r=-0.118, p=0.303 for the ipsilateral OOr; and r=-0.344, p=0.0002 for the 
FDI). 
5.4.3: Influence of side and contact location on muscle evoked potentials at rest 
Thresholds for the OOr (contralateral and ipsilateral) were significantly lower upon 
stimulation in the left compared with the right hemisphere, whereas there was no significant 
hemisphere effect with regard to the FDI (Table 5-2). There were increasing thresholds 
along the axis of the electrode from the lowest to the highest contact for the FDI (from 
3.1±0.8mA on contact 0, to 4.5±1.1mA on contact 3, p<0.0001 for trend; and from 
3.8±0.9mA on contact 8 to 4.2±1.1mA on contact 11, p=0.183 for trend), but not for the 
contralateral or ipsilateral OOr. A regression analysis taking into account hemisphere and 
contact location confirmed these findings (Table 5-2). 
Hemisphere and contact location did not influence amplitude or latencies of MEPs. 
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5.4.4: Correlation with imaging data 
CBTs and CSTs were successfully modelled, averaged and the average applied to each 
patient space. Next, VTAs were overlaid on CBTs and CSTs in each patient obtaining CBT 
volume activated and CST volume activated, respectively (Figure 3.3.2). As volumes of 
overlap linearly increased with increasing stimulation strength, we used volumes of overlap 
modelled at the maximum applied stimulation strength of 6.0 mA for correlations with RMTs 
(Table 3.3.3). The volume of CBT activated correlated inversely with the RMT of the 
contralateral OOr. Likewise, the volume of CST activated correlated inversely with the RMT 
of the FDI. For the ipsilateral OOr there was no such correlation. These findings were 
corroborated in a regression analysis, both unadjusted and adjusted for side and contact 
location (Table 3.3.3). 
The mean volume of overlap at the actual applied stimulation strength necessary for 
eliciting RMTs was higher for the OOr with 38.3±29.2 mm3 (95%CI; 33.7–43.5mm3) of CBT 
volume activated than for the FDI with 32.2±28.7 mm3 (95%CI; 27.4–37.0mm3) of CST 
volume activated (Z=-5.0, p<0.0001), but there was no difference between sides or across 
contacts. 
5.4.5: Active motor thresholds 
Thirteen patients underwent recordings of the three muscles during sustained contraction 
of (1) FDI by squeezing a roll of tape and (2) OOr by forming a smiling mouth. For these 
conditions stimuli were only elicited through the clinically used contacts on each side, with 
two patients having only unilateral assessments; thus a total of 24 contacts were assessed. 
Table 3.3.3 presents the thresholds for the three sites of recording and for the two 
conditions tested. AMTs were significantly lower compared with RMTs (Table 3.3.2) by 
around 30%–35% in the contralateral OOr (Z=-4.3, p<0.0001), ipsilateral OOr (Z=-4.1, 
p<0.0001), and FDI (Z=-4.2, p<0.0001), respectively. AMT of the contralateral OOr was 
similar to the FDI, but significantly lower compared with the ipsilateral OOr (Table 3.3.3). 
MEPs were elicited after a mean of 7.1±0.8ms in the contralateral, 7.1±0.9ms in the 
ipsilateral OOr (Z=-0.4, p=0.700), and after 20.4±2.1ms in the FDI (Z=-4.1, p<0.0001). 
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MEPs on activation occurred earlier than those at rest in all muscles (see above), however, 
achieving statistical significance in the FDI only (Z=-3.4, p=0.0008). 
There were inverse correlation of AMT with the volume of CBT/CST activated, which 
reached statistical significance only for the combination of FDI AMT with volume of CST 
activated (Table 3.3.3). 
Interestingly, activation of the OOr led also to a lowering of the threshold in the FDI and 
vice versa, which was intermediate between RMT and AMT (Table 3.3.3 and Figure 3.3.3). 
5.4.6: Evaluation of the chronaxie 
Seven patients underwent recordings of the three muscles with increasing pulse widths at 
the clinically used contacts, with two patients having bilateral assessments, thus assessing 
a total of 10 contacts. From the strength-duration curves (Figure 3.3.3) we determined a 
mean chronaxie of 142.5µs for RMT of the contralateral OOr, of 163.2µs for the ipsilateral 
OOr, and of 168.8µs for the FDI. These values were not significantly different (all p-values 
for comparison >0.100). 
5.4.7: Clinical-neurophysiological correlations 
Neither motor improvement upon stimulation nor dyskinesias were significantly related to 
the motor thresholds for any muscles (all spearman rank correlations p>0.140). However, 
there was a direct correlation of the clinically used stimulation amplitude with the RMT 
(significant for the contralateral OOr, r=0.406, p=0.0128) and with the AMT, which was 
significant for all three muscles (contralateral OOr, r=0.604, p=0.0014; ipsilateral OOr, 
r=0.495, p=0.0119; and FDI, r=0.498, p=0.0132). RMT were higher than the amplitude 
used for clinical benefit in all patients on both sides (all p values for all three muscles 
<0.0001). The same was generally true for AMT, but p-values were less significant, likely 
due to a few DBS contacts where AMTs were lower than the clinically used stimulation 
amplitudes (five for the contralateral OOr, p=0.0226; two for the ipsilateral OOR, p=0.0002; 
and three for the FDI, p=0.0018). 
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Overall, 148 contacts were clinically screened for side effects using a frequency of 130 Hz 
and 60 µs. In 34 contacts (23.0%) contralateral facial pulling was noted at a mean threshold 
of 2.7±0.6mA. In 18 contacts (12.1%) contractions of the contralateral fingers/hand were 
noted at a mean threshold of 2.9±0.4mA. The clinical observation of contralateral facial 
pulling was noted at a similar amplitude to the RMT of the contralateral OOr in the same 
contacts (2.8±0.7mA; Z=-0.4, p=0.660), and contractions of the contralateral hand/fingers 
was noted at a similar mean threshold to the RMT of the FDI in the same contacts 
(3.2±0.9mA; Z = -0.9, p=0.352). 
5.4.8: Speech assessments 
Mean postoperative speech intelligibility was 89.0% (74.0-94.3). In the 8 participants with 
a “medial type” of speech, RMTs of the FDI were higher and volume of pyramidal tract 
activation was lower compared to the 12 participants with a lateral type of speech. In 
participants with a “lateral” type of speech, speech intelligibility correlated with the RMT of 
the FDI upon stimulation of the clinically used contacts (r = 0.428; P = 0.0468), but not with 
the RMTs of the OOr. AMTs were non-significantly correlated with speech intelligibility (e.g., 
FDI; r = 0.345; P = 0.272), but numbers for this analysis were small. Medial type of speech 
did not correlate with motor thresholds of any of the muscles (all P > 0.1). 
A backward linear regression analysis incorporating other factors potentially impacting on 
speech (age, contact location, preoperative speech intelligibility, strength of stimulation, 
levodopa equivalent dose reduction) showed that 79.9% of the variance in speech 
intelligibility was explained by the four factors preoperative speech intelligibility 
(P = 0.0034), strength of stimulation (P = 0.0001), levodopa equivalent dose reduction post-
surgery (P = 0.0019), and RMT of the FDI (P = 0.0016). 
5.5: Discussion 
In this multimodal study, we assessed the activation of the pyramidal tract attributed to 
STN-DBS in PD. We distinguished between CBT and CST by means of both 
neurophysiological assessment with EMG and imaging assessment with tractography and, 
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importantly, found strong correlations between outcomes of these assessment tools within 
the corticobulbar and the corticospinal system, respectively, arguing for the validity of our 
approach. The most relevant findings of our study are as follows: (1) Subthalamic DBS 
induces MEPs bilaterally in the face and contralaterally in the hand at thresholds of 
stimulation strengths, which are within the range used in routine clinical practice; (2) this 
activation most likely occurs because of direct stimulation of corticobulbar and corticospinal 
fibres, as shown by our imaging analysis and supported by the strength-duration curve 
calculations; (3) although motor improvement with STN-DBS was not related to the 
threshold of the MEPs, motor thresholds are directly correlated to amplitude used for 
chronic stimulation; and (4) development of the lateral type of speech disturbances with 
stimulation is significantly related to activation of the pyramidal tract. 
5.5.1: Anatomical considerations 
Using stimulation strengths up to 6.0 mA, it was possible to elicit MEPs in 99% of 
contralateral OOr, 92% of ipsilateral OOr, and 94% of FDIs. Median RMT was 3.0 mA for 
the contralateral OOr and 4.0 mA for the ipsilateral OOr and contralateral FDI. There was 
a significant hemisphere difference with higher thresholds upon stimulation in the right, as 
compared with the left STN, which could result from the fact that all our patients were right-
handed. The increasing thresholds of FDI activation toward more superior contacts, also 
observed in an earlier study 310, may be attributed to a double oblique trajectory where 
electrode axes parallel the CBT coming from more anteriorly and include a small angle with 
the CST coming from more posteriorly 308. Location of the CBT and CST within the internal 
capsule has been a matter of debate, but our analysis supports findings from recent studies 
suggesting that both the CBT and the CST run closely together within the posterior limb of 
the lower peduncular part of the internal capsule with a considerable level of overlap 308. 
5.5.2: Neurophysiological considerations 
The most likely mechanism of induction of MEPs is activation of the pyramidal tract and 
orthodromic conductance of the action potential to motor brainstem nuclei and the anterior 
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horn of the spinal cord, as suggested by multiple studies 310,317,318. However, we here 
corroborate this hypothesis, for the first time, by correlating the threshold of facial MEPs to 
volume of corticobulbar activation and threshold for MEPs in the hand to corticospinal 
activation. The level of correlation was high and robust for the latter combination, whereas 
the correlation of corticobulbar volume activated with the OOr were slightly weaker 
contralaterally and not present ipsilaterally. Variability of the corticobulbar fibres at the level 
of the STN might be higher given that crossing of these fibres occurs slightly below and 
asymmetries between right and left and ipsilateral versus contralateral innervation have 
been demonstrated 321,322. Ipsilateral fibres may additionally be located further away from 
the STN, which would be in line with our findings of a higher threshold for eliciting MEPs 
ipsilaterally than contralaterally. Also, chronaxie measurements of the three muscles were 
all well within the reported range of large myelinated axons 316,323,324, making it unlikely that 
electrophysiological characteristics of innervating systems are different. This is further 
supported by the similar latencies for ipsilateral and contralateral MEPs in the OOr arguing 
in favour of a bilateral, probably oligosynaptic, projection with contralateral predominance, 
as suggested previously 321. Interestingly, we found a positive correlation of the latency 
with the amplitude of the MEPs. This may be explained by size principle in the recruitment 
of motoneurons with small and slower conducting ones reaching threshold before larger 
and faster conduction ones 325. 
Importantly, thresholds for pyramidal side effects observed during the screening procedure 
were around 3 mA, similar to the RMT as assessed by EMG. Moreover, AMTs were 
significantly lower than RMTs, and also voluntary activation of corticobulbar or corticospinal 
fibres may enhance excitability of spinal or bulbar motoneurons, respectively. Median 
AMTs were as low as 2.5 mA, suggesting that activation of pyramidal fibres may occur with 
routinely used stimulation setting during activation that might not be evident at rest. The 
clinical implications of the stimulation of pyramidal fibres attributed to STN-DBS in PD have 
not been systematically studied so far. 
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5.5.3: Clinical implications 
We found that in patients with lower AMTs and RMTs on the clinically used contacts, lower 
stimulation amplitudes for clinical benefit were used. This may point to (conscious or 
unconscious) avoidance of stimulation settings, which potentially activate the pyramidal 
tract in clinical routine. However, in our cohort, this did not translate into a significant 
relationship between motor improvement upon stimulation and the identified thresholds of 
pyramidal tract activation, but our cohort was rather small and patients were relatively early 
in their DBS treatment duration. With increasing disease and stimulation duration, higher 
stimulation current may be necessary to achieve sufficient symptom control at which point 
spread to the pyramidal tract might play a larger role. A contrasting interpretation, however, 
may be that stimulation of fibre tracts in close vicinity to the STN and the pyramidal tract, 
such as corticosubthalamic projections (e.g., the hyperdirect pathway), or pallidofugal 
fibres (e.g., ansa lenticularis or longitudinal fasciculus) might contribute to improved motor 
symptom control, as hypothesized by other studies 250,324,326, such that a slight stimulation 
of these fibres along with an unavoidable, but “subclinical” stimulation of the pyramidal tract 
could overall be beneficial. In line with these hypotheses, a recent study has shown that 
STN-DBS activates the cerebral cortex at 1 ms after stimulus onset, suggesting that 
antidromic activation of axons with cortical origin projecting to the subthalamic region could 
actually be part of the therapeutic mechanism of STN-DBS 305. 
A further important observation was the strong correlation of the RMT of the FDI with 
postoperative “lateral type” speech intelligibility; RMT of the FDI was a significant factor in 
a logistic regression analysis along with preoperative speech intelligibility, applied 
stimulation strength, and levodopa dose reduction in combination explaining 80% of the 
variance in postoperative speech intelligibility. RMT of the OOr was not significantly 
associated with postoperative speech intelligibility. This might relate to the fact that speech 
intelligibility can be compromised by activation of fibres innervating a large number of 
different muscles in the face and pharynx and also to the greater variance of the OOr EMG 
signal. Also, CBT and CST in the tractography analysis and the EMG signal of the OOr and 
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FDI were very closely related, to the extent that EMG of the FDI might be the most practical 
marker of pyramidal activation and related clinical implications. Interestingly, the observed 
characteristics of the lateral type of speech were in line with speech changes in previous 
reports of pseudobulbar speech impairment upon lacunar cerebral infarction 327.Medial type 
of speech did not relate to any of the thresholds observed in line with earlier studies, 
suggesting that it relates to stimulation of structures outside the pyramidal tract, possibly 
the fasciculus cerebellothalamicus adjacent to the medial zona incerta and the 
prelemniscal radiations 314,328. 
5.6: Conclusion 
Subthalamic DBS induces MEPs at rest and upon activation bilaterally in the face and 
contralaterally in the hand at thresholds of stimulation strength that are within the range 
used in clinical routine. This spread of current compromises increase in stimulation 
strengths and is related to the development of speech disturbances with chronic 
stimulation. Our study suggests that EMG may detect such current spread and might thus 
represent a valuable tool in troubleshooting in PD patients treated with STN-DBS. Further 
studies will have to elucidate whether current spread to the pyramidal tract directly impacts 
on motor improvement attributed to subtle, subclinical corticobulbar and/or corticospinal 
stimulation. 
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Table 5-1: Characteristics of the study participants 
 Mean ± standard deviation (median, 25th – 
75th percentile) 
Sex distribution 3 female, 17 male 
Age 57.9 ± 9.7 (60.6, 52.6–67.9) years 
Disease duration 10.9 ± 4.7 (11.3, 7.2–13.8) years 
Stimulation duration 1.2 ± 0.7 (1.0, 0.9–1.4) years 
Amplitude of stimulation 2.0 ± 0.7 (2.0, 0.5–3.5) mA 
Frequency of stimulation 127 ± 29 (130, 125–130) Hz 
Pulse width of stimulation 60 µs 
UPDRS-III; pre-OP, Off Meds 43.8 ± 13.6 (45.0, 35.5–51.5) 
UPDRS-III; post-OP, Off Meds, On 
Stim 
27.4 ± 11.8 (27.0, 17.0–35.0) 
Improvement pre- vs. post-OP 35.6 ± 19.7 (22.9–48.5) % 
Levodopa equivalent dose pre-OP 1452 ± 517 (1446, 1177–1978) mg 
Levodopa equivalent dose post-OP 776 ± 293 (650, 500–953) mg 
Dyskinesia Rating Scale scores 
post-OP (On Meds, On Stim) 
3.3 ± 3.2 (3.5, 0.0-6.0) 
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Table 5-2: Resting Motor Thresholds and effects of hemisphere and contact location 
Muscle 
Overall RMT 
(including all 
contacts from 
both electrodes) 
(mA) 
Comparison 
versus OOr 
contra 
Z-score 
p-value 
Comparison by hemisphere 
Regression analysis 
Beta-coefficient (95%CI) 
Left hemisphere 
(contacts 0–3) 
Right hemisphere 
(contacts 8–11) 
Z-scores 
Hemisphere: 
Left versus right 
Contact location: 
Inferior to superior 
OOr 
contra 
3.5 ± 1.0 
(3.0; 3.0–4.0) 
 
3.3 ± 1.1 
3.0 (2.5–3.5) 
3.6 ± 0.9 
3.5 (3.0–4.0) 
-2.7 
p=0.0068 
0.345 (0.025–0.666) 
p=0.0347 
0.029 (-0.114–
0.173) 
p=0.686 
OOr 
ipsi 
4.1 ± 1.1 
(4.0; 3.5–5.0) 
-7.5 
p<0.0001 
3.9 ± 1.2 
3.5 (3.0–5.0) 
4.4 ± 1.0 
4.0 (3.5–5.1) 
-2.8 
p=0.0052 
0.448 (0.086–0.809) 
p=0.0158 
0.039 (-0.123–
0.202) 
p=0.633 
FDI 
4.0 ± 1.2 
(4.0; 3.0–5.0) 
-5.0 
p<0.0001 
3.9 ± 1.2 
4.0 (3.0–5.0) 
4.1 ± 1.1 
4.0 (3.0–5.0) 
-2.2 
p=0.0312 
0.275 (-0.091–0.642) 
p=0.140 
0.242 (0.077–0.407) 
p=0.0044 
 
Results are reported in means ± standard deviation (medians, 25t h -75t h percentile). Two-sided, paired Wilcoxon signed rank test was  
used to calculate significance levels across muscles and between sides.  A linear regression analysis was performed to evaluate effects of 
hemisphere of stimulation and contact location along the axis of the electrode (independent variables), and on motor threshold  
(dependent variable). Abbreviations: FDI = First Dorsal Interosseus muscle; mA = mill iampere; µV = microvolt; MEP = Muscle Evoked 
Potential; OOr = Orbicularis Oris muscle; RMT = Resting Motor Threshold; 95%CI = 95% Confidence Interval 
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Table 5-3: Correlations of RMT with volumes of overlap 
 
Correlations Spearman rank 
coefficients (r) 
Regression analysis 
Beta-coefficient (95%CI) 
Muscle Overall Unadjusted 
Adjusted for hemisphere and contact 
location 
OOr contra* 
-0.349 
p<0.0001 
-0.021 (-0.030–-0.012) 
p<0.0001 
-0.028 (-0.038–-0.009) 
p<0.0001 
OOr ipsi* 
-0.023 
p=0.796 
0.000 (-0.010–0.010) 
p=0.997 
0.004 (-0.007–0.014) 
p=0.488 
FDI** 
-0.493 
p<0.0001 
-0.035 (-0.046–-0.024) 
p<0.0001 
-0.033 (-0.045–-0.022) 
p<0.0001 
 
*RMTs of the contralateral and ipsilateral OOr were correlated with volumes of corticobulbar tissue activated 
**RMTs and MEPs of the FDI were correlated with volumes of corticospinal tissue activated 
Beta-coefficients report the impact of volumes of overlap in voxels on RMT of respective muscles and were calculated with a l inear 
regression analysis.  
FDI = First Dorsal Interosseous muscle; OOr = Orbicularis Oris muscle; MEP = Muscle Evoked Potential; RMT = Resting Motor Threshold;  
95%CI = 95% confidence interval  
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Table 5-4: Active motor thresholds 
Condition Muscle Threshold (mA) Correlation with Volumes of Overlap 
Regression analysis 
Beta-coefficient (95%CI) 
p-value 
Unadjusted Adjusted for side and contact location 
Activation of the OOr 
OOr contra (AMT)* 2.4 ± 0.8 (2.5, 2.0–2.5) 
-0.288 
p=0.182 
-0.011 (-0.029–0.006) 
p=0.182 
-0.005 (-0.020–0.010) 
p=0.494 
OOr ipsi (AMT)* 2.9 ± 0.8 (3.0, 2.3–3.5) 
-0.186 
p=0.394 
-0.009 (-0.032–0.013) 
p=0.394 
-0.002 (-0.024–0.019) 
p=0.818 
FDI 3.2 ± 1.2 (3.0, 2.5–4.0)    
Activation of the FDI 
OOr contra 3.1 ± 1.0 (3.0, 2.1–3.9)    
OOr ipsi 3.8 ± 1.1 (4.0, 3.0–4.4)    
FDI 
(AMT)* 
2.6 ± 0.7 
(2.5, 2.1–3.0) 
-0.506 
p=0.0162 
-0.020 (-0.035–-
0.004) 
p=0.0162 
-0.012 (-0.028–0.004) 
p=0.137 
Results are reported in means ± standard deviation (medians, 25t h -75t h percentile). Two-sided, paired Wilcoxon signed rank test was  
used to calculate significance levels across muscles and between sides. * True AMT conditions; OOr contralateral vs. ipsilateral: Z=-3.7, 
p=0.0002; OOr contralateral vs.  FDI: Z=-1.6, p=0.111. Abbreviations: AMT = Active Motor Threshold; FDI  = First Dorsal Interosseus muscle; 
mA = mill iampere; mV = mill ivolt; MEP = Muscle Evoked Potential; OOr = orbicularis oris muscle. 
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Figure 5-1A: MEPs of the three muscles recorded in increasing stimulation 
strength (patient 17, contact 1-).  
 
RMT for the contralateral OOr was reached at 3mA of stimulation strength,  
whereas ipsilateral OOr and FDI showed MEPs starting from 4mA. 
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Figure 5-1B: MEPs of the three muscles recorded in increasing stimulation 
strength (patient 13, contact 8-) 
 
 
RMT for the contralateral OOr was reached at 2.5mA of stimulation strength,  
whereas ipsilateral OOr and FDI showed MEPs starting from 3mA. 
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Figure 5-2: Probabilistic tractography derived corticospinal tract (CST, 
orange) coming from the precentral cortex in and around the hand motor 
knob and corticobulbar tracts (CBT, blue) coming from the laterally and 
caudally adjacent precentral motor cortex.  
 
 
The subthalamic nucleus (STN) of subject number 13 is depicted in green and the 
volume of tissue activated (VTA) on the highest contacts (3- and 11-) is depicted 
in yellow. On coronal  (A) and axial (B) slices it can be appreciated that the CBT is 
located more anteriorly than the CST with diminishing distance towards caudally 
and a great level of overlap at the level of the STN. Enlarged images show level 
of overlap between CBT/CST and VTA (i.e. volume of corticobulbar/corticospinal  
tract activated) at 4 mA (C) and 2 mA (D) of stimulation strength as an example, 
which was greater for the left than for the right side in this case.  
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Figure 5-3: Strength-time duration curves depicting the relationship 
between pulse width and amplitude necessary for induction of RMT in 
the three muscles 
 
 
The data were linearized by plotting pulse width (x-axis; µs)  against the product 
of amplitude and pulse width (y-axis; mA*µs). To further confirm that motor 
responses in the OOr and FDI  were due to stimulation of large diameter 
myelinated fibres in the pyramidal tract,  we calculated the strength-duration 
time constant for these effects based on the Weiss’s law (Weiss, 1901, Ranck 
1975).  The time constant is given by the (negative) intercept of the linear 
regression line on the duration axis and was 142.5 µs for the contralateral  OOr, 
163.2 µs for the ipsilateral OOr, and 168.8 µs for the FDI. These chronaxies are 
well within the reported range of large myelinated axons as pyramidal tract fibres 
3 1 6 ,3 2 3 ,3 2 4,  making it unlikely that electrophysiological characteristics of 
innervating systems are different.  
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Section II: 
 
Connectivity in Tremor 
“When the hand trembled to receive  
A thrilling clasp, which seemed so near,  
And the heart ventured to believe, 
Another heart esteemed it dear” 
 
Frances, Charlotte Brontë (1816–1855) 
 139 
6. Connectivity derived thalamic segmentation in deep brain 
stimulation for tremor 
6.1: Abstract 
The ventral intermediate nucleus (VIM) of the thalamus is an established surgical target for 
stereotactic ablation and deep brain stimulation (DBS) in the treatment of tremor in 
Parkinson’s disease (PD) and essential tremor (ET). It is centrally placed on a cerebello-
thalamo-cortical network connecting the primary motor cortex, to the dentate nucleus of the 
contralateral cerebellum through the dentato-rubro-thalamic tract (DRT). The VIM is not 
readily visible on conventional MR imaging, so identifying the surgical target traditionally 
involved indirect targeting that relies on atlas-defined coordinates. Unfortunately, this 
approach does not fully account for individual variability and requires surgery to be 
performed with the patient awake to allow for intraoperative targeting confirmation.  The 
aim of this study is to identify the VIM and the DRT using probabilistic tractography in 
patients that will undergo thalamic DBS for tremor.  Four male patients with tremor 
dominant PD and five patients (three female) with ET underwent high angular resolution 
diffusion imaging (HARDI) (128 diffusion directions, 1.5 mm isotropic voxels and b value = 
1500) preoperatively. Patients received VIM-DBS using an MR image guided and MR 
image verified approach with indirect targeting. Postoperatively, using parallel Graphical 
Processing Unit (GPU) processing, thalamic areas with the highest diffusion connectivity 
to the primary motor area (M1), supplementary motor area (SMA), primary sensory area 
(S1) and contralateral dentate nucleus were identified. Additionally, volume of tissue 
activation (VTA) corresponding to active DBS contacts were modelled.  Response to 
treatment was defined as 40% reduction in the total Fahn-Tolosa-Martin Tremor Rating 
Score (FTMTRS) with DBS-ON, one year from surgery.  Three out of nine patients had a 
suboptimal, long-term response to treatment. The segmented thalamic areas corresponded 
well to anatomically known counterparts in the ventrolateral (VL) and ventroposterior (VP) 
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thalamus. The dentate-thalamic area, lay within the M1-thalamic area in a ventral and 
lateral location. Streamlines corresponding to the DRT connected M1 to the contralateral 
dentate nucleus via the dentate-thalamic area, clearly crossing the midline in the 
mesencephalon. Good response was seen when the active contact VTA was in the 
thalamic area with highest connectivity to the contralateral dentate nucleus. Non-
responders had active contact VTAs outside the dentate-thalamic area. We conclude that 
probabilistic tractography techniques can be used to segment the VL and VP thalamus 
based on cortical and cerebellar connectivity. The thalamic area, best representing the 
VIM, is connected to the contralateral dentate cerebellar nucleus. Connectivity based 
segmentation of the VIM can be achieved in individual patients in a clinically feasible 
timescale, using HARDI and high performance computing with parallel GPU processing. 
This same technique can map out the DRT tract with clear mesencephalic crossing. 
6.2: Introduction 
The ventral intermediate nucleus (VIM) of the thalamus is an established surgical target, 
for stereotactic ablation and deep brain stimulation (DBS) in the treatment of tremor in 
Parkinson’s disease (PD), essential tremor (ET) and multiple sclerosis 329-336. A subjacent 
area, the caudal zona incerta (cZI), is another effective DBS target for the treatment of 
tremor 284,337-340. 
The VIM is centrally placed on a cerebello-thalamo-cortical network in which  pathological 
oscillations, possibly triggered by pallidal dysfunction in the case of PD, is thought to be 
culpable for tremor 299. The cortical focus in this tremor network is in the primary motor 
cortex, connected to the dentate nucleus of the contralateral cerebellum through the 
dentato-rubro-thalamic tract (DRT) via the VIM 341-346. 
The VIM is not readily visible on conventional, stereotactic MR imaging sequences used in 
image guided and image verified surgery 347-350. Identifying the nucleus traditionally 
involves indirect targeting relying on atlas-defined coordinates in relation to the anterior 
commissure (AC) – posterior commissure (PC) points as landmarks, along with other 
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identifiable structures such as the lateral thalamic / internal capsule border 262. Needless 
to say, this approach does not fully account for individual variability. Furthermore, surgery 
often needs to be performed with the patient awake to allow for intraoperative confirmation 
of targeting, thus increasing patient discomfort 351. Moreover, intraoperative confirmation is 
not always readily feasible e.g. when performing a thalamotomy using Gamma Knife 352 or 
focused ultrasound 353. 
To overcome this, various imaging techniques have been proposed to identify the VIM. 
Ultra-high field MRI provides high contrast-to-noise ratio in-between thalamic nuclei, better 
segmenting the nucleus, however, this modality is not readily available in a clinical setting 
354. Another technique relies on contrast in coloured fractional anisotropy (FA) maps, a 
product of diffusion tensor imaging (DTI) 355,356. Simple visualisation of the first order tensor 
fields in DTI has also been used to generate deterministic tractography models of the DRT, 
which is then targeted by DBS 132,136,357,358. This modality is commonly accessible in clinical 
settings and imaging is relatively swift to acquire and process; however, it carries limitations 
related to disentangling crossing fibres, tracking in areas of low anisotropy (e.g. the 
thalamus) 80 and overall accuracy 100. 
An emerging modality utilises high angular resolution diffusion imaging (HARDI) and 
probabilistic connectivity based segmentation of the thalamus 80,94,359-361. This technique 
successfully models crossing fibres and grey matter (low anisotropy) connectivity and 
achieves high signal-to-noise ratio, but requires prolonged image acquisition and large 
computational resources which are impractical in clinical practice. Novel MRI acquisition 
techniques, such as Simultaneous Multi-Slice Imaging and Multi-Band Imaging 303 have 
reduced scanning time. Furthermore, advances in computer processing techniques and 
relying on graphical processing units to carry out diffusion analysis have facilitated the use 
of this modality in clinical practice 160,282. 
The objectives of this study were to examine the feasibility of using probabilistic, 
connectivity based segmentation techniques to segment the thalamus in a group of PD and 
ET patients one year from VIM DBS; to generate probabilistic tractography models of the 
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DRT tracts and to carry out a post-hoc analysis of the relation of the segmented VIM and 
DRT with volume of tissue activation (VTA) models around active contacts of the DBS lead. 
We show that the VIM is best segmented based on connectivity to the contralateral dentate 
nucleus and that patients with good response to treatment had active contact VTAs within 
the segmented VIM. 
6.3: Materials and methods 
6.3.1: Patients 
Four male patients with tremor dominant PD who met UK brain bank criteria 273 and five 
patients (three female) with ET were recruited, following selection for VIM-DBS, by a 
multidisciplinary team of specialized movement disorders neurologists and functional 
neurosurgeons (Table 6-1). Formal neuropsychological assessment and structural brain 
MRI were performed to rule out dementia and significant brain atrophy, respectively. PD 
patients underwent the L-DOPA challenge test during the routine selection process. The 
motor subsection of the unified Parkinson’s disease rating scale (UPDRS-III) was assessed 
in the OFF state at least 12 hours after omitting PD medications. The assessment was then 
repeated 30 minutes (or when clinically ON) after administration of the patient’s regular 
medications topped-up with an additional dose of 50mg/12.5mg dispersible Madopar/ 
Benserazide. Patients with ET underwent assessment with the Fahn-Tolosa-Marin Tremor 
Rating Scale (FTMTRS) 362. The scale consists of three sections rating severity of tremor 
from 0 (none) to 4 (severe). The first section assesses severity and location of tremor, the 
second section assesses ability to perform specific motor tasks, such as writing, drawing 
and pouring, and the third section assesses patient-reported functional disability resulting 
from the tremor (speaking, eating, drinking, hygiene, dressing, writing, working and social 
activities) 363.  Inclusion in the present study was limited to patients who could tolerate lying 
flat for the duration of the preoperative scan and who have no contraindications to 3T MRI. 
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6.3.2: Preoperative diffusion weighted MRI acquisition and preprocessing 
Details of diffusion weighted MRI acquisition and preprocessing are described in the 
general methods sections. 
6.3.3: Surgical procedure and intraoperative MRI acquisition 
DBS leads (3389 Medtronic) were implanted under local anaesthesia using a stereotactic 
MRI-guided and MRI-verified approach without microelectrode recording (using a Leksell 
frame model G, Elekta Instrument AB, Stockholm, Sweden), as detailed in previous 
publications on subthalamic nucleus DBS for PD 274,275. All patients had unilateral surgery 
except for one patient with PD tremor who underwent bilateral surgery. 
Three stereotactic, pre-implantation scans were acquired, as part of the surgical procedure, 
to guide lead implantation; a proton-density and a T2 weighted axial scan (partial brain 
coverage around the thalamus and cZI) with voxel size of 1.0×1.0 mm2 and slice thickness 
of 2 mm 62,364; and a T1 weighted 3D-MPRAGE scan with a 1.5 mm isotropic voxel size on 
a 1.5T Siemens Avanto interventional MRI scanner. Three-dimensional distortion 
correction was carried out using the scanner’s built-in module. Once scans were reoriented 
to have slices parallel with the anterior commissure (AC) – posterior commissure (PC) line, 
the trajectory was planned such that the deepest contact targeted the cZI and the proximal 
contacts targeted the VIM at the level of the AC-PC. The thalamo-capsular border, 
visualised on the proton-density scan, was used to aid the identification of the laterality of 
the VIM on imaging, which was then indirectly targeted using atlas coordinates in relation 
to the mid-commissural point - [X=12-14 mm, Y= (AC-PC length/3) - 2 mm anterior to PC, 
Z=0]. The cZI was identified on the axial T2-weighted scan medial to the postero-medial 
border of the STN. The MPRAGE scan was used to plan the lead’s entry point over the 
coronal suture ± 1 cm anteroposteriorly, with the lead trajectory avoiding the ventricles and 
sulci. A 1.5 mm thick radiofrequency probe (RF) was inserted first into the deepest target 
(cZI), using impedance recording. The last 6 mm of the trajectory were traversed using 2 
mm steps whilst simultaneously assessing the implantation effect on tremor in the 
outstretched contralateral upper limb. The RF lead was then replaced with the DBS lead, 
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temporarily fixed in situ. Fibrin sealant (Tisseel, Baxter, USA) was used in the burr hole to 
prevent CSF leak and pneumocephalus 260. An external stimulator was then used to deliver 
monopolar stimulation to each contact using increasing amplitudes to assess efficacy and 
side-effect profile. Transient tingling in the palm upon stimulation was considered a sign of 
good placement. Patients were stressed, using verbal recollection and arithmetic tasks, to 
elicit the tremor. Thresholds for capsular effects and dysesthesia were also assessed. In 
the case of poor response or unacceptable side-effects, the lead was removed and the 
process repeated following appropriate targeting adjustments. Imaging was repeated 
immediately following lead implantation to confirm lead placement. The specific absorption 
rate (SAR) was kept < 0.4 W/kg by reducing the number of acquired T2 weighted slices 
covering the distal leads to 12-14. The leads were then connected to an implantable pulse 
generator (IPG) (Activa SC or PC, Medtronic, Minneapolis, Minn., USA) implanted in the 
infra-clavicular region on the same day or within a week. 
6.3.4: Outcome measures 
6.3.4.1: Effective stimulation parameters 
All DBS contacts were screened by a movement disorders neurologist once implantation 
effects had worn off (2-14 days). Patients were then followed-up in clinic to adjust and fine 
tune stimulation parameters in the first 12 months after surgery.  
6.3.4.2: Fahn-Tolosa-Marin Tremor Rating Scale 
All patients underwent assessment both in the OFF and ON DBS states 12 – 24 months 
from surgery. This was carried out by an experienced movement disorders neurologist. The 
assessment was carried out with DBS ON first and then 10 minutes after switching 
stimulation off. Good response to DBS was defined as an improvement ³ 40% in total 
FTMTRS with ON stimulation. 
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6.3.4.3: DBS contacts volume of tissue activated (VTA) modelling 
SureTune® (Medtronic Inc. Minnesota), a DBS therapy planning platform was used to 
model VTAs around individual contacts. The platform applies neuron models coupled to 
finite element simulations as described by Åström and colleagues in order to generate DBS 
therapy VTA 162. Intraoperative MRI scans were uploaded and a two-step linear registration 
was used to co-register the pre-implantation and post-implantation stereotactic MPRAGE 
scans. The first step involved manually aligning the volumes with the pre-implantation 
MPRAGE. The second step employed automated co-registration with a restricted volume 
of fusion centred around the diencephalon/ mesencephalon. This was carried out to 
minimise registration error resulting from eventual brain shift incurred during surgery, 
despite minimal brain shift with our surgical technique 260. Registration accuracy was 
carefully inspected and the process iterated if necessary. All volumes were realigned with 
a plane parallel to the AC-PC line. 
Post-implantation MPRAGE scans were used to fit the DBS lead model within the MRI 
artefact produced by the leads. Individual VTAs were then generated around active DBS 
contacts with corresponding stimulation amplitudes. Binary image files of VTAs with 
corresponding transformation matrices were exported and processed in MATLAB 
(MathWorks Inc.) using an in-house software to generate Neuroimaging Informatics 
Technology Initiative (NIfTI) volumes for further analysis. Right sided individual contact 
VTAs were lateralised to the left by swapping the x axis (x, y, z > -x, y, z) using Fslswapdim 
(FSL v5.0). 
6.3.5: Image Pre-processing 
Pre-implantation MPRAGE scans were brain extracted using BET (Brain Extraction Tool, 
FSL v5.0) 277. Two-step transformation was used to register native scans to the MNI152 
standard-space T1-weighted average structural template image (1mm resolution) 278. The 
first step employed linear (affine) transformation using FLIRT (FMRIB's Linear Image 
Registration Tool) using 12 degrees of freedom, correlation ratio cost function and normal 
search 279,280. The output from this step was used to execute non-linear registration (second 
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step) using FNIRT (FMRIB's Non-Linear Image Registration Tool) 281. This process 
produced individual native to standard (MNI space) non-linear warp fields, which were then 
applied to VTAs acquired from SureTune in order to transform all volumes to standard 
space. 
6.3.6: Analysis 
6.3.6.1: Regions of interest (ROI) definition 
Cortical reconstruction and volumetric segmentation of the MNI-152, T1 weighted (1mm) 
volume was performed with the Freesurfer image analysis suite. Resulting ROIs were used 
for connectivity based thalamic segmentation and tractography of the dentato-rubro-
thalamo-cortical tract (DRTC). Cortical volumetric masks of the primary motor cortex (M1 
[Brodmann’s area 4]), primary sensory cortex (S1 [Brodmann’s areas 3,1,2]), 
supplementary motor area (SMA), premotor cortex (PMC) (both constituting Brodmann’s 
area 6) and subcortical thalamic volumetric masks were generated. Cerebellar masks of 
the superior cerebellar peduncle and the cerebellar white matter (containing the dentate 
nucleus) were manually segmented using ITK-SNAP 365 (Figure 6-1). 
6.3.6.2: Tractography 
Probabilistic tractography was generated in ProbtrackX2 GPU version (Behrens 2007) 282 
(FSL v5.0) (number of samples=5000, curvature threshold=0.2, step length=0.5 mm 
subsidiary fibre volume fraction threshold=0.01). The process repetitively samples from the 
distributions of voxel-wise principal diffusion directions generated in BedpostX, each time 
computing a streamline through these local samples to generate a ‘probabilistic streamline’ 
or a ‘sample’ from the distribution on the location of the true streamline, building up a spatial 
‘connectivity distribution’ or global connectivity (i.e. the probability of the existence of a path 
through the diffusion field between any two distant points, a surrogate measure of 
anatomical connectivity) 103. Streamlines truly represent paths of minimal hindrance to 
diffusion of water in the brain, but they are reasonable indirect estimates of long-range 
white matter connections 283. 
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6.3.6.3: Connectivity based thalamic segmentation 
Thalamic segmentation was carried out for all patients using probabilistic tractography. The 
resulting volumes were used to create group averages. Seed voxels in the thalamus were 
classified according to the probability of connection to the defined cortical and cerebellar 
target masks (ipsilateral S1, M1, SMA/PMC and contralateral cerebellar masks). This 
process has been previously described by Behrens et al 94. CSF termination and 
contralateral cerebrum/ ipsilateral cerebellum exclusion masks were applied to exclude 
false positive streamlines and commissural tracts. 
6.3.6.4: Tractography of the dentato-rubro-thalamo-cortical pathway 
 
Probabilistic tractography was generated, for each patient, from the cerebellar seed to the 
contralateral M1 target using the contralateral thalamic mask as waypoint and the ipsilateral 
cerebrum and contralateral cerebellum as exclusion masks. CSF termination masks were 
used to exclude false positive streamlines. The process was repeated using the M1 mask 
as seed and the cerebellar mask as target. The two resulting tracks were merged to create 
a single DRTC tract. All tracks were then used to create group averages. 
6.4: Results 
6.4.1: Patients 
Preoperative scanning and surgery proceeded with no adverse events. The mean pre-
operative UPDDRS-III tremor subsection score (highest possible score = 28) for the PD 
patients was 12.5 (8-17) points off medications and 9.8 (8-12) points on medications with 
a modest average improvement of 18%. Two out of the four patients with PD did not show 
improvement in tremor with levodopa administration.  
The ET group had a preoperative FTMTRS score of 81.6 (55-97) points.  
All patients were right hand dominant. There was no surgical morbidity or mortality. One 
patient with PD had bilateral surgery in one procedure. The remainder had left sided 
surgery making up a total of 10 implanted DBS leads (five in each group) (Table 6-1). 
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6.4.2: DBS profile 
All patients improved with DBS albeit to varying degrees (Table 6-1). PD3 had a marked 
improvement in tremor following lead implantation (bilateral DBS). The tremor re-emerged 
a week later just before IPG insertion. Once DBS was switched on there was a significant 
improvement in tremor, however, 24 hours later, the patient became agitated. This was felt 
to be largely due to sleep deprivation and resolved on resumption of normal sleep. ET1 
had a significant improvement at 2 Volts, however, mild slurring and slowing of speech 
occurred at 2.5 Volts. ET2 had tingling and discomfort in the right side of the face, right arm 
and part of the right leg when stimulating the deepest contact (cZI) and facial pulling at 1.9 
Volts when stimulating the second deepest contact. ET4 developed very mild balance 
deterioration and a feeling of exhaustion and ET5 developed mild and transient 
paraesthesia with stimulation. 
6.4.3: Postoperative clinical outcomes 
All PD patients experienced tremor rebound when DBS was switched off. The mean 
improvement in FTMTRS was 58% in the PD group and 34% in the ET group, comparing 
off to on stimulation. Three out of five patients in the ET group had a poor response to 
treatment (<40%) (Table 6-1).  
6.4.4: Connectivity-based thalamic segmentation 
Appropriate thresholds of (1,000) and (100) samples per voxel were applied to cortical and 
cerebellar group average thalamic clusters respectively using Fslmaths (FSL v5.0). The 
clusters were in the ventrolateral thalamus with some overlap between SMA/PMC and M1 
clusters; and between M1 and S1 clusters. The contralateral cerebellar (dentate) cluster 
lies completely within the inferior portion of the M1 cluster (Figure 6-1). Cluster-based 
inference using Cluster (FSL v5.0) was carried out to extract the clusters and local maxima 
in outputs (Table 6-2). 
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Table 6-2: Connectivity-based thalamic clusters of cortical and cerebellar 
areas showing volumes and MNI (AC-PC) coordinates of maximum intensity 
and centre of gravity (Left hemisphere)  
Thalamic 
Cluster 
VOL 
(mm3) 
Maximum intensity coordinates 
MNI (AC-PC) 
Centre of gravity coordinates 
MNI (AC-PC) 
X Y Z X Y Z 
S1 704 -17 (-16.5) -23 (-11) 4 (8) -17 (-16.5) -22 (-10) 4.8 (8.8) 
SMA/PMC 743 -15 (-14.5) -8 (4) 5 (9) -13 (-12.5) -10 (2) 5.6 (9.6) 
M1 1021 -20 (-19.5) -19 (-7) 8 (12) -16 (-15.5) -19 (-7) 6 (10) 
Dentate 141 -10 (-9.5) -18 (-6) -3 (1) -15 (-14.5) -17 (-5) 1.5 (5.5) 
 
MNI: Montreal Neurological Institute; AC-PC: anterior commissure – posterior 
commissure; VOL: volume; S1: primary sensory area; M1: primary motor area; 
SMA: supplementary motor area; PMC: premotor cortex 
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Table 6-1: Demographics, preoperative UPDRS-III (PDT patients), FTMTRS 
(ET patients), postoperative FTMTRS ON/ OFF DBS and stimulation 
parameters 
Patient PD1 PD2 PD3 PD4 Mean ET1 ET2 ET3 ET4 ET5 Mean 
Age (yr.)* 67 63 64 67 65.3 56 49 66 78 70 63.8 
Surgery Left Left Bilat. Left  Left Left Left Left Left  
Disease duration (yr.)* 5 6 10 10 7.8 10 10 6 12 11 9.8 
Follow-up (month) 36 23 19 15 23.3 35 31 27 13 12 23.6 
Preop. UPDRS-III 
tremor 
subsection 
(PD patients) 
OFF 
MED. 
12 8 17 13 12.5 - - - - -  
ON 
MED. 
12 8 11 8 9.8 - - - - -  
IMP 
(%) 
0  
(0%) 
0  
(0%) 
6 
(35%) 
5 
(38.4%) 
2.8 
(18.4%) 
- - - - -  
Preop. FTMTRS  
(ET patients) 
- - - -  55 66 93 97 97 81.6 
Postop. FTMTRS 
OFF 
DBS 
32 33 129 55 62.3 44 71 93 89 63 72 
ON 
DBS 
14 15 44 24 24.3 29 47 81 47 36 48 
IMP 
(%) 
18 
(56%) 
18 
(55%) 
85 
(66%) 
31 
(56%) 
38  
(58%) 
15 
(34%) 
24 
(34%) 
24 
(13%) 
24 
(47%) 
24 
(43%) 
24 
(34%) 
ACTIVE 
CONTACTS 
X- 1 2 2 0  1 
0 plus 
1 
1 
0 plus 
3 
3  
X+ - - 10 -  - - - - -  
AMP 
(Volt) 
2 2 2.6 1.8 2.1 2 2 2 2.5 2.5 2.2 
PW 
(µS) 
60 60 60 60 60 60 60 60 60 60 60 
FREQ 
(HZ) 
130 150 130 130 135 130 180 130 150 180 154 
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6.4.5: Tractography of the DRTC 
Left and right group average streamlines connect the dentate nucleus to the contralateral 
primary motor cortex, passing through the contralateral red nucleus and thalamus. The 
path through the thalamus clearly traverses the cerebellar cluster and overlapping portion 
of the M1 cluster (Figure 6.2). 
6.4.6: VTA Modelling and relationship to thalamic clusters and DRTC 
VTA volumes corresponding to the active contacts stimulation for the seven patients with 
good response were averaged taking the median voxels. The good response group 
average fell on the dentate-thalamic cluster at the level of the AC-PC extending inferiorly 
into the cZI, on the DRTC. The three patients with poor response fell adjacent to, or on the 
DRTC but outside the dentate-thalamic cluster. See Figure 3 for group average responders 
VTA and non-responders VTAs in relation to the DRTC and the dentate-thalamic cluster. 
6.4.7: Feasibility of stereotactic DBS targeting of the dentate-thalamic cluster 
Employing the methods described, segmentation and registration of the dentate-thalamic 
cluster was achieved in less than 10 minutes per subject using a local, purpose built GPU 
high performance computer with 10,752 Compute Unified Device Architecture (CUDA) 
cores. Diffusion preprocessing, using the same cluster, was achieved in under 45 minutes. 
See figure 6-4 for individual dentate-thalamic clusters registered to post- and preoperative 
stereotactic MPRAGE scans. 
NeuroinspireTM surgical planning software (Renishaw PLC, United Kingdom) was used to 
carry out mock stereotactic targeting. The package has the capability of loading NIfTI 
volumes as well as DICOM image formats. The dentate-thalamic cluster voxels were 
subtracted (removed) from the stereotactic preoperative MPRAGE scan using Fslmaths 
(FSL V5.0). This process resulted in a new NIfTI volume with the clusters “punched out”. 
Planning was then carried out routinely with the added identification of the dentate-thalmic 
cluster, at the level of the AC-PC as demonstrated in Figure 6-5. 
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Figure 6-1: Thalamic clusters with corresponding cortical and cerebellar 
ROI masks (S1: blue - M1: red - SMA/PMC: green - dentate: yellow) 
 
S1: primary sensory area; M1: primary motor area; SMA: supplementary motor 
area; PMC: premotor cortex 
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Figure 6-2: The left (blue) and right (red) dentato-rubro-thalamo-cortical 
tracts shown with decussation in the midbrain and path through the 
thalamic clusters 
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Figure 6-3: (A) Responders group average VTA (hot) and (B) non-
responders VTAs (copper) in relation to the DRTC and the dentate-thalamic 
cluster 
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Figure 6-4: Individual dentate-thalamic clusters registered to postoperative 
(top) and preoperative (bottom) stereotactic scans 
 
The arrows point to the DBS lead artefact in relation to the dentate-thalamic 
cluster  
 
6.5: Discussion 
In this work, we segmented the VIM nucleus of the thalamus, using connectivity based 
probabilistic techniques, applied to individual HARDI datasets, in five patients with ET and 
four patients with PD tremor, one year from thalamic DBS. Furthermore, we generated 
probabilistic streamlines representing the DRTC tracts, clearly connecting the M1 area with 
the contralateral dentate nucleus of the cerebellum via the VIM showing clear crossing in 
the brainstem. Three out of nine patients had a suboptimal, long-term response to 
treatment as demonstrated on improvement on FTMTRS. Post-hoc analysis of active DBS-
contacts VTA models, showed that a good response is seen when the VTA was in the 
segmented VIM. 
  
156 
Figure 6-5: Left VIM DBS planning using NeuroinspireTM surgical planning 
software using preoperative stereotactic T2-weighted slab registered to 
MPRAGE T1 NIfTI volume with dentate-thalamic clusters punched-out 
 
 
Individualised, image guided and image verified targeting of the VIM has been a quest of 
many in the field of functional neurosurgery. Inter-individual variability in the VIM’s location 
has been illustrated in several studies. This was clearly shown in a functional connectivity 
study that analysed resting state fMRI scans in 58 healthy subjects 115.  Considerable 
individual variability of atlas-based VIM targeting was again demonstrated in a study that 
examined the VIM’s relation to surrounding major fibre tracts using deterministic 
tractography in 10 patients with thalamic DBS for ET 141. 
In 2003, Behrens et al published a report detailing the use of probabilistic tractography in 
delineating boundaries between different thalamic nuclei, based on connectivity patterns 
between the thalamus and various cortical areas 94. This was the first time probabilistic 
tractography was used to parcellate grey matter structures, obtaining the quality of results 
that traditional maximum-likelihood or streamline approaches have failed to produce 366. 
The resulting thalamic segmentation corresponded well with previous histological findings 
367 and tracer studies in non-human primates 368-375. This technique was further validated 
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in another study in 2004 376. Other grey matter structures have also been segmented with 
a similar approach 96,97,112. 
Several studies have since used probabilistic tractography to examine VIM connectivity to 
cortical and cerebellar areas 139,140,377, or to segment the VIM based on said connectivity 
138. Interestingly, a post hoc analysis with connectivity based segmentation of six patients 
with bilateral VIM DBS showed the effective DBS contacts to be in the thalamic region with 
the highest probability of connection to the premotor and supplementary motor cortices 138. 
This goes against prior anatomical knowledge 367 and the consistent findings from other 
connectivity studies 115,139,140,377 and transcranial magnetic stimulation (TMS) studies 296. It 
is likely that this inconsistency resulted from using diffusion MR acquisition parameters 
intended for conventional clinical applications, such as mapping major white matter tracts 
prior to surgical intervention with low angular resolution (number of diffusion directions = 
20), low spatial resolution (isotropic voxel size = 2 mm) and low angular contrast (b-
value=1000 s/mm2) 138.  
Choosing the appropriate diffusion imaging parameters is paramount to achieving accurate 
segmentation of grey matter structures such as the thalamus 359-361. In vivo probabilistic 
tractography studies in the cerebellum, brainstem and diencephalon carry significant 
challenges. Motion artefacts, caused by the highly pulsatile nature of the region, can 
degrade the MRI signal during diffusion image acquisition, reducing the signal-to-noise 
ratio (SNR). This is complicated by the presence of myriad criss-crossing axons and 
reticular brain regions 104,105. One way of dealing with this is by using pulse-gating and 
respiratory rate monitoring during diffusion imaging. Likewise, by acquiring multiple 
diffusion scans, at a high angular resolution (increasing acquisition time), SNR is improved 
91,103. 
We acquired 270 diffusion scans per patient (in 2 × 128 directions sets) over 62 minutes. 
We meticulously and systematically corrected artefacts and examined the processed 
imaging data for quality control. We modelled three crossing fibres per voxel and used 
probabilistic tractography to ameliorate difficulties posed by crossing or kissing fibres and 
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tunnelling effect 92,103. To keep the analysis focused, a set of tractography rules based on 
knowledge from anatomical studies was used, without being too restrictive. 
Our analysis shows that the thalamic area, with highest connectivity to the contralateral 
dentate nucleus lies within the much larger area with highest connectivity to M1 in a ventro-
lateral position. The area with highest connectivity to the SMA and PMC was anterior to the 
M1 area. The area with highest connectivity to S1 was posterior to the M1 area. This is in 
keeping with known anatomical information 378. The ventral posterior (VP) thalamic nuclear 
complex relays impulses of sensory systems to S1, whilst ventral lateral (VL) nuclear 
complex relays information from the cerebellum, basal ganglia and substantia nigra (SN) 
378. The VL complex is generally subdivided into the pars anterior (VLa), pars posterior 
(VLp) and pars medialis (VLm). The VLa relays afferents from the globus pallidus interna 
(GPi) to the PMC and SMA 262,379-384; whilst the VLm relays input from the SN to the PMC 
and prefrontal cortex 368,385,386. The VLp, receives a large, topographically organised input 
from the cerebellar nuclei, projecting principally to M1 378,380,382,387,388. The VIM corresponds 
to the inferior part of the VLp 368. 
It is important to bear in mind that the subdivisions of the thalamus by 389 or 390 are primarily 
based on histochemical staining of serial sections of human thalami, rather than anatomical 
connectivity. It is entirely possible that the optimal “functional” target straddles these 
subdivisions. Moreover, it is mechanistically likely that network connectivity of the target 
area will be a better predictor of efficacy than its histochemical properties. 
Previous work focused on relation of DBS contacts to areas with cortical connectivity rather 
than cerebellar connectivity 138. We have shown these areas to be non-specific and with 
varying degrees of overlap. Whilst the dentate-thalamic area is more representative of the 
actual VIM, it is harder to segment due to inherent difficulties in diffusion connectivity 
techniques highlighted above. This is, to our knowledge, the first time such a parcellation 
has been made possible, on the individual level, using in vivo 3T MRI. 
Deterministic approaches have so far failed to produce anatomically accurate 
representations of the DRTC, generally showing the tract to arise from the ipsilateral, not 
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the contralateral dentate nucleus 132,136,358, or stopping at the upper brainstem decussation 
level 357. This may not be problematic when the DRTC itself is being targeted, as it is the 
case in these reports; however, to accurately segment the VIM based on cerebellar 
connectivity, the crossing cerebellar streamlines must be mapped. We show clear crossing 
of the DRTC from the contralateral dentate nucleus, which passes through the segmented 
dentate area in the thalamus all the way to M1. The average VTA of the responders group 
lies in the inferior dentate thalamic area and on the DRTC in the CZi, possibly capturing 
the DRTC fibres as they enter the VIM.  
6.5.1: Using the FTMTRS as an outcome measure 
Despite the prevalence of tremor amongst movement disorders, there is no universally 
accepted method of quantifying and rating its severity 362,363,391-393. Several tremor scales 
exist but they are often disease specific 394. In 2013, a task force established by the 
Movement Disorders Society reviewed several rating scales for the assessment of tremor 
and recommended the use of five severity scales, one of which was the FTMTRS. The 
scale was assessed for reliability, validity and sensitivity to change 395. Moreover, in view 
of the mixed patient group in this study, the FTMTRS has the advantage of being non-
disease specific 396. 
In this study, we examined the change in FTMTRS with DBS-OFF and -ON, 12 - 24 months 
from surgery. We did not calculate the improvement in FTMTRS in relation to preoperative 
baseline scores. This was since FTMTRS scores were not part of the routine preoperative 
assessment for PD patients which is a limitation of this study. It is interesting to notice the 
apparent ‘lesion effect’ in three out of five ET patients (two responders and one non-
responder) illustrated by reduction in FTMTRS in the postoperative DBS-OFF 
measurements when compared to baseline. Indeed, the overall percentage of improvement 
with DBS-ON would have been higher had the preoperative FTMTRS been used as a 
denominator in the ET group. 
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6.5.2: Limitations 
The limitations of the VTA model used in this study and the rationale behind using this 
model have been described in chapter 2 (2.10.4). 
By employing multiple registration steps, we have introduced error to the system. 
Nonetheless; we meticulously confirmed registration accuracy at each step to alleviate the 
impact of this issue. 
Lastly, the relatively long scan duration is a drawback. This was accepted to achieve the 
required SNR and resolution. However, since this study was conducted, novel MRI 
acquisition techniques, such as Simultaneous Multi-Slice Imaging and Multi-Band Imaging 
303 have been developed that will allow future studies to run similar protocols within half the 
time without compromising the SNR. Further improvements in diffusion imaging, with 
higher spatial and angular resolution, better MRI gradients and shorter acquisition times 
with emergence of multi-band acquisition will add to the value of this modality 102,283. Lastly, 
the number of patients in this study is relatively small with mixed aetiologies. However, the 
data suggest that imaging can be used to optimise efficacy of tremor control. We intend to 
expand our experience with this technique in each pathology in the coming years. 
6.6: Conclusion 
Probabilistic tractography techniques can be used to segment the VL and VP thalamus 
based on cortical and cerebellar connectivity. The thalamic area, best representing the 
VIM, is connected to the contralateral dentate cerebellar nucleus. Patients with VTAs in 
this area attained good treatment response, whilst those with VTAs outside it did not. 
Connectivity based segmentation of the VIM can be achieved in individual patients in a 
clinically feasible timescale, using HARDI and high performance computing with parallel 
GPU processing. This same technique can map out the DRTC with clear mesencephalic 
crossing. Future studies may focus on improving data acquisition and processing time; and 
apply this technique prospectively in patients undergoing thalamic DBS or lesioning for 
tremor.
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Section III: 
 
 DBS for Trigeminal Autonomic 
Cephalalgias and Connectivity in 
Cluster Headache 
“Of pain you could wish only one thing: that it should stop. 
Nothing in the world was so bad as physical pain. In the face 
of pain there are no heroes.” 
 
George Orwell, 1984 
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7. Ventral Tegmental Area Deep Brain Stimulation for 
Refractory Chronic Cluster Headache 
7.1: Abstract 
Cluster headache (CH) has a prevalence of 0.1-0.2%. Ten to 15% of patients have a 
chronic form (CCH) at times intractable to medical therapies. We present outcomes in a 
cohort of medically-intractable CCH with ventral tegmental area (VTa) deep brain 
stimulation (DBS). In an uncontrolled open-label prospective study, twenty-one patients (17 
male; mean age 52 years) with medically refractory CCH were selected for ipsilateral VTa-
DBS by a specialist multi-disciplinary team including headache neurologist and functional 
neurosurgeon. Patients had also failed, or were denied access to occipital nerve stimulation 
within the UK National Health Service. The primary endpoint was the improvement in the 
headache frequency. Secondary outcomes included other headache scores (severity, 
duration, headache load), medication use, disability and affective scores, quality-of-life 
(QoL) measures and adverse events. Median follow-up was 18-months (range 4-60). At 
the final follow-up point, there was 60% improvement in headache frequency (p=0.007) 
and 30% improvement in headache severity (p=0.001). The headache-load (a composite 
score encompassing frequency, severity and duration of attacks) improved by 68% 
(p=0.002). Total monthly triptan intake of the group dropped by 57% post-treatment. 
Significant improvement was observed in several QoL, disability and mood scales. Side-
effects included diplopia, which resolved in two-patients following stimulation adjustment, 
and persisted in one-patient with a history of ipsilateral trochlear nerve palsy. There were 
no other serious adverse events. This study supports that VTA-DBS may be a safe and 
effective therapy for refractory CCH patients who failed conventional treatments. This study 
provides Class IV evidence that ventral tegmental area deep brain stimulation decreases 
headache frequency, severity and headache load in patients with medically intractable 
chronic cluster headaches. 
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7.2: Introduction 
Cluster headache (CH) is a trigeminal autonomic cephalalgia (TAC)397 characterized by 
attacks of severe, strictly unilateral cranial pain associated with ipsilateral cranial autonomic 
features.398,399 CH has a prevalence of 0.1-0.2% and chronic cluster headache (CCH) 
occurs in 10-15% of sufferers whose attacks occur for more than one year without 
remission, or with remissions lasting less than one month.400 401-403 404 
Standard medical therapy comprises acute and prophylactic treatments, which are usually 
effective.405 However, in a small but significant number of highly disabled individuals, 
attacks are intractable. For these patients, peripheral [occipital nerve stimulation (ONS) 
and/or sphenopalatine ganglion stimulation] and central neuromodulation [ventral 
tegmental area (VTa) deep brain stimulation (DBS)] have been carried out with promising 
results.68,123,124,406-408 
Here we investigate the efficacy of VTa-DBS when used as a humanitarian intervention in 
patients who had exhausted every other option available to them with the framework of the 
UK NHS. We present a prospective study of 21 consecutive patients with CCH, treated 
using a magnetic resonance imaging (MRI)-guided and MRI-verified approach to VTa-DBS, 
focusing on changes in headache characteristics, quality of life, disability and mood. 
7.3: Methods 
Standard Protocol Approvals, Registrations, and Patient Consents 
The UK National Institute for Health and Care Excellence (NICE) published guidance 
concerning DBS for intractable TACs in March 2011 
(https://www.nice.org.uk/guidance/ipg381/chapter/1-Guidance), advising arrangements for 
clinical governance, consent, audit and research. In keeping with this, and under the 
supervision of our institution’s Clinical Effectiveness Supervisory Committee (CESG), we 
offered VTa-DBS to CCH patients who had failed ONS or in whom NHS funding for ONS 
had been declined. The procedure was provided on the basis of a “humanitarian 
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intervention”. Patients were provided with CESG approved patient information booklets and 
gave written consent. 
7.3.1: Patient selection 
Included patients fulfilled the ICHD-II diagnostic criteria for CCH397 and had experienced 
highly disabling, medically refractory symptoms for at least two years. CCH was classified 
as medically intractable if patients failed adequate trials of at least five of the following 
seven drugs: verapamil, lithium, methysergide, topiramate, melatonin, gabapentin, and 
valproate. A failed trial was defined as an unsatisfactory response, side effects intolerance 
or contraindication to the agent’s use.409 All patients were considered for ONS prior to DBS 
and had either been refused funding or had failed to respond adequately. Sphenopalatine 
ganglion stimulation was not available in the UK during the study period. Referrals were 
made by a single tertiary specialist headache clinic to a DBS multidisciplinary team at the 
same centre. Neuropsychological evaluations and MRI brain scans were performed to rule 
out cognitive impairment, brain lesions or significant brain atrophy.  
7.3.2: Outcome measures and follow up 
Outcome data were collected and recorded prospectively and included headache 
frequency, headache severity, headache load, disability scores, affective scores, quality of 
life measures, adverse events (including surgical complications, stimulation-induced 
adverse events and morbidity) and reduction in preventative and acute treatment.  
Headache severity was measured on the verbal rating scale (VRS) for pain (0 being no 
pain, and 10 being the worst pain imaginable). Patients reported the mean headache 
intensity during individual attacks. The individual scores were then averaged over the 
observation period. Headache frequency was defined as the number of CH attacks/day. 
Headache load (HAL) was defined as ∑ [severity (on the verbal rating scale)] x [duration 
(in hours)] of all headache attacks occurring over a 2 week period. These measures were 
assessed using headache diaries collected preoperatively (baseline), at commencement 
of DBS therapy, at 3 months, 6 months, 12 months and yearly thereafter. Patients with 
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multiple headache types kept separate diaries for CH attacks and other headache 
syndromes; headache parameters were calculated for each headache type. 
Responders were defined as patients with sustained HAL reduction ≥30% since this was 
deemed meaningful in line with the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials  (IMMPACT) guidelines.410 
Disability measures, quality of life and affective scores were collected using questionnaires. 
The Short Form-36 (SF36) measuring both the physical component summary (PCS) and 
mental component summary (MCS) scores was used to assess health-related quality of 
life at baseline and after stable improvements in responders, or after a year of continuous 
stimulation in non-responders.411 Since specific tools for measuring the disability of CH 
have not yet been validated, disability was assessed using the Migraine Disability 
Assessment Scale (MIDAS)412 and the Headache Impact Test-6 (HIT-6).413 MIDAS and 
HIT-6 have been used extensively to assess primary headache disorders. They have 
previously been used to assess the disability of CH and hemicrania continua patients 
treated with ONS.414,415 The Hospital Anxiety and Depression Scale [(HAD-A) and (HAD-
D)]416 was used to evaluate the presence and degree of anxiety, and depression before 
and after surgery. Other questionnaires included the Beck Depression Inventory II (BDI-II) 
and the EuroQol (EQ-5D). 
7.3.3: Surgical procedure 
DBS leads were implanted using a stereotactic MRI-guided and MRI-verified approach 
without microelectrode recording as detailed in previous publications (Leksell frame model 
G, Elekta Instrument AB, Stockholm, Sweden).61,274 The first 11 patients, had lead 
implantation performed under local anaesthesia; in the remaining 10 patients leads were 
implanted under general anaesthesia.61 The anatomical target was the ipsilateral VTa. The 
location for the deepest contact of the 3389 Medtronic lead was defined on a 1.5T T2-
weighted axial stereotactic MR image at a level immediately above the mammillary bodies, 
anteromedial to the hypointense red nucleus and posterolateral to the hypointense 
mammillothalamic tract. Immediately after lead implant, location was verified with a 
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stereotactic MRI scan (Figure 7-1) in patients without ONS. Postoperative stereotactic CT 
scan was performed in patients with implanted ONS hardware. The lead was then 
connected to a single or dual channel Implantable Pulse Generator (IPG) (Medtronic, 
Minneapolis, Minn., USA) implanted in the infra-clavicular region on the same day of lead 
implantation or within a week, as a staged procedure under general anaesthesia. 
7.3.4: DBS programming 
In the weeks following surgery, open label programming was conducted to define optimal 
stimulation parameters. Six patients (29%) had a delay of one to three months before their 
stimulation was started. This was because they reported a clear ‘stun’ effect period post-
operatively, during which attacks improved without any stimulation. In these patients, DBS 
was not initiated until they reported a return to baseline in terms of attack frequency. All 
devices were programmed with a frequency of 185Hz and a pulse width of 60µs as 
described by Franzini et al 124.  Voltages were adjusted according to self-limiting side effects 
(diplopia, vertigo, oscillopsia and ophthalmoplegia) in single or multiple steps, depending 
on the patient. Stimulation parameters were kept constant for the first three months and 
were adjusted after this if patients were not responding. 
7.3.5: Statistical analysis 
IBM SPSS Statistics package v22 was used for all the statistical analyses.  
Percentage change from baseline was used where appropriate. The data at baseline was 
assessed for normality using Kolmogorov-Smirnov test and by inspecting the Q-Q plot and 
frequency distribution histogram prior to determining appropriate statistical tests. Whenever 
the distribution was not normal, non-parametric tests were used and the median was given 
instead of the mean. Wilcoxon signed-rank test was used to compare treatment effect at 
each time-point from baseline. To adjust for multiple comparisons, Bonferroni corrections 
were applied by multiplying each test-statistics p-value by the number of comparisons. 
Statistical significance was set at 5%. Raw and normalized data were tested and 
descriptive statistics were reported where applicable.  
  
168 
7.3.6: Research questions 
When carried out in patients with refractory CCH; 
1) Does VTa-DBS improve headache frequency, severity and headache load? (Class 
4 evidence) 
2) Does VTa-DBS improve disability, mood and quality of life? (Class IV evidence) 
3) Is VTa-DBS safe? (Class IV evidence) 
7.4: Results 
7.4.1: Patient sample 
Between April 2009 and November 2013, 21 patients (17 male) with a mean (SD) age of 
52 (10) years, underwent VTa-DBS for CCH. CCH was the sole headache diagnosis in 
sixteen patients (76%). Other primary headaches were present in the remaining 5 patients 
(24%), including episodic migraine, sporadic hemiplegic migraine and short-lasting 
unilateral neuralgiform headache with conjunctival injection and tearing (SUNCT). The 
mean (SD) time from CH onset until surgery was 15 (7) years. The mean (SD) time from 
CH onset until the last follow-up point was 18 (8) years. Sixteen patients received unilateral 
DBS electrode implantation (8 left) for strictly unilateral cluster CH; the remaining five 
patients (24%) underwent bilateral DBS electrode implantation for side-variable CH 
attacks. Six (29%) patients had prior ONS implanted with limited or short lasting effect with 
a median time of 4 years prior to undergoing DBS. Of these, three patients had the ONS 
removed before undergoing DBS surgery (Table 7-2). Co-morbidities in this patient group 
included depression (n=10), previous suicide attempts or ideation (n=4), cancer (n=3), 
other chronic headache syndromes (n=5), epilepsy (n=3), Parkinson’s disease (n=1), 
chronic fatigue syndrome (n=1), stroke (n=1), heart disease (n=1), hereditary spastic 
paraparesis (n=1) and temporo-mandibular joint dysfunction (n=1). Four patients were 
smokers and three were ex-smokers. 
Implanted leads were within a mean (SD) of 0.8 (0.4) mm from the planned target. 
Postoperatively three patients complained of intermittent diplopia that resolved in two 
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patients following stimulation parameters adjustment and persisted in the other patient who 
had a previous history of ipsilateral trochlear nerve palsy following a head injury; this 
diplopia persisted even when stimulation was switched off. One patient developed a keloid 
scar over the IPG incision. A superficial wound infection developed in one patient, which 
resolved with antibiotics treatment. There was no surgical mortality or other significant 
morbidity. Post-operative follow up ranged from 4 months to 5 years with 19 patients having 
at least one year follow up. 
7.4.2: Frequency and severity of headache attacks (VRS) 
At the final follow up point, there was a 60% overall improvement in the median headache 
frequency from 5 to 2 attacks/day (p=0.007). The percentage of patients who had at least 
30% and 50% reduction in median frequency of attacks was 62% and 52% respectively.  
The overall improvement in median headache severity was 30% from 10 to 7 points on the 
VRS (p=0.001). The percentage of patients who had at least 30% and 50% reduction in 
median headache severity on the VRS was 43% and 24% respectively at the final follow 
up point (Table 7-3 shows effect of DBS on CH attack frequency, severity and duration at 
last follow-up). 
7.4.3: Headache load (HAL) 
Eleven patients (52%) showed a maximum reduction in the HAL of more than 80% during 
the follow up period. Within three months of surgery, the median change in HAL was 62%, 
at 6 months it was 59% and at twelve months it was 79% (Table 7-1, and Figures 7-2a, 7-
2b). 
The percentage of patients who had at least 30% and 50% reduction in headache load was 
81% and 76% respectively at the final follow-up point. Four patients (19%) failed to respond 
to treatment (< 30% reduction in HAL). Three of these had also failed to respond to ONS 
treatment previously. The subset of patients with prior ONS (n=6) had a failure rate of 50% 
(n=3). There was no change in the median HAL at 3 months, deterioration of 3% at 6 
months and of 23% at 12 months (n=6). In this subgroup, the three patients who improved 
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had a modest but meaningful reduction of the median HAL of 34%, 30% and 34% at 3, 6 
and 12 months respectively.  
7.4.4: Reduction in acute and preventative treatment  
Seven patients were on preventative medications prior to DBS insertion. Six continued to 
take preventative medications after surgery although, four of these reduced the dose of a 
medication and three stopped at least one medication.  One patient increased the dose of 
verapamil as it had an improved effect on preventing attacks post-DBS.  Eleven patients 
were taking triptans prior to treatment and 12 were using oxygen.  At the last follow-up 
point, seven patients were using triptans and 11 were using oxygen.  One patient started 
to use triptans again post treatment as it was found to be effective whereas previously it 
had not.  The total monthly triptan intake of the whole group was 873 doses pre-treatment 
and 376 doses post-treatment - a reduction of 57% (Table 7-5). 
7.4.5: QoL, mood and disability measures 
Median improvement in HIT-6 was 4 points (corrected-p=0.018) at 6 months and 6 points 
(corrected-p=0.034) at 12-months. The PCS section of the SF-36 scores showed an 
improvement of 13% (corrected-p=0.038) at 6-months (Table 7-4 and Figure 7-3). 
7.5: Discussion 
This open-label prospective study suggests that MRI-guided and MRI-verified DBS of the 
VTa is a safe and effective procedure in patients with CCH whose symptoms are refractory 
to other treatments. Symptomatic improvement was sustained over time and was 
accompanied by significant improvements in a number of quality of life scales. 
In 1998, a positron emission tomography study reported increased activation in the 
posterior hypothalamic region during CH attacks, though the maximal activation was 
centred over the VTa.417,418 This led to the first DBS procedure in 2001 with attacks 
disappearing within 48 hours of starting stimulation.123 This pioneering group referred to 
the anatomical target as the “posterior hypothalamus (PH)” rather than the VTa, and went 
on to report the first series of 5 patients in 2003 and 19 patients in 2013.124,419 To date, 
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different centres have published data on over 70 patients with DBS for medically-intractable 
CCH with varying response rates but an overall good safety record with the exception of 
one fatal intracerebral haemorrhage during a microelectrode guided 
procedure.68,69,406,407,419 
A randomized controlled crossover trial of DBS for CCH did not show any significant 
difference between sham and active stimulation during the blinded crossover period 
(Fontaine et al 2009). However, 1-year outcome revealed that 6/11 patients had >50% 
reduction in attack frequency and three patients were pain-free. The difference in outcome 
may be explained by the short 1 month crossover period within 3 months of surgery. Such 
a design does not allow for residual micro-lesion effects in the postoperative period or the 
observed increase in stimulation efficacy over 3-months of continuous stimulation in open-
label trials. 
Our study shows a clear reduction in the headache frequency and severity of CCH attacks 
with VTa-DBS, with greater benefit on frequency. However, using one aspect alone - 
headache severity or headache frequency - may not represent the real response of CCH 
attacks to an intervention. Therefore, this study introduces the concept of HAL that may 
provide a more meaningful measure of symptom severity. VTa-DBS resulted in significant 
improvement in the HAL as early as three months post operatively which continued until 
the final follow-up point. Nevertheless, the clinical meaningfulness of HAL as a primary 
end-point needs validation by studies in larger cohorts. 
The monthly triptan intake of the group as a whole dropped by 57% (497 doses/month).  
Using current UK costing estimates 420 this can be calculated to be a saving of £8291 a 
month for the 21 patients or around £395 a month per patient on triptans alone. 
None of the quality of life, disability and mood outcome measures deteriorated following 
surgery and a number improved significantly from baseline (HIT-6, SF36-PCS and 
EuroQol). The largest improvement was seen in in the SF36-PCS at 6 months. 
Improvement in quality of life measures did not have the same magnitude as that observed 
with HAL. The relatively long duration of the disease (average 15 years) may have resulted 
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in socio-economic and psychosocial adjustments to chronic illness that are unlikely to 
improve immediately following improvement in the headache symptoms. Other factors to 
consider are other co-morbidities in our cohort of patients. 
The brain region used for DBS was first described as a surgical target by Sano et al who 
performed stereotactic lesions in 51 patients with pathologically aggressive behaviour.421 
Although this area has been widely described as the ‘posterior hypothalamus’, the 
anatomical accuracy of this label has been contested. The mammillo-thalamic tract 
represents the posterior border of the hypothalamus and the target area lies posterior to 
this within the ventral tegmentum of the midbrain.418,422 This brain region has also been 
used as a target in DBS for depression.423 
Our general practice is to perform DBS surgery under general anaesthesia when the brain 
target can be well visualized with MRI to guide electrode insertion.61,274 However, we 
elected to perform surgery under local anaesthesia for the first eleven patients. This 
allowed intraoperative testing with macro-stimulation to study any possible intraoperative 
side effects of stimulation. With higher voltages these included tachycardia, raised blood 
pressure, vertical diplopia and a feeling of “panic” or “impending doom”. These effects were 
reproducible in all tested patients. Once the procedure was well established locally, we 
performed the surgery under general anaesthesia, relying on MRI-verified targeting. 
Limitations apply to any open-label study. A placebo effect cannot be excluded; however, 
this is unlikely to be large with follow up over one year. Moreover, there were a number of 
incidents where attacks recurred when stimulation was inadvertently switched off. 
The six patients who had a short lasting or no response to ONS therapy prior to receiving 
DBS had a much higher failure rate and no overall improvement in HAL. Furthermore, those 
who did respond to DBS showed a very modest improvement in HAL when compared to 
that seen across the entire patient group. Moreover, two of the five patients with bilateral 
CCH were non-responders. A failure to respond to ONS and the presence of bilateral 
symptoms may be predictors of poor outcome following DBS; however, these patient 
subgroups are too small to draw any firm conclusions. 
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Lack of response to VTa-DBS in some patients has been reported in previous series in 
spite of well positioned DBS electrodes.422 Despite an increase in HAL in these patients 
(Figure 7-2b), our cohort of patients experienced significant improvement as a group. 
Further work into structural and functional connectivity may reveal underlying differences 
between responders and non-responders, improving patient selection and outcome of DBS 
in CH. This study suggests that MRI-verified VTa-DBS may be a safe and effective 
treatment for drug-refractory CCH and could be considered for suitable patients who fail 
conventional treatment. We also noted positive effects of DBS for CCH on patient-reported 
quality of life, disability and mood. 
Table 7-1: Median Headache Load  
 Baseline 3 Months 6 Months 12 Months Last F/U 
Median 696 258 (n=17, 
p=0.002) 
198 (n=16, 
p=0.01) 
156 (n=20, 
p=0.003) 
208 (n=21, 
p=0.002) 
MAD 235 175 155.5 146 162 
Median Improvement (%) 62% 59% 79% 68% 
Median Headache Load at baseline and at postoperative follow-up points with 
percentage of improvement in Headache Load relative to baseline. MAD: Median 
Absolute Deviation. P values are Bonferroni corrected; they represent change 
relative to baseline 
 
Figure 7-1: Immediate post-operative stereotactic axial T2-weighted and 
coronal T1-weighted MR images demonstrating the deep brain stimulation 
lead in the left ventral tegmental area 
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Table 7-4: Quality of life, disability and mood 
 
*: p value ≤0.05; Med: Median 
** Normally distributed data presented in mean and SD instead of median and 
MAD 
Quality of l ife, disability and mood data at baseline, 3, 6 and 12 months post-
surgical follow-up 
MIDAS: Migraine Disability Assessment Score, HIT6: Headache Impact-6, HAD-A: 
Hospital Anxiety and Depression Scale (Anxiety component), HAD-D: Hospital  
Anxiety and Depression Scale (Depression component), BDI-II: Beck Depression 
Inventory II,  SF36-PCS: Short Form 36 Physical Summary Score, SF36-MCs: Short 
Form 36 Mental Summary Score. MAD: Median Absolute Deviation.  P values are 
Bonferroni corrected 
 Baseline 6 Months 12 Months 
 Med MAD n Med MAD n p-val Med MAD n p-val 
MIDAS 137 74 18 100 91 18 0.16 29 29 17 0.08 
HIT-6 69 4 19 65 5 19 0.02* 64 8 16 0.03* 
HAD-A** (11) (5) 19 (9) (5) 19 0.22 (9) (5) 17 0.5 
HAD-D** (12) (6) 19 (10) (6) 19 0.22 (10) (5) 17 0.32 
BDI-II 28 11 18 25 12 18 0.27 20 8 15 0.47 
SF36-PCS 32 6 14 36 9 14 0.04* 35 6 13 0.27 
SF36-MCS 32 9 14 36 12 14 1.10 34 16 15 1.94 
Euro-QoL 0.65 0.09 11 0.68 0.07 11 1.25 0.71 0.07 10 0.08 
Euro-Scale 49 19 11 55 15 11 0.28 45 17 10 1.89 
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Table 7-2: Patient demographics  
Patient 
Age 
(years) 
at time 
of 
implant 
Sex 
Duration 
of CH 
from 
onset to 
time of 
implant 
(years) 
Other 
headache 
types 
Laterality 
of DBS 
electrode 
MRI scan result 
Total duration 
of DBS therapy 
at last follow up 
(years) 
1†† 59 M 16  Left Normal 1.5 
2 50 F 6 Episodic 
migraine 
Right Normal 0.8 
3 40 M 27 SUNCT 
Post traumatic 
migraine 
Right 
Normal 
2.0 
4†† 49 M 23  Right Normal 1.0 
5 51 M 23  Left Normal 1.5 
6 54 F 16  Left Normal 5.0 
7 61 M 16 Episodic 
migraine 
Right Normal 5.0 
8 43 F 6  Bilateral Normal 1.5 
9† 47 M 9  Right Right petrous bone 
cholesteatoma 
1.3 
10† 61 M 21  Bilateral Normal 1.5 
11 41 M 6  Bilateral Normal 1.6 
12 37 M 20  Right Normal 4.5 
13 46 M 5 Sporadic 
hemiplegic 
migraine 
Bilateral 
Normal 
0.8 
14† 55 M 22  Left Normal 1.8 
15 71 M 30 SUNCT Left Left cerebello-pontine 
angle arachnoid cyst  
3.5 
16†† 35 F 13  Bilateral Normal 1.2 
17 43 M 18  Left Normal 1.8 
18 70 M 10  Right Normal 3.5 
19 70 M 18  Left Mature infarct in the 
right cuneus  
3.5 
20 48 M 11  Right Normal 1.0 
21 57 M 9  Left Developmental venous 
anomaly (DVA) 
0.3 
Median 
(range) 
50 (35-
71) 
 16 (5-27)    1.5 (0.3-5) 
 
† Patients with implanted occipital nerve stimulator (ONS), †† denotes removal 
of the ONS prior to DBS. SUNCT: short-lasting unilateral neuralgiform headache 
with conjunctival injection and tearing, CH: cluster headache,  M: male, F: female. 
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Table 7-3: Effect of DBS on headache characteristics 
 
Follow-
up after 
DBS 
(years) 
Median 
frequency/day 
(range) 
Median severity on 
VRS (range) 
Median duration in 
HOURS (range) Headache Load 
Percentage of 
improvement 
of the 
headache load 
Patients 
estimation of 
benefit since 
implantation Before After Before After Before After Before After 
1 1.5 2 (1-2) 2 (1-2) 7 (6-8) 7 (7-8) 
2.5 (1-
4) 
2 (1-3) 
840 260 69% 
0% 
2 
0.8 
3 (2-3) 3 (2-3) 
7 (7-10) 5 (3-
6) 3 (0.25-3) 
0.5 
(0.5-
0.6) 696 239 
66% 
70% 
3 
2.0 
5 (4-5) 
1 (1) 10 (9-
10) 
8 (8) 1.5 
(0.5-
2.5) 
1 (1-
1.5) 
764 78 
90% 
75% 
4 1.0 3 (2-3) 2 (1-2) 6 (5-6) 3 (2-6) 2 (2-4) 
2 (1-4) 
379 208 53% 
60% 
5 1.5 4 (3-4) 0 (0-1) 10 (10) 0 5 (5-6) 6 (6-8) 1341 0 100% 95% 
6 
5.0 
5 (4-6) 
3 (2-3) 10 (9-
10) 
9 (6-
10) 3 (3-4) 
1.5 
(0.75-
4) 1995 529 
73% 
30% 
7 
5.0 
3 (2-3) 
0 (0-1) 10 (9-
10) 
8 (8-
9) 2 (0.75-3) 
0.3 
(0.25-
0.7) 474 270 
43% 
50% 
8 1.5 5 (3-5) 0 (0-1) 9 (6-9) 6 (6) 2 (2-2.75) 
2.5 
(2.5) 1964 347 82% 
99% 
9 
1.3 
4 (4-6) 
2 (2-4) 8 (8) 6 (6-
9) 
1.5 
(0.3-
1.5) 
1 (0.3-
1.25) 
532 180 
66% 
80% 
10 1.5 7 (5-7) 7 (5-7) 9 (7-9) 8 (7-9) 
1.5 
(0.8-
1.8) 
1.2 
(0.75-
22.0) 
519 603 -16% 25% 
11 1.6 6 (4-5) 1 (0-4) 8 (5-9) 8 (8) 2 (0.5-3) 
0.5 
(0.5-
2.5) 
221 20 91% 70% 
12 4.5 4 (3-4) 0 (0) 10 (10) 0 1 (0.75-1) 0 (0) 751 0 100% 99% 
13 1.4 7 (5-7) 3 (3-4) 10 (10) 7 (4-9) 3 (1-4) 
1.5 (1-
2) 2020 743 63% 30% 
14 1.8 6 (5-8) 5 (4-6) 10 (9-10) 
10 
(10) 1 (1-2) 
1.5 
(0.5-3) 961 1255 -31% 5% 
15 3.5 10 (6-10) 8 (4-8) 8 (5-9) 
8 (8-
9) 
0.5 
(0.25-
0.5) 
0.5 
(0.2-3) 153 330 -115% 0% 
16 1.2 4 (2-4) 4 (2-7) 10 (10) 10 (10) 2(1.5-3) 
1.5 
(1.5-2) 706 700 0.9% 0% 
17 1.8 10 (7-10) 
9 (8-
10) 
10 (8-
10) 
10 
(10) 
0.6 
(0.3-2) 1 (1-2) 372 135 64% 0% 
18 3.5 8 (8) 0 10 (9-10) 
0 0.3 
(0.3-1) 
0 
524 0 100% 
100% 
19 
3.5 
8 (4-8) 
8 (5-8) 10 (10) 9 (8-
9) 
1.5 
(0.25-
2.5) 
0.2 
(0.2-
1.25) 250 80 
68% 
0% 
20 1.0 6 (4-6) 1 (0-2) 7 (5-7) 3 (3-4) 
1 (1-
1.5) 
1 (1) 
461 46 90% 
70% 
21 0.3 2 (1-2) 0 8 (7-8) 0 2 (2-3) 0 720 0 100% 99% 
Median 
(range) 
1.5 
(0.3-5) 
5 
(2-10) 
2 
(0-10) 
10 
(6-10) 
7 
(0-10) 
1.75 
(0.3-5) 
1 
(0-6) 
696 
(153-
2020) 
208 
(0-
1255) 
68% 
(-115-100)% 
60% 
(0-100)% 
 
Effect of DBS on CH attack frequency,  severity and duration at last follow-up
  
VRS: Verbal rating scale (0 = no pain to 10 = very severe pain); The Headache 
score was derived from the two week diaries patients kept prospectively at 
baseline and prior to each assessment using the formula: Σ [duration (min) x 
severity (VRS)]  
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Table 7-5: Use of preventive and acute treatments  
 Preventative Treatment Acute Medication 
 Prior to DBS (daily dose) After DBS (daily dose) Prior to DBS After DBS 
1 Nil Nil Rizatriptan tablets 10mg x2/day 
Rizatriptan 
tablets10mg x2/day 
2 Verapamil 720mg, Baclofen 15mg 
Verapamil 720mg Oxygen daily Oxygen once week 
3 Nil Nil Nil Nil 
4 
Nil Nil S/C sumatriptan 
x2/day, nasal 
sumatriptan x3/day 
Nasal sumatriptan x1-
2/day 
5 Nil Nil Nil Nil 
6 Nil Nil Nil Nil 
7 
Methysergide 12mg Methysergide 9mg S/C sumatriptan 
x2/day, oxygen daily 
S/C sumatriptan 
x2/week, oxygen 
x2/week 
8 
Nil Nil Nasal sumatriptan 
x3/day, oromorph 
20mg x2/week, nasal 
lidocaine daily 
Nil 
9 Nil Nil S/C sumatriptan x2/day, oxygen daily 
Oxygen daily 
10 Nil Nil S/C sumatriptan x2/day, oxygen daily 
S/C sumatriptan 
x2/day, oxygen daily 
11 
Nil Nil S/C sumatriptan 
x2/day, frovatriptan 
2.5mg x1/day, oxygen 
daily 
S/C sumatriptan 
x2/day, frovatriptan 
2.5mg x1/week, 
oxygen daily 
12 Verapamil 360mg, Lithium 1200mg 
Verapamil 360mg, 
Lithium 1200mg 
S/C sumatriptan 
x4/day 
Nil 
13 Nil Nil Nasal sumatriptan x1/day, oxygen daily 
Nasal sumatriptan 
x2/day, oxygen daily 
14 Nil Nil Oxygen daily Oxygen daily 
15 Nil Melatonin 16mg Oxygen once week Oxygen daily 
16 
Baclofen 60mg, Melatonin 
14mg 
Levitracetam 1g, 
Melatonin 2mg, Baclofen 
60mg 
Oxygen daily Oxygen daily 
17 Verapamil 720mg Verapamil 960mg S/C sumatriptan x4/day, oxygen daily 
S/C sumatriptan 
x4/day, oxygen daily 
18 Gabapentin 3600mg, Gabapentin 300mg Nasal sumatriptan x3/day, oxygen daily 
Nil 
19 Verapamil160mg, Melatonin 9mg 
Melatonin 15mg Oxygen daily Oxygen daily 
20 Melatonin 16mg Nil Nasal sumatriptan x2-3/month 
Nil 
21 Nil Nil Nil Nil 
 
Use of preventive treatments and acute treatments for CH prior to and after D
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Figure 7-2: Median Headache Load Evolution 
 
MAD: Median Absolute Deviation 
2a: Median Headache Load (HAL) at baseline and over the course of follow-up 
2b: Median HAL of Responders and Non-responders 
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Figure 7-3: Improvement in quality of life, disability and mood 
 
 
*: p value ≤0.05. P values are Bonferroni corrected; they represent individual tests at each time point relative to baseline (number of 
comparisons = 2 for tests at 6 and 12 months) 
Median percentage of improvement in quality of l ife (SF36,  EuroQoL),  disability (MIDAS, HIT6), and mood (HADS-A, HADS-D, MIDAS: 
Migraine Disability Assessment Score,  HIT6: Headache Impact-6, HADS-A,  HADS-D: Hospital Anxiety and Depression Scale,  BDI-II: Beck 
Depression Inventory II,  SF36-PCS: Short Form 36 Physical Summary Score, SF36-MCs: Short Form 36 Mental Summary Score.
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8. Ventral tegmental area deep brain stimulation in refractory 
short-lasting unilateral neuralgiform headache attacks 
8.1: Abstract 
Short-lasting unilateral neuralgiform headache attacks are primary headache disorders 
characterized by short lasting attacks of unilateral pain accompanied by autonomic 
features.  A small minority are refractory to medical treatment.  Neuroimaging studies have 
suggested a role of the posterior hypothalamic region in their pathogenesis.  Previous case 
reports on deep brain stimulation of this region, now understood to be the ventral tegmental 
area, for this disorder are limited to a total of three patients.  We present a case-series of 
11 new patients treated with ventral tegmental area deep brain stimulation in an 
uncontrolled, open-label prospective observational study. Eleven patients with refractory 
short-lasting unilateral neuralgiform headache attacks underwent ipsilateral ventral 
tegmental area deep brain stimulation in a specialist unit. All patients had failed, or been 
denied access to, occipital nerve stimulation within the United Kingdom’s National Health 
Service. Primary endpoint was change in mean daily attack frequency at final follow-up.  
Secondary outcomes included attack severity, attack duration, headache load (a composite 
score of attack frequency, severity and duration), quality of life measures, disability and 
affective scores. Information was also collected on adverse events. Eleven patients (six 
male) with a median age of 50 years (range 26-67) were implanted between 2009 and 
2014. Median follow-up was 29 months (range 7-63).  At final follow-up the median 
improvement in daily attack frequency was 78% (IQR 33%).  Response rate (defined as at 
least a 50% improvement in daily attack frequency) was 82% and four patients were 
rendered pain free for prolonged periods of time.  Headache load improved by 99% (IQR 
52%). Improvements were observed in a number of quality of life, disability and affect 
measures. Adverse events included mild incision site pain, subcutaneous displacement of 
the implantable pulse generator, transient oscillopsia and minor wound infection. One 
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patient required removal of the system due to wound infection. Ventral tegmental area deep 
brain stimulation may be an effective treatment option for refractory short-lasting unilateral 
neuralgiform headache attack patients who have failed other therapies. 
8.2: Introduction 
Short-lasting unilateral neuralgiform headache attacks are a rare form of primary headache 
disorder characterised by frequent attacks of excruciating unilateral pain occurring in the 
trigeminal distribution, centred on the eye and temple, with associated autonomic features.  
They are included in the group known as the trigeminal autonomic cephalalgias and The 
International Classification of Headache Disorders (ICHD3-beta) describes two subtypes 
(Table 8-1): short-lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing (SUNCT) and short-lasting unilateral neuralgiform headache attacks 
with cranial autonomic features (SUNA) 424.  The disorder is said to be chronic when it 
occurs for more than a year with remission periods lasting less than one-month.  Short-
lasting unilateral neuralgiform headache attacks can be difficult to treat medically.  In the 
past, intractable patients have been subjected to destructive procedures of the trigeminal 
nerve with poor long-term results 425.  Peripheral (occipital nerve stimulation [ONS]) and 
central (ventral tegmental area [VTa] deep brain stimulation [DBS]) neuromodulation 
techniques have been carried out with more promising results 426-429. 
To date there are three published case reports of DBS for short-lasting unilateral 
neuralgiform headache attacks 426-428.  We present a consecutive series of 11 patients with 
intractable chronic short-lasting unilateral neuralgiform headache attacks treated with VTa-
DBS as a humanitarian intervention reporting on changes in attack characteristics, quality 
of life, headache disability, affect scores and adverse events. 
8.3: Methods 
This was an observational study based on a prospective, open label cohort initiated in 2009. 
Under the supervision of our institution’s Clinical Effectiveness Supervisory Committee with 
arrangements for clinical governance, consent and audit, we offered VTa-DBS to medically 
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intractable short-lasting unilateral neuralgiform headache attacks who had failed ONS or 
had been declined NHS funding for ONS. The procedure was provided on the basis of a 
“humanitarian intervention”. In addition, ethic board approval for data collection and 
publication was granted by Northwick Park Hospital Research Ethics Committee, 
Hampstead, London, UK. 
All patients were seen by a single specialist headache team at the National Hospital for 
Neurology and Neurosurgery, Queen Square, London UK and referred to a single 
multidisciplinary DBS team at the same centre.  All patients fulfilled the International 
Classification of Headache Disorders-2 criteria at diagnosis but also met revised ICHD-
3beta criteria 424,430.  Patients with prolonged attacks had a trial of Indomethacin (oral or 
intramuscular) to rule out Indomethacin-sensitive headaches 431.  Unlike chronic cluster 
headache or chronic migraine, intractability is not defined for short-lasting unilateral 
neuralgiform headache attacks 409.  Patients were considered suitable for VTa-DBS if they 
had had disabling medically intractable chronic short-lasting unilateral neuralgiform 
headache attacks for at least two years and had failed adequate trials of lamotrigine, 
topiramate, gabapentin, pregabalin and at least one of either carbamazepine or 
oxcarbazepine 429.  Disability was defined as a Headache Impact Test Score (HIT-6) in the 
severely affected range (i.e. above 60).  Agents were selected on the basis of reported 
efficacy in this disorder and local experience 432,433.  A failed trial was defined as lack of 
response, intolerable side effects or contradiction to the use of the drug.  One patient (P9) 
did not meet the criteria for medical intractability as they had not trialled carbamazepine or 
oxcarbazepine but this patient was implanted primarily for co-existent intractable chronic 
cluster headache.  All patients were considered for ONS prior to VTa-DBS and had either 
been declined funding or failed to respond.  Microvascular decompression of the trigeminal 
nerve was not being offered to this patient group during the study period.  
Neuropsychological evaluations and MRI brain scans were performed to exclude possible 
contraindications to surgery such as significant cognitive impairment, brain lesion or 
significant brain atrophy. 
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8.3.1: Outcomes 
The two primary outcome measures were the change in median daily attack frequency in 
the two weeks prior to implant  and the two weeks before final follow-up, and clinical 
response to VTa-DBS, defined as an at least 50% reduction in daily attack frequency.  
Secondary outcomes included reduction in the daily attack severity and frequency, 
headache specific disability scores, quality of life and affect scores.  
Outcome data was collected and recorded prospectively.  Patients were seen at three 
monthly intervals post implant over the first year and six monthly thereafter.  Timing of 
additional appointments was dependent on clinical condition.  Data collected included 
demographics, diagnosis, previous and current treatments, attack frequency, attack 
severity, headache load, headache disability scores, quality of life scales, affective scores, 
DBS settings and complications.   
Headache load (HAL) is a composite score defined as Σ(severity [verbal rating scale]) x 
(duration [hours]) of all attacks over a two week period 434.   Patients were asked to record 
these data in a headache diary completed for at least two weeks before every assessment.  
Headache severity was measured on a verbal rating scale (VRS; 0=no pain – 
10=excruciating pain).  Patients with multiple headache types were able to differentiate 
their phenotypes and kept a separate diary for each headache syndrome. 
Although specific tools for measuring the associated disability of trigeminal autonomic 
cephalalgias have yet to be validated, Migraine Disability Assessment Scores (MIDAS) and 
Headache Impact Test-6 Scores (HIT-6) were recorded pre and post-DBS to monitor 
disability.  These scores have been widely used in the assessment of primary headache 
disorders and have previously been used to monitor response to cluster headache, 
hemicrania continua and short-lasting unilateral neuralgiform disorders in ONS 415,429,435.  
Beck Depression Inventory II Score (BDI-II), Hospital Anxiety (HAD-A) and Depression 
(HAD-D) Scores were used to monitor mental state pre- and post-ONS implant and quality 
of life was assessed using the EuroQoL (EQ-5D) and Short-Form 36 (SF36).  
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Data were collected prospectively and entered onto a clinical database (Microsoft Excel, 
Microsoft Corporation, Redmond, WA, USA).  
8.3.2: Surgical Procedure 
Deep brain stimulation surgery was performed with the Leksell frame (model G, Elekta 
Instrument AB, Stockholm, Sweden), using an MRI-guided and MRI-verified approach 
without microelectrode recording.  This approach has previously been described for 
alternative DBS targets 61,274.  Surgery was performed under local anaesthesia for patients 
one to four and under general anaesthesia for all others (P5-11).  The anatomical target 
was the VTa ipsilateral to the side of attacks.  The location of the deepest contact of the 
Medtronic 3389 lead was defined on an axial 1.5T T2-weighted stereotactic MRI image at 
a level immediately superior to the mammillary bodies, anteromedial to the hypointense 
red nucleus and posterolateral to the hypointense mammillothalamic tract, midway on a 
line joining the center of the nucleus ruber to the center of the mamillary body.  Immediate 
postoperative low energy stereotactic MRI 63 with frame still on the head, was used to verify 
electrode location (in patient 9 with ONS in situ, an immediate postoperative CT scanning 
was used) (Figure 8-1). All DBS leads were located within 1mm of the intended target 
point.  The lead was then connected to a Medtronic implantable pulse generator (IPG) 
located in the infra-clavicular region. 
8.3.3: DBS Programming 
All patients underwent initial programming to define optimal stimulation parameters.  The 
contact point that produced typical patient complaints of transient vertical diplopia, vertigo, 
oscillopsia and ophthalmoplegia at the lowest amplitudes was chosen as the initial 
stimulation contact.  Four patients had stimulation started immediately. The remaining 
seven patients had a delay of four to seven weeks before stimulation was started due to 
the presence of a stun effect post-operatively where attacks transiently improved without 
use of stimulation.  In those with a stun effect, DBS was not initiated until attacks returned 
to normal pre-surgical frequency.  All devices were programmed with frequency of 185Hz 
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and a 60μs pulse width.  Voltage was adjusted according to patient reported side effects 
(see above) aiming for a maximum of 4.0V.  Adjustments in voltage were undertaken in 
single or multiple steps dependent on patient tolerability.  Stimulation parameters remained 
constant for three months after each re-programming session.  Adjustments in stimulation 
parameters were made depending on clinical response.  
8.3.4: Statistics 
All statistical analyses were conducted using IBM SPSS Statistics version 22 (IBM Corp. 
Int.).  In descriptive analysis, continuous variables were summarized using median and 
interquartile range and categorical variable using percentages.  Wilcoxon signed-rank tests 
were used to measure changes in baseline values.  A last observation carried forward 
technique was used in the case of missing data. All statistical tests were two-sided with a 
significance level of 5%. 
8.4: Results 
8.4.1: Patient demographics 
Eleven patients (six male) with short-lasting unilateral neuralgiform headache attacks 
underwent VTa-DBS between October 2009 and September 2014.  Patient demographics 
and baseline headache characteristics are shown in Table 8-2.  Median age at implant was 
50 years (range 26-67).  Three patients were diagnosed with SUNA and eight SUNCT.  
Nine patients had been chronic since onset.  Median duration of the chronic phase was 9 
years (range 4-20).  Five patients had additional headache syndromes including chronic 
migraine (three patients), chronic cluster headache (three patients) (Table 8-2).  In those 
with cluster headache, attacks of short-lasting unilateral neuralgiform headache attacks 
were ipsilateral to their cluster attacks in all but one patient (P9) who had left sided cluster 
attacks and unilateral but side variable SUNCT attacks (more common on the left).  Eight 
patients had unilateral DBS electrodes implanted and three had bilateral implants (P7, P9 
and P10) for side variable attacks (Table 8-3).  Two patients (P5 and P9) had previously 
undergone ONS implantation with little (P9) or no effect (P5) on their SUNCT.  Patient 5 
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had had the ONS device removed prior to VTa-DBS and Patient 10 still had the ONS in-
situ given its partial effect on their cluster headaches. 
All patients had undergone MRI brain scans prior to VTa-DBS of which two showed 
evidence of neurovascular conflict of the ipsilateral trigeminal nerve.  
Patients had tried a median of 11 treatments (IQR 3) including oral preventative drugs and 
injectable treatments (Table 8-4 and 8-5).  Nine of ten patients that received lidocaine 
infusions reported transient benefit and ten patients failed to receive any benefit from 
greater occipital nerve blocks.  
8.4.2: Follow up and final outcome  
Post-operative follow-up ranged from seven to 63 months with a median of 29 months (IQR 
20).  One patient had her DBS system removed at time of follow-up.  At final follow up, 
median attack frequency had reduced by 78% (IQR 33%) from 45 (IQR 10) to 2 (IQR 180) 
attacks per day (p=0.003) (Figure 8-2A and 8-2B and Table 8-6).  A positive clinical 
response, defined as at least a 50% reduction in attack frequency, was seen in 82% (9 
patients).  Of the two who failed to respond, one (P5) had the stimulator switched off for 
around 12 months during the 32-month follow-up due to tolerability issues but still obtained 
a more than 30% reduction in attacks.  The other (P6), reporting a 25% reduction in attack 
frequency at follow-up did not have an implant in-situ having had the DBS system removed 
17 months into her 24 month follow-up due to a wound infection.  Previous to implant 
removal, the patient was reporting a 90% reduction in daily attack frequency (Figure 8-2B). 
Patient estimate of improvement was 70% (IQR 95%) (Table 8-6) and all patients said they 
would recommend the treatment to others.  The median time to reach a 50% improvement 
was 1 month (range 1-2 months).  Only one responder had the system switched off for any 
period of time (P6) and attack frequency returned to baseline within 1 month of DBS 
removal. In those with co-existent headache disorders, cluster headache attacks 
decreased in two patients (P3 and P9) by 72% and 25% respectively.  Migrainous 
headaches failed to respond in the three patients (P3, P6 and P10) reporting them. 
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8.4.3: Attack severity, duration and headache load  
At final follow-up, median attack severity reduced by 50% from 10 (IQR 2) to 5 (IQR 10) 
points on VRS (p=0.020).  Median attack duration reduced by 99% (IQR 100) from 7200 to 
30 seconds but this change was not statistically significant (p=0.066).  Headache load 
showed a median reduction of 99% (IQR 52) (p=0.026).  Neither of the patients categorized 
as clinical non-responders (P5 and P6) showed a more than 50% reduction in HAL.  One 
patient (P9) who recorded a 66% reduction in attack frequency failed to show a matching 
response to HAL (48% reduction) (Table 8-6).  
8.4.4: Headache associated disability scores, quality of life and affect measures  
Baseline median MIDAS and HIT-6 scores were 81 (IQR 254) and 70 (IQR 12) respectively, 
both scores being within the severely affected range (Table 8-7).  At final follow-up 
statistically significant reductions were seen in HIT-6 but not MIDAS.  Median HIT-6 fell by 
15 points (p=0.015) well above the three point minimally important change 436.  MIDAS fell 
by 39 points (p=0.678) which although not statistically significant is above the nine-point 
difference separating moderate from severe disability. Summary measures of the physical 
(SF-36P) and mental (SF-36M) SF-36 scale showed a non-significant improvement (Table 
8-6).  No significant change was seen in the separate domain scores of SF-36 scale 
(Figure 8-3).  Euro-QoL 5D and EuroScale scores did not show any significant change 
post implant (Table 8-7).  Prior to implant all affective scores indicated the presence of 
moderate mood disorders.  Post treatment, both HAD-A and BDI-II scales indicated mild 
disorder scores but HAD-D continued to indicate moderate levels of depression (Table 8-
7).  Despite this clinical change, there was no statistically significant change in affective 
scores at follow-up. 
8.4.5: Adverse Events 
Adverse events were recorded if any issues had arisen during the time of treatment.  Events 
were classified as “hardware related” if they involved a malfunction of any device 
component, “biological” if they involved pain or other biological reactions related to the 
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device or the surgical procedure to implant it and “stimulation-related” if they were thought 
to be related to stimulation. One hardware related event was noted with a patient requiring 
surgical revision of their IPG due to the IPG moving or “flipping”.  Biological adverse events 
included mild to moderate neck stiffness in three patients, keloid scar in one patient and 
persistent pain over wound sites in two patients. One patient suffered a small wound 
dehiscence in the first three weeks post-operatively with no evidence of wound infection. 
One patient suffered a wound infection at the lead/cable connector site 17 months post-
implant (P6).  Due to the risk of spread of infection, the whole DBS system was removed.  
All patients reported transient stimulation related adverse effects (described in DBS 
programming section above) related to DBS programming resolving within minutes to 
hours. One patient complained of symptoms compatible with oscillopsia on reading for six 
weeks after their initial programming session that resolved spontaneously.  One patient 
(P5) complained of intolerable worsening of chronic nausea with any change in stimulation, 
however, with blinded changes in stimulation and in a 12-month period without stimulation 
there was no change in the nausea and it was judged that this complaint was not related 
to stimulation. A total of two surgical interventions were required during follow-up (Table 8-
8). 
8.4.6: Concomitant drug use 
Nine patients were taking preventative medications for short lasting unilateral neuralgiform 
headache attacks at time of implant (Table 8-9).  At final follow-up, four patients had 
stopped all preventatives for their SUNCT/SUNA and a further two had been able to reduce 
their doses of one or more medications. 
8.4.7: Stimulation parameters 
A summary of stimulation parameters is given in Table 8-10.  Median stimulation amplitude 
at follow-up was 3.0V.  Subjects had a median of 6 changes to stimulation parameters 
during follow-up. 
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8.5: Discussion 
Previous case reports of VTa-DBS treatment in short lasting unilateral neuralgiform 
headache attacks have suggested a benefit in three patients 426-428. Our open-label 
prospective series of eleven patients suggests that VTa-DBS may be an effective and safe 
treatment in patients with intractable short lasting unilateral neuralgiform headache attacks 
who have proved refractory to all other available treatment modalities.  In our group of 
eleven patients there was a significant reduction in daily attack frequency of 78% with four 
patients remaining pain free for prolonged periods of time. Overall nine patients had a 
positive response to VTa-DBS with a 50% or more reduction in attack frequency.  
Improvement was seen in headache specific disability scores (HIT-6) but not in quality of 
life scales or measures of depression. 
Deep brain stimulation for another trigeminal autonomic cephalalgia chronic cluster 
headache (CCH) was first undertaken by Leone et al in 2001 123.  This procedure was 
based on the findings of a 1998 study which showed increased activation on positron 
emission tomography in the posterior hypothalamic region during cluster headache attacks 
121.  To date, there is now published data on over 70 patients with intractable CCH treated 
with DBS.  One series which pools 58 of these patients reports that 62% showed a 50% or 
greater reduction in attack frequency 406.  Similar findings of activation of the ipsilateral 
inferior posterior hypothalamic region was also observed during SUNCT attacks and 
therefore the same DBS target was proposed to be potentially beneficial in the treatment 
of short lasting unilateral neuralgiform headache attacks 437.  Only three case reports have 
been published, all showing substantial and sustained reductions in attack frequency 
without any serious adverse events 426-428.  Since the initial work of May and Leone, further 
anatomical clarification of the surgical target has been undertaken and the target has been 
shown to be in the ventral tegmental area of the midbrain rather than the posterior 
hypothalamic region 418,422. 
Our series shows improvements in both attack frequency (78%) and severity (50%) with 
VTa-DBS.  This finding has been described in CCH cases treated with VTa-DBS but not 
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short lasting unilateral neuralgiform headache attack cases 406.  This series also reports 
the headache load (HAL) as an outcome measure for the group.  This composite score 
reflects all three domains of headache burden (frequency, severity and duration). Attack 
frequency has always been the focus of previous outcome reports for VTa-DBS for 
headache.  However, the use of a single outcome may not represent the actual benefit 
perceived by the patient.  Headache load showed a significant improvement (99%) at final 
follow-up.  In our group, only one patient showed a discrepancy between attack frequency 
and HAL response (P9).  This patient exhibited a 66% reduction in attack frequency (and 
so a positive response to VTa-DBS) but a 48% reduction in HAL. It is interesting to note 
that this patient stated they had not perceived any benefit from the treatment.  The clinical 
usefulness of HAL as a primary outcome measure needs validation in larger cohorts in the 
future. 
As in previous VTa-DBS for primary headache series our subjects reported a delay in 
clinical response.  In CCH this delay is several months long but in the short lasting unilateral 
neuralgiform headache cases ranged from days to a maximum of three months 
406,426,427,435,438,439.  In our series, the time taken to see positive clinical response was 1 
month (range 1-2 months).  This delay likely reflects the neuroplastic response underlying 
successful VTa-DBS treatment. 
Clinically and statistically important differences were seen in HIT-6 scores following VTa-
DBS but no significant improvement was seen in quality of life measures.  Factors to 
consider in this observation include the small sample size, the long duration of chronic pain 
(9 years) and co-morbidities in these patients all of which may have resulted in 
psychosocial issues unlikely to improve with change in symptoms.  Similar observations 
have been made in VTa-DBS for CCH 438. Little has been published regarding quality of 
life data in the trigeminal autonomic cephalalgias including short lasting unilateral 
neuralgiform attack disorders and no specific headache disability or quality of life scales 
exist for these disorders.  It has been suggested that in headache disorders, generic scales 
(such as SF36) may not be useful in measuring changes over time and that disorder 
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specific measures (such as HIT-6) may be more representative 440. Until such scales have 
been developed the quality of life tools available may not accurately reflect the headache 
groups they are applied to. 
One serious adverse event of subcutaneous infection leading to system removal occurred 
in our series.  Infection of the DBS system has been reported by two other CCH series 
(4/19 and 1/11 patients) 419,441, although their operative technique differed from our unit. A 
report from Belgium on the death of a patient from an intracerebral haemorrhage following 
microelectrode (MER) guided DBS for CCH has raised serious safety concerns regards 
this procedure 68. However, there is no recognised neuronal firing pattern or “signature” for 
the VTa, casting doubt on the clinical utility of MER for this anatomical target. Moreover, 
the target area is visible on a stereotactic thin-slice T2-weighted MRI. Hence, the use of an 
MRI-verified surgical technique without the use of MER provides direct visualisation of the 
individual target area and is associated with a significantly lower risk of haemorrhage during 
DBS procedures 69.  The use of microelectrode recording when targeting this area has also 
been avoided by using an endoventricular approach to DBS lead placement 442 .  The 
stimulation induced ophthalmic side effects reported by our patients have all been 
documented in CCH series and, much like our series, have all been transient.  It is likely 
that this transient vertical diplopia is due to stimulation of the nearby rostral interstitial 
nucleus of the medial longitudinal fasciculus that forms part of the vertical gaze center 443. 
The main limitation of this study is the lack of placebo control.  Although there is 
undoubtedly a placebo effect for headache treatments, it is unlikely our findings can be 
explained by this alone.  Placebo response rates for ONS in migraine are low (below 20%) 
and there is no reason to expect the contrary in this disorder or procedure 444-446.  Likewise, 
the intractable nature of the group, the sustained response and the re-emergence of attacks 
when stimulation was stopped all argue against a placebo response.  Although a previous 
randomized controlled trial of DBS in CCH failed to show a difference between sham and 
active stimulation this was likely due to methodological issues with short 1-month crossover 
periods.  Unfortunately, given the rarity of short lasting unilateral neuralgiform headache 
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attacks, it seems unlikely that high quality, properly powered randomised control trials of 
VTa-DBS will ever be performed. 
Microvascular decompression, occipital nerve stimulation and deep brain stimulation have 
all been found to be effective in open-label series with response rates of over 75% 
426,428,429,447. The invasiveness of surgery, associated risks, the need for implanted 
hardware and the cost of treatment will all influence individual patient options.  With these 
in mind, we may in the future recommend that patients with intractable short lasting 
unilateral neuralgiform headache attacks first undergo microvascular decompression if they 
have ipsilateral neurovascular compression of the trigeminal nerve, that ONS be reserved 
for those without neurovascular compression or failing microvascular decompression and 
DBS (as the most invasive neuromodulation option) be left as an option when patients have 
failed all other procedures. 
This study suggests that VTa-DBS may provide an effective and sustained benefit in 
intractable short lasting unilateral neuralgiform headache attacks. However, MRI-verified 
VTa-DBS should be reserved for those patients having failed all other medical and surgical 
options available to them. 
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Table 8-1: International Classification of Headache Disorders diagnostic 
criteria for short lasting unilateral neuralgiform headache attacks 
Short lasting unilateral neuralgiform headache attacks 
• At least 20 attacks suffered 
• Moderate to severe unilateral head pain with trigeminal distribution, lasting 
1-600 seconds and occurring as single stabs, series of stabs or in a saw-
tooth pattern 
• At least one cranial autonomic symptom or sign ipsilateral to the pain: 
• Conjunctival injection and/or lacrimation 
1. nasal congestion and/or lacrimation 
2. eyelid oedema 
3. facial sweating 
4. facial flushing 
5. fullness in the ear 
6. ptosis and/or miosis 
• Attacks occur at least once a day for more than half the time the disorder 
is active 
Short lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing 
• As short lasting unilateral neuralgiform headache attacks 
• Autonomic symptoms of both conjunctival injection and lacrimation 
Short lasting unilateral neuralgiform headache attacks with autonomic 
features 
• As short lasting unilateral neuralgiform headache attacks 
• Autonomic symptoms include only one of or neither of conjunctival 
injection and lacrimation 
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Table 8-2: Patient demographics 
 Age/ 
years 
Sex SUNCT/S
UNA 
Chronic 
duration 
Side Other  
Headaches 
Attack 
Frequency/ 
Day 
Average Attack 
duration 
Triggered attacks/ 
Spontaneous 
attacks/Both* 
MRI for 
neurovascul
ar conflict** 
1 56 M SUNCT 14 R NIL 20 5min Spontaneous NIL 
2 63 M SUNCT 16 R NIL 360 10 sec Both-touch/wind Right 
3 39 M SUNCT 9 R CCH (R) 
CM 
20 15 sec Spontaneous NIL 
4 67 M SUNCT 13 L CCH (L) 40 10min Spontaneous NIL 
5 64 F SUNCT 9 R NIL 6 3min Spontaneous NIL 
6 55 F SUNCT 20 L CM 120 2 min BOTH – touch/chewing/ 
wind 
NIL 
7 41 F SUNCT 4 L 90% 
R 10% 
NIL 200 3 min Spontaneous NIL 
8 26 F SUNA 8 R NIL 800 2 sec BOTH – talking/touch/ 
eating/wind 
NIL 
9 50 M SUNCT 6 L 70% 
R 30% 
CCH (L) 3 5min Spontaneous NIL 
10 42 F SUNA 
 
19 L 40% 
R 60% 
CM 95 2min Spontaneous NIL 
11 46 M SUNA 9 R NIL 45 30 sec  Spontaneous Right 
Median 
(IQR) 
50 
(22) 
6M 
5F 
8 SUNCT 
3 SUNA 
9 
(7) 
6 R 2 L 
3L/R 
3 CCH 
3 CM 
45 
(20) 
2 min 
(5) 
8 Spontaneous 
3 Both 
2 Ipsilateral  
NVC 
*In case of triggered attacks, typical triggers are listed ** Neurovascular conflict of trigeminal nerve at level of root entry zone seen on 
MRI 
M, male; F, female; SUNCT, short lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing; SUNA, short 
lasting unilateral neuralgiform headache attacks with autonomic features; R, right; L, left; L/R, left or right; CCH, chronic cluster 
headache; CM, chronic migraine; MO, medication overuse; NVC, neurovascular conflict 
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Table 8-6: Headache characteristics before and after treatment 
 Follow 
Up/ 
months 
DAILY ATTACK 
FREQUENCY 
ATTACK SEVERITY HEADACHE LOAD ATTACK DURATION  
(seconds) 
Estimated 
ImprovementŦ 
Patient 
recommendŦŦ 
  Pre 
DBS 
Post 
DBS 
% 
Change 
Pre 
DBS 
Post 
DBS 
% 
Change 
Pre 
DBS 
Post 
DBS 
% 
Change 
Pre 
DBS 
Post 
DBS 
% 
Change 
  
1 63 20 6 70 8 2 75 69 3 96 18000 30 99 95 Yes 
2 40 360 0 100 7 0 100 14 0 100 10 0 100 100 Yes 
3 33 10 0 100 10 0 100 7 0 100 15 0 100 100 Yes 
4 41 40 2 95 7 7 0 94 1 99 36000 1 100 70 Yes 
5 32 6 4 33 10 10 0 42 35 17 10800 7200 33 5 Yes 
6 ≠ 29 120 90 25 9 10 0 225 304 0 7200 7200 0 0 Yes 
7 23 200 58 71 10 5 50 1400 304 78 10800 60 99 70 Yes 
8 14 800 0 100 10 0 100 62 0 100 2 0 100 100 Yes 
9 7 3 1 66 10 10 0 23 12 48 18000 18000 0 0 Yes 
10 29 95 0 100 10 0 100 44 0 100 7200 0 100 100 Yes 
11 28 45 5 89 8 8 0 56 12 79 2160 18000 -7 58 Yes 
MEDIAN 
(IQR) 
29 
(20) 
45 
(20) 
2 
(10) 
78* 
(33) 
10 
(2) 
5 
(10) 
50* 
(100) 
62 
(202) 
3 
(35) 
99* 
(52) 
7200 
(17985) 
30 
(7200) 
99 
(100) 
70 
(95) 
 
 
The average daily attack frequency and severity is l isted before and after treatment.   Headache load, a composite score reflecting attack 
frequency, severity and duration is also shown.  Patient satisfaction is shown using their estimated level of improvement and their  
recommendation of treatment to other patients. 
*p<0.05; Ŧ Patient estimate of improvement at f inal follow-up; ŦŦ  Patient asked if they would recommend the procedure to another person 
with short lasting unilateral neuralgiform headache attacks; ≠ Deep brain stimulation system removed at time of follow-up; DBS, Deep 
brain stimulation 
 196 
Table 8-7: Headache specific disability, affect and quality of life score 
changes with deep brain stimulation 
 Pre-DBS 
Median (IQR) 
Post-DBS 
Median (IQR) 
Median % Change 
% (IQR) 
P-value 
MIDAS 81 (254) 65 (12) 0 (63) 0.678 
HIT-6 70 (12) 65 (14) 8 (19) 0.015* 
HAD-A 12 (11) 8 (13) 17 (28) 0.035* 
HAD-D 12 (8) 11 (10) 0 (42) 0.721 
BDI-II 23 (23) 16 (29) 0 (24) 0.929 
SF-36 
Physical 
23 (26) 29 (18) 0 (24) 0.594 
SF-36 Mental 30 (27) 46 (27) 23 (39) 0.208 
Euro-QoL 0.63 (0.18) 0.64 (0.18) 0 (1.0) 0.208 
Euro-Scale 30 (50) 32 (50) 0 (45) 0.483 
 
IQR, Interquartile range; MIDAS, Migraine Disability Assessment Scale; HIT-6,  
Headache Impact Test; HAD-A, Hospital Anxiety and Depression scores-anxiety 
specific; HAD-D, Hospital Anxiety and Depression scores – depression specific; 
BDI-II,  Becks Depression Inventory; SF-36, Short Form 36.  
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Table 8-8: Adverse events related to deep brain stimulation 
Adverse Event (n) Resolution (surgical/medical/spontaneous/no intervention) 
Hardware Related  
IPG “flips” or moves in chest skin pocket (1) Surgical intervention – repositioning of IPG 
Biological 
Neck stiffness (3) No intervention 
Pain over wound site (2) No intervention 
Keloid scar over IPG site (1) No intervention 
Wound infection (1) Surgical intervention – removal of system 
Wound dehiscence, no infection (1) Medical  
Stimulation Related 
Diplopia, nausea, vertigo, ophthalmoplegia with changes of programming (11) Spontaneous 
Possible worsening of nausea (1) Medical – DBS switched off with no change in symptoms.  
Decision made symptoms not related to DBS 
Oscillopsia when reading (1) Spontaneous resolution after 6 weeks 
 TOTAL SURGICAL INTERVENTIONS = 2 
 
IPG, implantable pulse generator; DBS, deep brain stimulation 
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Figure 8-1: 1.5T MRI scan showing DBS lead placement 
 
 
Post-operative 1.5T T2-weighted, 2mm-thick, axial stereotactic MRI immediately 
after implant shows the DBS lead positioned in the right ventral tegmental  area 
of the midbrain (white arrow)
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Figure 8-2: Reduction in daily attack frequency following deep brain 
stimulation 
Figure 8-2A 
 
 
Figure 8-2B 
 
(A) Reduction in median daily attack frequency in the whole cohort with shaded 
area representing median absolute deviation error band. (B)  Reduction in median 
daily attack frequency of responders and non-responders following implant 
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Figure 8-3: SF36 domain scores pre and post-DBS  
 
PF, physical  functioning; RP, role-physcial;  BP, bodily pain; GH, general  health; 
VT, vitality; SF, social functioning; RE, role-emotional; MH, mental health; PCS, 
physical composite score; MCS,mental health composite score 
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Table 8-4: Preventative medications previously tried by patients undergoing deep brain stimulation 
 Lamotrigine Topiramate Gabapentin Pregabalin Carbamazepine Oxcarbazepine Other 
1 600mg 350mg 3600mg 600mg 1600mg NT Melatonin, Indomethacin 
2 400mg 400mg DUK DUK 800 300 Melatonin, Baclofen, Phenytoin 
3 600mg 1000mg 3600mg 600mg DUK NT Duloxetine, Melatonin, Venlafaxine 
4 200mg 200mg 3600mg 300mg NT 1500mg Duloxetine, Melatonin 
5 600mg 400mg DUK DUK 900mg 300mg Duloxetine, Mexiletine, Melatonin, ONS 
(removed) 
6 200mg 450mg 2400mg 50mg 1200mg 1200mg Duloxetine, Lacosamide, Phenytoin, Baclofen, 
Zonisamide 
7 400mg 300mg 2700mg 300mg DUK 2400mg Duloxetine, Indometacin 
8 1200mg 400mg 1800mg 300mg 1200mg 1200mg Duloxetine, Baclofen, Lacosamide, VNS 
9 400mg 200mg 600mg 600mg NT NT ONS(in-situ) 
10 400mg 200mg 900mg 600mg DUK 2100mg Duloxetine, Mexiletine, Lacosamide, Ketamine 
11 200mg 25mg 300mg 1200mg NT 1500mg Duloxetine, Indometacin 
NT, drug not tried; DUK, dose unknown; ONS, occipital nerve stimulation; VNS, non-invasive vagal nerve stimulation (GammaCore)  
Table Legend: The daily dose of the preventative medications with stated efficacy in short lasting unilateral neuralgiform headache 
attacks taken by each patient prior to undergoing deep brain stimulation.   A list of additional medications trialled for the condition is  
also shown.  
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Table 8-5: Injectable transitional treatments given for short lasting unilateral neuralgiform headache attacks prior to deep brain 
stimulation 
 Lidocaine Infusion (7-10 days) Greater Occipital Nerve Injection (lidocaine and steroid) 
 Response* Number of 
treatments 
Duration of response 
(days) 
Response** Side of 
injection 
Duration of response 
(days) 
1 Yes  1 10 days No Right 3 days 
2 Yes 1 On infusion only++ No Right 0 days 
3 Yes 1 On infusion only++ No Right 0 days 
4 Yes 1 On infusion only++ No  Left 0 days 
5 Yes 2 On infusion only++ No Right 0 days 
6 No 1 Nil No Left 0 days 
7 Yes 7 1 month  No Left 0 days 
8 Yes 1 On infusion only++ No Right 0 days 
9 N/A - - No Bilateral 0 days 
10 Yes 4 10 days Yes Bilateral 2 weeks 
11 Yes 2 Infusion only++ No Bilateral  5 days 
*Response defined by at least 50% reduction in daily attack frequency  
** Response defined by at least a 50% reduction in attack frequency for at least one week post procedure 
++ Patient reported response only during time on treatment and which stopped as soon as infusion ended 
N/A, patient not tried treatment 
 203 
Table 8-9: Summary of changes in preventative medications following deep brain stimulation 
 Medication Prior to DBS Medication Post DBS Reduction in Dose 
1 Pregabalin 600mg 
Lamotrigine 600mg 
Pregabalin 600mg 
Lamotrigine 600mg 
No 
No 
2 Lamotrigine 700mg 
Carbamazepine 800mg 
Lamotrigine 400mg 
Oxcarbazepine 300mg 
Yes 
Yes (relative doses) 
3 Lamotrigine 600mg Nil Yes 
4 Nil Nil N/A 
5 Lamotrigine 600mg 
Topiramate 400mg 
Lamotrigine 600mg 
Lacosamide 50mg 
No 
No 
6 Zonisamide 100mg 
Lamotrigine 200mg 
Zonisamide 100mg 
Lamotrigine 200mg 
No 
No 
7 Oxcarbazepine 1800mg 
Topiramate 300mg 
Nil Yes 
Yes 
8 Lamotrigine 600mg 
Lacosamide 300mg 
Lamotrigine 600mg 
Lacosamide 300mg 
No 
No 
9 Lamotrigine 400mg (+ONS) Nil (+ONS) Yes 
10 Topiramate 200mg Nil Yes 
11 Nil Nil N/A 
 
DBS, deep brain stimulation; N/A, not applicable as patient not on medication 
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Table 8-10: Summary of deep brain stimulator settings for each patient  
 Implant Location Amplitude Range 
(V) 
Frequency 
(Hertz) 
Pulse width 
(µs) 
Contact points settings* 
1 Right 1.3-3.0 185 60 C+/1- 
2 Right 1.5-3.0 185 60 C+/1- 
3 Right 2.4-3.0 185 60 C+/0-, C+/0-1- 
4 Left 1.3-3.5 185 60 C+/1-, C+/1-2- 
5 Right 0-2.6 185 60 C+/0-, C+/1- 
6 Left 0.0-3.0 185 60 C+/0-, C+/0-1- 
7 Bilateral 2.2-3.0 185 60 Left (Activated from onset): C+/1-, C+/0-1 
Right (Activated after 7 months): C+/8- 
8 Right 3.0-3.5 185 60 C+1-, C+/0-1- 
9 Bilateral 3.0 185 60 Left (Activated from onset): C+/0-, C+/1-, C+/0-
1 
Right (Not activated at  follow-up) 
10 Bilateral 3.0-3.5 185 60 Left: C+/0-, C+/0-1- 
Right: C+/9-, C+/8-9- 
11 Right 1.5-2.8 185 60 C+/1-, C+/0- 
Median 
(IQR) 
6 Right 
2 Left 
3 Bilateral 
 
1.5 (2.7)-3 (0.5) 
185 60  
 
*Lead set as cathode and contact point as anode 
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9. Optimal deep brain stimulation site and target connectivity 
for chronic cluster headache 
9.1: Abstract 
High frequency deep brain stimulation (DBS) in the ventral tegmental area (VTa) is a safe 
and effective treatment for patients with refractory chronic cluster headache. Whereas the 
stimulation target was revealed on functional imaging studies, the mechanism of action of 
this treatment is yet to be understood. Furthermore, the optimal stimulation site within the 
target area has not been fully determined. Seven patients (5 male) with refractory chronic 
cluster headache were studied. High spatial, high angular resolution diffusion 3T MRI was 
acquired preoperatively. DBS electrode implantation into the VTa was performed using an 
MRI-guided and MRI-verified approach, unilaterally in 5 patients and bilaterally in two. 
Volumes of tissue activation were generated around active lead contacts using a finite 
element model. Twelve-months after surgery, voxel-based morphometry was used to 
identify voxels associated with higher reduction in headache load, defined as ∑ [severity 
(on the verbal rating scale)] x [duration (in hours)] of all headache attacks occurring over a 
2-week period. Probabilistic tractography was used to identify the brain connectivity print 
of the DBS activation volumes in responders, defined as patients with a reduction of ≥ 30% 
in headache load. There was no surgical morbidity. Average follow-up length was 34 (±14) 
months. Patients showed a 76% (±33) reduction in headache load, 46% (±41) in attack 
severity, 58% (±41) in headache frequency, and 51% (±46) in attack duration at the last 
follow-up. All patients, except one, responded to treatment.  Greatest reduction in 
headache load was associated with activation in an area cantered at 6 mm lateral, 2 mm 
posterior and 1 mm inferior to the third ventricle’s mid-commissural point. Average 
responders’ deep brain stimulation activation volume lay on the trigemino-hypothalamic 
tract, connecting the trigeminal system and other brainstem nuclei associated with 
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nociception and pain modulation, with the hypothalamus, and the prefrontal and mesial 
temporal areas. 
9.2: Introduction 
Chronic, high frequency deep brain stimulation (DBS) in the ventral tegmental area (VTa) 
has been shown to be a safe and effective treatment modality for patients with refractory 
chronic cluster headache (CCH) 68,123,124,406-408,448,449. 
The underlying pathophysiology in cluster headache (CH) is not fully understood 450-457. 
Though the exact trigger site for CH attacks is not clear, the  hypothalamus has been 
implicated in the disease process 121,122,458-460 and pathological activation of the trigemino-
parasympathetic brainstem reflex is thought to be responsible for simultaneous activation 
of trigeminal nerve and craniofacial parasympathetic nerve fibres, respectively, leading to 
the characteristic ipsilateral cranial pain and autonomic features 455,461 
The periodicity of individual attacks, the relapsing-remitting course and the seasonal 
recurrence of headache bouts are all suggestive of possible hypothalamic role in CH 398,455. 
This is supported by neuro-endocrinological studies 458,459 and neuroimaging studies 121,122. 
The latter pointed to increased activity and neuronal density in what was termed ‘the 
posterior hypothalamic region’ ipsilateral to the headache attacks 121,122,460. However, 
further investigation of the area referred to in these studies has shown it to lie in the ventral 
tegmental area (VTa) and not the hypothalamic region 418,422,448. These findings led to the 
emergence of this region as a target for DBS for CCH 68,123,124,406,407,419,448,462 
Occipital nerve stimulation (ONS) and cervical spinal cord stimulation for CH are thought 
to work through activation of the trigemino-cervical complex (TCC) 463,464. The exact mode 
of action of DBS for CH and the neural networks involved remain poorly understood. 
Furthermore, the optimal stimulation site is yet to be identified  68,123,124,406,407,418,419,422. 
Activation of the trigeminal nerve and ganglion have been demonstrated with hypothalamic 
stimulation 417, possibly mediated by the trigemino-hypothalamic tract (THT) described in 
non-human studies 465,466. 
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The objectives of this study were to identify the optimal VTa stimulation site for 
improvement in headache load and to explore the connectivity or fingerprint of stimulation 
tissue volumes in responders to identify the THT, by proceeding through the following 
steps:  
 
1. To generate volume of tissue activated models for all active DBS contacts 
2. To carry out a voxel based morphometry (VBM) style regression analysis of 
modelled activation volumes and their associated efficacy profiles 
3. To perform tractography from modelled activation volumes of active DBS contacts 
in responders using a probabilistic approach and state of the art high angular 
resolution diffusion imaging (HARDI) 
9.3: Materials and methods 
The DBS procedure was provided on the basis of a “humanitarian intervention” for patients 
who had failed ONS or in whom National Health Service funding for ONS had been 
declined. This was in keeping with the UK National Institute for Health and Care Excellence 
(NICE) guidance (https://www.nice.org.uk/guidance/ipg381/chapter/1-Guidance). All 
patients were given information booklets approved by our institution’s Clinical Effectiveness 
Supervisory Committee and provided written informed consent. 
9.3.1: Patients 
Seven patients (5 male) were recruited. Five patients belonged to a cohort that has been 
published previously concerning efficacy and safety of DBS for CCH 448. All patients fulfilled 
the ICHD-II and ICHD-III beta diagnostic criteria for CCH  and had experienced highly 
disabling, medically refractory symptoms for at least two years 397,424. CCH was classified 
as medically intractable if patients failed adequate trials of at least five of the following 
seven drugs, where at least two came from the first three drugs listed: verapamil, lithium, 
methysergide, topiramate, melatonin, gabapentin, and valproate. A failed trial was defined 
as an unsatisfactory response, side effects intolerance or contraindication to the agent’s 
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use 409. Referrals were made by a single tertiary specialist headache clinic to a DBS 
multidisciplinary team at the same centre. Neuropsychological evaluations and MRI brain 
scans were performed to rule out cognitive impairment, brain lesions or significant brain 
atrophy.  Inclusion in the present study was limited to patients who could tolerate lying flat 
for the duration of the preoperative scan and who had no contraindications to 3T MRI. 
Sphenopalatine ganglion stimulation was not available in the UK during the study period. 
9.3.2: Preoperative magnetic resonance imaging data acquisition 
Imaging pertinent to this study was performed prior to surgery on a 3T Siemens Magnetom 
Trio TIM Syngo MR B17 using a 32 channel receive head coil. Padding was used inside 
the head coil to reduce discomfort and head motion. 
9.3.2.1: Diffusion weighted MRI 
Details of diffusion weighted MRI acquisition and preprocessing are described in the 
general methods sections.  
9.3.2.2: Surgical procedure and intraoperative magnetic resonance imaging data 
acquisition 
DBS leads were implanted under general anaesthesia using a stereotactic 1.5 T MRI-
guided and MRI-verified approach (Leksell frame model G, Elekta Instrument AB, 
Stockholm, Sweden) without microelectrode recording as detailed elsewhere  69,448. The 
anatomical target was the ipsilateral VTa. Two patients with bilateral CCH underwent 
bilateral surgery in a single procedure. Two stereotactic, pre-implantation scans were 
acquired, as part of the surgical procedure, to guide lead implantation: a T2 weighted axial 
scan (partial brain coverage around the midbrain and hypothalamus with voxel size of 
1.0×1.0 mm and slice thickness of 2 mm; and a T1 weighted 3D-MPRAGE scan with a 1.5 
mm3 isotropic voxel size on a 1.5T Siemens Avanto interventional MRI scanner. Three-
dimensional distortion correction was applied using the scanner’s built-in module. Once 
scans were reformatted parallel to the anterior commissure (AC) – posterior commissure 
(PC) line, the deepest contact location of the 3389 Medtronic lead was defined on the T2-
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weighted MRI at a level immediately above the mammillary bodies, anteromedial to the 
hypointense red nucleus and posterolateral to the hypointense mammillothalamic tract. The 
MPRAGE scan was used to plan the lead’s entry point over the coronal suture ± 2cm in the 
sagittal plane and at a laterality of 3-5cm ensuring a trajectory avoiding the sulci and lateral 
ventricle. Stereotactic imaging was repeated immediately following lead implantation to 
confirm lead placement. Care was taken to keep the specific absorption rate (SAR) < 0.4 
W/kg; this was generally achieved by reducing the number of acquired T2 slices covering 
the distal leads to 12-14 63. The leads were then connected to an implantable pulse 
generator (IPG) (Activa SC or PC, Medtronic, Minneapolis, Minn., USA) implanted in the 
infra-clavicular region on either on the same day of lead implantation or within a week of it, 
as a staged procedure. 
9.3.3: DBS programming 
In the weeks following surgery, open label programming was conducted to define optimal 
stimulation parameters. All devices were programmed with a frequency of 185Hz and a 
pulse width of 60µs 124.  Voltages were adjusted according to self-limiting side effects 
(diplopia, vertigo, nausea, oscillopsia and ophthalmoplegia) in single or multiple steps, 
depending on the patient. Stimulation parameters were kept constant for the first three 
months and were adjusted after this if patients were not responding. 
9.3.4: Outcome measures and follow-up 
Outcome data were collected and recorded prospectively. These included daily attack 
frequency, attack severity, attack duration, headache load and adverse events (including 
surgical complications, stimulation-induced adverse events and morbidity). Headache 
severity was measured on the verbal rating scale (VRS) for pain (0 being no pain, and 10 
being the worst pain imaginable).  Attack frequency was defined as the number of CH 
attacks/day and duration as the time in hours of each recorded attack. The individual scores 
from both of these were then averaged over the 2-week observation period.  Headache 
load (HAL) was defined as ∑ [severity (on the verbal rating scale)] x [duration (in hours)] of 
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all headache attacks occurring over a 2-week period. We have introduced this measure 
previously and suggested that it effectively reflects response to treatment 448. These 
measures were assessed using 2-week duration headache diaries collected preoperatively 
(baseline), at commencement of DBS therapy, at 3 months, 6 months, 12 months and 
yearly thereafter. 
Responders were defined as patients with sustained HAL reduction ≥30% since this was 
deemed meaningful in line with the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT) guidelines 410. 
9.3.5: Analysis of activation volumes 
9.3.5.1: DBS contacts volume of tissue activated modelling 
SureTune® (Medtronic Inc. Minnesota), a DBS therapy planning platform (pre-release Beta 
version) was used to model activation volumes around individual contacts. The platform 
applies neuron models coupled to finite element simulations as described by Åström and 
colleagues in order to generate DBS therapy activation volumes 162. Post-operative, 
stereotactic MPRAGE scans were manually aligned with pre-implantation stereotactic 
MPRAGE scans. Automatic co-registration was then carried out with a restricted volume of 
fusion centred on the hypothalamus/ mesencephalon. This was carried out to minimise 
registration error resulting from brain shift incurred during surgery despite minimal brain 
shift with our surgical technique 260. Registration accuracy was carefully inspected and the 
process iterated if necessary. All volumes were realigned with a plane parallel to the AC-
PC line. 
The post-implantation MPRAGE was used to fit the DBS lead model within the MRI artefact 
produced by the leads. Activation volumes were generated around active DBS contacts 
with corresponding voltages. Binary image files of activation volumes with corresponding 
transformation matrices were exported and processed in MATLAB (MathWorks Inc.) using 
an in-house software to generate Neuroimaging Informatics Technology Initiative (NIfTI) 
volumes for further analysis.  
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9.3.5.2: Inter-subject alignment 
Pre-implantation MPRAGE scans were brain extracted using BET (Brain Extraction Tool, 
FSL v5.0) which deletes non-brain tissue from a whole head MRI 277. Two-step 
transformation was used to register native scans to the MNI152 standard-space T1-
weighted average structural template image (1mm resolution) 278. The first step employed 
linear (affine) transformation using FLIRT (FMRIB's Linear Image Registration Tool) with 
12 degrees of freedom, correlation ratio cost function and normal search 279,280. The output 
from this step was used to execute non-linear registration (second step) using FNIRT 
(FMRIB's Non-Linear Image Registration Tool) 281. This process produced individual native 
to standard (MNI space) non-linear warp fields which were then applied to the DBS 
activation volumes acquired from SureTune in order to transform all volumes to standard 
space.  
9.3.5.3: Average DBS activation volume and efficacy cluster 
All lateralized volumes were merged using Fslmerge (FSL v5.0) into a 4D data file. A single-
group average (one-sample t-test) general linear model (GLM) design was used to test 
against percentage improvement in HAL. 
Nonparametric permutation inference was then carried out on each voxel using Randomise 
(FSL v5.0) with 5000 permutations to build up the null distribution to test against. 
Percentage improvement in HAL was demeaned and single group t-test with threshold-free 
cluster enhancement (TFCE) was used as test statistic 164. Cluster-based inference using 
Cluster (FSL v5.0) was carried out to extract the clusters and local maxima in outputs. 
9.3.6: Analysis of white matter tracts 
9.3.6.1: Tractography 
Probabilistic tractography was generated in ProbtrackX2 GPU version (Behrens 2007) 282 
(FSL v5.0) (number of samples=5000, curvature threshold=0.2, step length=0.5 mm 
subsidiary fibre volume fraction threshold=0.01). The process repetitively samples from the 
distributions of voxel-wise principal diffusion directions generated in BedpostX, each time 
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computing a streamline through these local samples to generate a ‘probabilistic streamline’ 
or a ‘sample’ from the distribution on the location of the true streamline, building up a spatial 
‘connectivity distribution’. Streamlines truly represent paths of minimal hindrance to 
diffusion of water in the brain, but they are reasonable indirect estimates of long-range 
white matter connections 283. 
Probabilistic tractography was generated, for all responders, using the DBS activation 
volume as seeds and the cerebellum and contralateral hemisphere as exclusion mask. 
CSF termination masks were used to exclude false positive streamlines. 
9.4: Results 
9.4.1: Patients 
Scanning and surgery proceeded with no adverse effects. The mean (SD) follow-up was 
33 (14) months (median = 34 months). Six patients responded to DBS. The patient who did 
not respond (CH2) was also the only patient to have received ONS prior to DBS. This was 
removed after five years for lack of response. There was no surgical morbidity or mortality. 
Two patients underwent bilateral surgery making up a total of nine implanted DBS leads. 
Table 9-1 shows demographics, disease duration, length of follow-up, stimulation 
amplitudes and change in headache load, attack severity, attack frequency and attack 
duration at the final follow-up point from baseline along with patient’s estimated percentage 
of improvement after surgery. 
9.4.2: Stimulation-induced adverse events 
There were no serious adverse effects from DBS. Two patients developed transient 
dizziness, one patient developed nausea and one patient developed intermittent diplopia, 
all improved with adjusting stimulation amplitude. One patient (CH2) developed 
troublesome diplopia, oscillopsia and nystagmus with DBS amplitudes above 2 volts. 
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9.4.3: DBS activation volume modelling and efficacy cluster 
Responders average DBS activation volume, non-responder (CH2) DBS activation volume 
and statistically significant cluster correlated to higher stimulation efficacy (improvement in 
HAL) are shown in Figure 9-1. The responders average activation volume lies in the ventral 
tegmental area in the area between the red nucleus and the mammillo-thalamic tract. The 
cluster predictive of improvement in HAL lies in the superior, posterior and lateral portion 
of the group average activation volume. The activation volume for the non-responder lies 
outside the efficacy cluster. See Table 9-2 for average activation and cluster volumes with 
MNI coordinates 
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Table 9-1: Patients’ demographics, disease duration, length of follow-up, 
stimulation amplitudes and outcome after surgery 
Patient CH1 CH2 CH3 CH4 CH5 CH6 CH7 Mean STD Med. 
Gender F M M M M F M       
Age (yr.)* 50 47 56 45 47 61 42 50 7 47 
Duration of symptoms (yr.)* 5 21 9 4 10 16 25 13 8 10 
Side Right Left Left Bilat. Right Bilat. Left       
Length of follow-up (month) 48 34 33 48 41 14 14 33 14 34 
HAL 
Pre. HAL 696 756 720 967 461 520 983 729 199 720 
Post. HAL 70 588 0 0 18 294 146 159 216 70 
IMP% 90 15 100 100 96 43 85 76 33 90 
Severity (VAS) 
Pre. severity 9 9 10 10 6 10 6 9 2 9 
Post. severity 7 7 0 0 4 8 6 4 4 6 
IMP% 22 22 100 100 33 20 0 46 41 22 
Frequency 
(day) 
Pre. freq. 3 2 2 7 3 9 2 5 3 3 
Post. freq. 3 2 0 0 0.43 5 1 2 2 1 
IMP% 0 0 100 100 86 44 50 58 41 50 
Duration (min) 
Pre. duration 180 180 180 150 120 30 300 147 83 180 
Post. duration 45 180 0 0 100 30 90 53 60 45 
IMP% 75 0 100 100 17 0 70 51 46 70 
Patient estimated IMP% 60 15 100 100 65 60 30 66 31 60 
DBS amplitude (volt) 3.5 2.4 3 3.5 3.7 3.6 3.5 3.3 0.5 3.5 
 
DBS: deep brain stimulation; STD: standard deviation; Med.: median; yr.: year; 
min: minute; Bilat.:  bilateral;  IMP%: percentage of improvement; freq.: 
frequency.  
 
9.4.4: Tractography  
Group average streamlines generated from individual responders DBS activation volume 
are shown in Figure 9-2. Anteriorly, the streamlines traverse the hypothalamus and then 
split into two pathways; an infero-lateral pathway towards the mesial temporal lobe and 
amygdalar complex, possibly via the amygdalofugal pathway, and an antero-superior 
pathway towards the prefrontal area via the anterior limb of the internal capsule. Posteriorly, 
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the streamlines run medial to the red nucleus towards the periaqueductal grey and then 
caudally through the pons and upper medulla in a dorso-lateral position towards the 
trigeminal tract and nuclei 
Table 9-2: Group average activation volume and high efficacy cluster with 
MNI (AC-PC) coordinates of maximum intensity and centre of gravity (Left 
hemisphere)  
DBS Cluster VOL (mm3) 
Maximum intensity coordinates Centre of gravity coordinates 
p-value MNI (AC-PC) MNI (AC-PC) 
X Y Z X Y Z 
Average 
responders 254 -3 (-3) -13 (-2) -8 (-3) -4 (-4) -12 (-1) -8 (-3) - 
Maximum 
efficacy 14 -6 (-6) -13 (-2) -6 (-1) -4 (-4) -12 (-1) -5 (0) <0.001 
 
MNI: Montreal Neurological Institute; AC-PC: anterior commissure – posterior 
commissure; VOL: volume. AC-PC coordinates are in relation to mid-commissural  
point 
 
Figure 9-1: Average DBS activation volume (green) with DBS efficacy 
cluster (red) and activation volume for the non-responder (blue)  
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Figure 9-2: Group average probabilistic tractography streamlines (red-
yellow) with group average DBS tissue activation volume (green) 
 
9.5: Discussion 
Voxel based statistical analysis of active DBS contacts activation volumes, at the last 
follow-up point after VTa DBS was used in 7 patients with medically refractory chronic 
cluster headache to identify a statistically significant cluster in the stimulation area, 
reflecting the highest efficacy zone. The responders’ activation volumes (six patients, eight 
DBS contacts) were also used to generate probabilistic tractography streamlines to identify 
the trigemino-hypothalamic tract. 
We show that patients were appropriately selected (Table 9-1) as demonstrated in disease 
duration and headache characteristics. Furthermore, six out of seven patients had indeed 
responded well to DBS as demonstrated by the improvement in headache load, duration, 
frequency and severity. 
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9.5.1: Optimal VTa stimulation site 
The first patient 123 and patient series 124 to undergo DBS for CCH, had the target in what 
was termed the hypothalamic grey. The target came to light after a positron emission 
tomography (PET) study found increased activation in this area in CH patients during 
attacks 121. The target in this area, which we identify as the VTa, is not readily demarcated. 
This is due to three factors; firstly, the target has to be identified using surrounding 
landmarks on MRI (e.g. the red nucleus, the mammillothalamic tract); secondly, the 
stimulation amplitude (an average of 3.3 volts in this study) covers a comparatively large 
brain tissue area around the active DBS contact, hence allowing some leeway in targeting 
accuracy; and thirdly, PET studies are subject to misalignment during the co-registration 
process, potentially introducing a spatial error 467. This has been reflected in the  
discrepancy in the reported coordinates of activation with another PET study 468 and with a 
functional MRI study 469. 
The original target’s coordinates were 2 mm lateral to the midline, 6 mm behind the mid-
commissural point (MCP) and 8 mm below the AC-PC 123. This is the same area identified 
in an earlier PET study 121. The target was then modified to 2 mm lateral to the midline, 3 
mm posterior and 5 mm below the MCP 124. This last “Franzini” target has been generally 
adopted in the other surgical series 422,438,470. 
A study of ten patients with CCH implanted with unilateral DBS leads using Franzini’s target 
employed postoperative AC-PC coordinates of the active DBS contact centres, projected 
on the Schaltenbrand atlas 262 and a three-dimensional 4.7 Tesla MRI atlas of the 
diencephalon-mesencephalic junction atlas to identify the anatomical location of the 
effective DBS electrodes 422. Five patients responded to treatment.  The mean coordinates 
of the active contacts in the responders were 3 mm lateral, 3.5 mm posterior and 3.3 mm 
below the MCP. The study, however, did not find a statistically significant difference 
between the responder and non-responder groups. The authors pointed out the limitation 
from the method used to localize the contacts, i.e. projection of AC–PC coordinates on 
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atlases 422. These coordinates are within 1.5 mm from the co-ordinates of the average 
volume of DBS activation (maximum intensity point) in the responders in our study. 
Our voxel based morphometry, regression analysis shows the coordinates of the higher 
efficacy predictive cluster (maximum intensity point) to be further lateral and superior (6 
mm lateral, 2 mm posterior and 1 mm inferior to the MCP). This seems to be supported by 
the relation of the DBS activation volume of the single non-responder in our study to the 
efficacy cluster lying outside it as shown in Figure 9-1. 
9.5.2: Tractography of the trigemino-hypothalamic pathway (THT) 
The difficulty in explaining the mechanism of action of DBS in CH is partly caused by the 
lack of a definitive understanding of the pathophysiological process itself 471,472. Some 
authors suggest that simple local blockade of the ‘posterior hypothalamic grey’ or VTa 
activity is not a likely mechanism for improvement in headache. However, many patients 
experience a micro-lesion or “stun” effect with complete abolition of attacks for a few days 
or even weeks following DBS lead implantation alone, suggesting disruption of pathological 
neural activity in the region 448,455,471. However, this does not explain the latency in 
achieving maximal DBS efficacy that has been seen across several studies, including our 
own. Increased threshold for cold pain at the site of the first trigeminal branch ipsilateral to 
the stimulated side in chronically stimulated patients could be caused by modulation of the 
anti-nociceptive system 473, however; a generic anti-nociceptive effect does not explain why 
DBS is effective for the trigeminal autonomic cephalalgias but not “atypical facial pain” 
455,471,472,474. DBS has been shown to modulate a complex network of pain-processing 
areas 417.  Stimulation induced local activation around the active DBS contact as well as 
distant activation in the ipsilateral thalamus, somatosensory cortex and precuneus, the 
anterior cingulate cortex and the ipsilateral trigeminal nucleus and ganglion; coupled with 
deactivation in the middle temporal gyrus, posterior cingulate cortex, inferior temporal gyrus 
bilaterally and contralateral anterior insula 417. This study was the first to document a 
functional connection between the hypothalamus and the trigeminal system in human 
beings in vivo. The activation in the trigeminal system however does not seem to provoke 
  
219 
CH pain attacks or the typical sensations that commonly accompany trigeminal activation 
417. This connection has been previously observed following injection of the neuropeptide 
orexin B into the ‘posterior hypothalamic region’ of the rat which increased spontaneous 
activity in the caudal trigeminal nucleus (with discharges persisting for several minutes) 
and heightened responses in the nucleus to dural stimulation and noxious thermal 
stimulation of the face. 466 
The connection between the trigeminal system and the hypothalamus is crucial in 
integrating somatosensory and visceral information (e.g. innervation from cranial skin, 
intracranial blood vessels, and meninges) with endocrine and autonomic responses 465. 
Single-unit recording and antidromic microstimulation techniques in rats have established 
a direct two-way connection between the posterior hypothalamus and the spinal trigeminal 
nucleus through the THT 465. 
Other brainstem nuclei have neurons that respond to noxious and innocuous 
somatosensory and visceral stimulation 475-479. These nuclei also give efferents to the 
hypothalamus, such as the parabrachial nuclei 480-482, nucleus of the solitary tract 483,484, 
periaqueductal gray 485-488, and caudal ventrolateral medulla 489,490 suggesting that 
somatosensory signals reach the hypothalamus through several polysynaptic pathways 465. 
Previous work has explored the structural connectivity of the DBS target using probabilistic 
tractography in healthy controls491. Comparable connections to the frontal and temporal 
areas were described alongside connections to the periaqueductal grey. At the time, image 
acquisition parameters were not sufficient for accurate tracking in the brainstem which we 
present here. 
Our tractography results show that the DBS activated area, posterior to the hypothalamus, 
in the ventral tegmentum lies on a tract that connects the hypothalamus, prefrontal and 
mesial temporal regions anteriorly with brainstem areas in the proximity of the parabrachial 
nuclei, nucleus of the solitary tract, periaqueductal grey and ending in the region of the 
trigeminal nucleus and tract and the superior salivatory nucleus (SSN) (Figures 9-2 and 
9-3). 
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Although this finding does not explain the mechanism of action of DBS, it confirms the 
relevance of the target site by means of its connections to anatomically relevant brainstem 
areas. One possibility is by exerting a top-down anti-nociceptive effect, while another 
possibility, is by modulation of the trigeminal parasympathetic reflex, commonly activated 
in primary headache disorders 492 and is thought to mediate the cranial autonomic 
symptoms in CH 493. This pathway can be triggered by hypodermic capsaicin injection in 
the first trigeminal nerve division area 494 as well as a variety of trigeminal nociceptive 
triggers 472. Nociceptive trigeminal activation, in the first division of the trigeminal nerve, is 
relayed into the spinal trigeminal nucleus and the C1/C2 dorsal horns (i.e. the trigemino-
cervical complex or TCC) 495 which has a reflex connection to the SSN in the pons 496. The 
output is then carried via the parasympathetic pathway of the facial nerve, through the 
geniculate ganglion within the greater superficial petrosal nerve 497 to the sphenopalatine 
ganglion (SPG) 472,498.  
It must be noted however, that the pain and the autonomic phenomenon can at times occur 
independently 461 especially in patients taking preventive medications, suggesting either 
anatomically separate pathways albeit partly, or different activation thresholds mediating 
these two features 400,498  
9.5.3: The use of improvement in HAL as a determinant of treatment response 
The International Headache Society guidelines for cluster headache clinical trials advocate 
a reduction of 50% in headache frequency as a marker for treatment response 499. Though 
we present change in headache frequency, severity and duration following treatment as 
suggested by these guidelines; it is our experience that patients who achieve a significant 
improvement in only one of the variables can be extremely satisfied with the therapy 
provided. For example, a patient with 6 attacks of one-hour duration per day with severity 
of 8/10 who, after DBS, then experiences 5 attacks of one-hour per day with a 2/10 severity 
will not be a responder in terms of headache frequency but is certainly a responder in terms 
of headache load and quality of life. Within this group we have had patients who had >30% 
response in terms of headache load but <50% response to headache frequency who were, 
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nevertheless, very pleased with the improvement in their symptoms. We have therefore 
opted to use the reduction in HAL as the marker for treatment response as we have done 
so in a previous publication 448 
 
Figure 9-3: Illustration showing two cross-sections in the pons at the level 
of the trigeminal nerve, main sensory and mesencephalic trigeminal nuclei 
(top); and spinal trigeminal nucleus and tract, superior salivatory nucleus 
and solitary tract (bottom) 
 
9.5.4: Limitations 
The principal weakness in this study is the small number of patients. Cluster headache is 
an orphan condition with a prevalence of 0.1-0.2%, with only 10-15% of sufferers 
developing the chronic form, a small minority of which will be refractory to medical therapies 
and hence qualify for neuromodulation 400-404. This explains the reason the number of 
patients treated with DBS in the literature remains in double digits 448. As a result of the 
small population in our study, we identified a single non-responder in keeping with our 
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published failure rate of 19% 448. This patient had also failed to respond to ONS which 
raises the possibility of other unidentified disease factors related to failure as opposed to 
DBS active contact location. Unfortunately, this does not allow a two group statistical 
analysis of the tractography results, however, the single group regression analysis we 
carried out was able to identify the voxels that predict the highest improvements in HAL. 
The limitations of the VTA model used in this study and the rationale behind using this 
model have been described in chapter 2 (2.10.4). A further limitation is due to inherent 
diffusion MRI imperfections. In vivo tractography studies in the brainstem carry significant 
challenges. Motion artefacts, as a result of the highly pulsatile nature of the region, can 
degrade the MRI signal during diffusion image acquisition, reducing the signal-to-noise 
ratio (SNR). This is complicated by the presence of myriads of criss-crossing axons and 
reticular brain regions 104,105. One way of dealing with this is by using pulse-gating and 
respiratory rate monitoring during diffusion imaging. Likewise, by acquiring multiple 
diffusion scans, at a high angular resolution (increasing acquisition time), SNR is improved 
91,103. 
In this study, 270 diffusion scans per patient (in 2 × 128 directions sets) were acquired over 
62 minutes. We meticulously and systematically corrected artefacts and examined the 
processed imaging data for quality control. We modelled three crossing fibres per voxel 
and used probabilistic tractography to ameliorate the crossing fibre problem. Further 
improvements in diffusion imaging, owing to higher spatial and angular resolution, better 
MRI gradients and shorter acquisition times with emergence of multi-band acquisition will 
add to the value of this modality 102,283. 
By employing multiple registration steps, we have introduced error to the system. 
Nonetheless, we meticulously inspected registration accuracy at each step to alleviate the 
impact of this issue. Prior to carrying out the VBM cluster analysis, we lateralized the right 
sided DBS contacts to the left. This is an approach commonly used in imaging studies, 
however, it assumes no functional / structural differences between the left and right 
hemispheres, in the regions of interest at the least. 
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Lastly, the relatively long scan duration is a drawback. This was chosen to achieve the 
SNR and resolution needed, however, since the conduction of this study, novel MRI 
acquisition techniques, such as Simultaneous Multi-Slice Imaging and Multi-Band Imaging 
303 have been developed which allow a similar protocol to be run within half the time without 
compromising the SNR. 
Despite these caveats and drawbacks, the methodology used has confirmed anatomical 
connections that have been implicated in the pathophysiology of cluster headache. 
9.6: Conclusion 
Following VTa-DBS in patients with medically refractory chronic cluster headache, the 
largest reduction in headache load appears to correspond to activation in an area 6 mm 
lateral, 2 mm posterior and 1 mm inferior to the MCP. Active contact DBS activation in 
responders lies on the trigemino-hypothalamic tract, connecting the trigeminal system and 
other brainstem nuclei linked with nociception and pain modulation with the hypothalamus, 
prefrontal and mesial temporal areas. 
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10. General Discussion 
10.1: Contributions to the field of functional neurosurgery 
This thesis presents a study into the application of MRI connectivity in the field of functional 
neurosurgery. The methods and models used, albeit in selected patient groups undergoing 
DBS surgery, could be applied to other patient groups. This will help refine targeting, build 
predictive models of treatment and map out the underlying brain networks to better 
understand the mechanism of action of DBS. This is not restricted to patients undergoing 
DBS but includes ablative stereotactic procedures. 
10.1.1: Connectivity in Parkinson’s Disease 
In this chapter, we explored the applications of functional connectivity, structural 
connectivity and neurophysiology (EMG) to build predictive models of response to L-DOPA 
and STN-DBS. We also mapped out hyperdirect pathways and explored their influence on 
efficacy. Understanding the relationship between the functional connectivity and clinical 
effects of dopamine helps shed light on the disease process in the advanced stage. We 
inferred that networks linked to cognitive (proactive) motor inhibition show relatively higher 
connectivity whilst networks linked to reactive motor inhibition show lower connectivity with 
better dopamine response. Furthermore, connectivity was relatively stronger in between 
basal ganglia structures with better dopamine response. Future studies may be able to 
validate these results and explore markers at the ‘individual level’ by employing machine 
learning algorithms to build predictive models of response to treatment, thus validating, or 
even corroborating the L-DOPA challenge test. This could potentially aid with patient 
selection and help with understanding the mechanism of action of DBS.  
We identified in the second experiment the optimal STN deep brain stimulation site for 
patients with Parkinson’s disease for tremor, bradykinesia and rigidity. These appeared to 
correspond to different (though closely related) areas in the motor STN.  Stimulation in the 
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central portion of the superior STN was most effective for tremor, whilst stimulation in 
further medial and posterior areas, within the superior portion, gave highest improvements 
in bradykinesia and rigidity. These areas, although distinct, could readily be targeted with 
a single DBS electrode. The findings should, however, help refine the targeting strategies.  
We showed that DBS-cortical connectivity, along the hyperdirect pathways, to M1 was 
predictive of maximum improvement in tremor, to SMA was predictive of maximum 
improvement in bradykinesia and to both SMA and PFC was predictive of maximum 
improvement in rigidity. This revealed the diffuse cortical involvement in DBS for PD. Future 
developments, especially in the field of adaptive stimulation 500,501 will benefit from this 
understanding. 
We used DBS volume of tissue activation models in this thesis. The overlap between the 
models and corticospinal tracts identified on tractography correlated well with EMG 
findings. Despite the limitations of said models, we showed that they can be validated using 
a multimodal imaging-neurophysiology approach. This spread of current compromises 
increase in stimulation strengths and is related to the development of speech disturbances 
with chronic stimulation. Furthermore, we proposed that EMG may be used to detect such 
current spread and may thus represent a valuable tool in troubleshooting in PD patients 
treated with STN DBS.  
10.1.2: Connectivity in Tremor 
Probabilistic tractography techniques were successfully used to segment the VL and VP 
thalamus based on cortical and cerebellar connectivity. The thalamic area, best 
representing the VIM, was connected to the contralateral dentate cerebellar nucleus. 
Connectivity based segmentation of the VIM were achieved in individual patients in a 
clinically feasible timescale, using HARDI and high performance computing with parallel 
GPU processing. This same technique can map out the DRTC tract with clear 
mesencephalic crossing. Future studies may focus on improving data acquisition and 
processing time; and apply this technique prospectively in patients undergoing thalamic 
DBS or lesioning for tremor.  
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10.1.3: DBS of Trigeminal Autonomic Cephalalgias and Connectivity in Cluster Headache 
In this chapter, we first established the safety and efficacy of DBS in the ventral tegmental 
area (VTa) for two trigeminal autonomic cephalalgias (TAC) entities; chronic cluster 
headache and SUNA. We also noted positive effects of DBS for CCH on patient-reported 
quality of life, disability and mood. 
Following from this, we strived to elucidate the optimum target for stimulation and the 
involved network. Active contact DBS activation in responders lay on the trigemino-
hypothalamic tract, connecting the trigeminal system and other brainstem nuclei linked with 
nociception and pain modulation with the hypothalamus, prefrontal and mesial temporal 
areas. This is a novel finding that helps us in understanding the mechanism of action of 
VTa-DBS as well as in shedding a light on the pathophysiology of CH and possibly other 
TACs. 
10.2: Limitations of the thesis 
This thesis draws upon several experimental methodologies and patient groups to explore 
the application of connectivity studies in functional neurosurgery. There are numerous 
limitations and caveats to these methodologies, each discussed in the relevant chapters. 
One conspicuous issue is that of reproducibility. In contrast to studies that explore a 
therapeutic intervention, whether pharmacological or surgical where the treatment can 
often be standardised and verified; connectivity imaging studies are inherently difficult to 
reproduce. This is attributed to the plethora of MRI acquisition and processing techniques. 
Furthermore, by employing multiple registration steps, errors are introduced to the system. 
Nonetheless; meticulous confirmation of registration accuracy at each step can alleviate 
the impact of this issue.  
In this thesis, we used state of the art MRI sequences to achieve the spatial resolution and 
SNR necessary to run the experiments. Unfortunately, this meant that the acquisition time 
was rather lengthy. This poses difficulties for many patients undergoing DBS surgery, 
mainly those undergoing surgery for movement disorders. The patients who participated in 
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the studies here were all very carefully selected and vetted before recruitment. Despite all 
of this, a small number could not tolerate the lengthy imaging protocol and the scan was 
therefore abandoned. This may be acceptable in group studies aiming to explore 
pathophysiological models but not in clinical applications in individual patients. Novel MRI 
acquisition techniques, such as Simultaneous Multi-Slice Imaging and Multi-Band Imaging 
303, have been developed since the commencement of this work that will allow future 
studies to run similar protocols within half the time without compromising the SNR. 
Another limitation is the use of a patient specific, finite element model to create DBS 
volumes of tissue activated 143. This is a simplified linear model that does not account for 
local impedance inhomogeneity. While it is important that efforts are put into improving 
models of DBS to resemble reality as much as possible, it may not help to add details to a 
rough model when the basic knowledge of the DBS mechanisms of actions are still 
debated. Indeed, various models over- or under-estimate the VTA 142. The presence of 
axons of different diameters and cell bodies, with variable action-potential thresholds, in 
the DBS region, complicates matters further. Other justification for not using a more 
complex model is the fact that minute variations in VTAs are unlikely to have a large effect 
on statistical analysis and tractography results, due to the relatively coarse spatial 
resolution of our structural and diffusion MRI data. Lastly, the package used to generate 
the VTAs is not yet commercially available. This make reproducing these models, albeit 
theoretically, difficult. With time, the software mentioned is likely to be mainstream, 
alleviating this problem. 
There are also limitations associated with some of the techniques used, especially 
functional connectivity, which is largely limited to group-level analysis. While this is useful 
in exploring group-wise changes, inferences on the individual level cannot be readily made, 
especially on a diagnostic/predictive capacity. This may limit the clinical application of the 
technique in individual patients. 
Lastly, one of the principal weakness in this thesis is the relatively small number of patients 
and the mixed aetiologies. Some of the disorders included orphan conditions (CH 
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prevalence is 0.1-0.2%, with only 10-15% of sufferers developing the chronic form, a small 
minority of which will be refractory to medical therapies and hence qualify for 
neuromodulation 400-404). This makes recruitment rather difficult. Additionally, to achieve the 
required postoperative follow-up period prior to carrying out the analysis, limited 
recruitment is possible in the time span of a PhD project. 
10.3: Future challenges 
10.3.1: Standardisation of methods 
Method standardisation is by far the biggest challenge facing the field. Diffusion data are 
noisy and the sequences are highly variable and configurable. Moreover, data analysis is 
based on statistics and has many options and alternatives with more than one “right” way 
(but many wrong ways) of analysis 80. This, combined with the relative paucity of patients 
undergoing connectivity studies and functional neurosurgery, makes it essential rather than 
desirable to have standardized imaging paradigms and processing in order to reproduce 
and validate the results of these studies. 
10.3.2: Quantification of connectivity (functional and structural) 
A real challenge in connectivity studies, especially in measuring grey matter connectivity, 
is coming up with a quantifiable measure of connectivity 102. We proposed a connectivity 
index in chapter 4 using normalised streamline count. This is by no means a perfect 
solution. Tractography has many biases and can result in false positive/ negative tracts. It 
is also affected by crossing fibres, distance, size of seed/ target masks and the 
straightness/ curvature of the streamlines.   
10.3.3: DBS volume of tissue activation 
This is certainly a challenging area that will require further development. The available 
models including the one used in this thesis are oversimplified and often do not consider 
inhomogeneity in local impedance 502. Improving the existing models cannot, however, rely 
only on improving the mathematical model as it depends on a better understanding of the 
  
229 
mechanism of action of DBS therapy itself 162. It is likely that the emergence of more 
‘steered’ stimulation with directional electrodes will enrich the available models by providing 
more specific efficacy and side-effect data to correlate with virtual stimulation models. We 
attempted to verify the finite element VTA model used in this thesis in chapter 9. 
10.3.4: Clinical applications in functional neurosurgery 
The next step, and indeed the ultimate aim of this work is to use the proposed methods in 
clinical practice. Some of the challenges that this poses are related to multimodal image 
fusion and integration within commercially available neuronavigation and targeting 
packages. We have presented an example of integrating tractography data (segmented 
VIM) within Renishaw’s Neuroinspire package in chapter 6. Improved image fusion and 
coregistration is essential, especially when spatial distortion must be kept at a minimum in 
stereotactic surgery. This will be achieved with improved diffusion and BOLD data noise 
and artifact, amalgamated with better distortion correction and coregistration algorithms. 
Improving structural MRI data will also help better segment deep brain structures (e.g. the 
STN). This will help focus registration, as well as reducing observer error in manual 
segmentation in group studies (Chapter 4 and 5). Acquiring ‘stereotactic’ diffusion and 
fMRI data in the future, with newly developed MR safe frames is bound to improve spatial 
accuracy by improving co-registration. The newest iteration of the Leksell frame is 3T MRI 
safe. The frame is made from plastic resin and therefore does not cause artifact with EPI 
sequences. As surgery is increasingly performed under general anaesthesia, stereotactic 
diffusion/ fMRI data could be acquired at the same time as stereotactic planning MRI and 
instantaneously processed and integrated with structural imaging to aid with targeting (e.g. 
VIM DBS for tremor).   
10.4: Future developments 
Perhaps the biggest development in the field of brain connectivity will come from the 
completion of the Human Connectome Project next year 117,503. The 5-year project has set 
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out to provide data and analysis pipelines of very high quality to map the macroscopic brain 
connections and their variability in healthy adults for a large population of 1,200 subjects. 
By doing so, the findings will provide a frame of reference for future studies on pathological 
brains, not to mention new standards in image acquisition and connectivity processing. 
Other developments are certain to arise from the continuous progress in MRI, which may 
be improvements in structural, diffusion or functional imaging. Higher spatial resolution and 
SNR with shorter acquisition times are bound to provide better data and applicability in 
clinical settings. There has been already a big stride forward with Simultaneous Multi-Slice 
Imaging and Multi-Band Imaging techniques 303. Since the completion of the experiments 
in this thesis, the Siemens Trio 3T MRI scanner used has been upgraded to a Siemens 
Magnetom Prisma 3T MRI scanner with upgraded gradient magnets. We have tested Multi-
Band diffusion MRI sequences utilising three and two bands along with single band 
acquisitions on both the Prisma and the Trio (used in this thesis). The sequences had the 
same imaging parameters. It seemed appropriate that the subject whose brain was studied 
was the writer. The three-band (3B) sequence took only 15 minutes to acquire, the two-
band sequence (2B) took 30 minutes whilst the single band (1B) took 45 minutes on the 
Prisma. These times compare favourably with the 61 minute (1B) acquisition time on the 
Trio. Three fibre modelling was achieved as per standard methodology described in this 
thesis, the results of which are shown in Figure 10-1. 
Perhaps not surprisingly the best SNR and quality of crossing fibre modelling was seen in 
the 1B scan on the Prisma. Nevertheless, the 2B scan, which took only 30 minutes, was 
visually comparable, if not of better quality than the 1B scan on the Trio scanner (Figure 
10-1). 
Machine learning and artificial intelligence (AI) are likely to change the way multimodal data 
are analysed in the future 504. Multivariate pattern analysis of neuroimaging data achieves 
increased sensitivity in detecting spatially distributed effects not usually detected by 
univariate analysis 504. Using machine learning algorithms will allow for the use of data from 
group studies (such as in chapter 3.1) to apply to individual datasets. This can significantly 
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increase the clinical applicability of connectivity studies, which often require large groups 
to overcome biases from the spatial reconstruction of connections resulting in false positive 
and/ or false negative results 102,283. 
Another important development will come from further advances in computational power 
and GPU parallel processing techniques. This has already led to a substantial reductions 
in big dataset processing time (as demonstrated in this thesis), allowing the use of 
connectivity studies in clinical settings 160. 
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Figure 10-1: Diffusion MRI acquisit ions at 3B, 2B and 1B (Trio - Prisma) 
along with preprocessed images 
 
FA: fractional  anisotropy; DYADS: distribution of mean diffusion direction vector 
(1 = principal, 2 = secondary and 3 = tertiary); B: band 
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10.5: Conclusions 
Progress in functional neurosurgery has been inextricably linked to progress in 
neuroimaging techniques. Advances in MRI have made it possible to directly target deep 
brain structures with DBS or ablative surgery and confirm the result as well as improve 
safety. The use of advanced MRI connectivity studies take our understanding of brain 
networks to the next level and provide us with new tools to refine targeting and patient 
selection, as well as to better understand the treatment mechanisms of action and disease 
pathophysiology. 
The use of these techniques should come with caution. Heavy reliance on complex 
statistical methods and variability in image acquisition and analysis pose real challenges. 
Clinicians delving into this world ought to have a good understanding of the science and 
the methods in order to achieve accurate results and meaningful outcomes. Doing 
otherwise will not only result in erroneous interpretations of the data thus potentially 
harming patients, but can also cause harm to the reliability of the techniques themselves, 
jeopardising progress in this exciting field. 
 
“Concern for man and his fate must always form the chief 
interest of all technical endeavors. Never forget this in the 
midst of your diagrams and equations.” 
Albert Einstein (1879 – 1955) 
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DIFFUSION IMAGE ACQUISITION 
Coil 32 Ch T&R Reference Scan Mode  single-shot EPI 
Voxel size 1.5×1.5×1.5 mm Distortion Corr.  Off 
TA 04:41 Prescan Normalize  Off 
Slices  85 Raw filter  Off 
Dist. factor  0% Elliptical filter  Off 
Position  L4.0 A11.0 F25.7 Hamming  Off 
Orientation  T > C-8.2 > S-1.5 Coil Combine Mode  Adaptive Combine 
Phase enc. dir.  R >> L (6) + L >> R (6) Auto Coil Select  Default 
Rotation  90.00 / -90.00 deg Shim mode  Standard 
Phase oversampling 0% ? Ref. amplitude 1H  0.000 V 
FoV read  219 mm Adjustment Tolerance Auto 
FoV phase  80.8% Physio   
Slice thickness  1.5 mm 1st Signal/Mode  None 
TR  12200 ms PMU Recording  off 
TE  99.6 ms Resp. control  Off 
Averages 1 Diff   
Concatenations 1 Diffusion mode  Free 
Filter  None Diff. weightings  1 
Coil elements  HEA;HEP b-value  1500 s/mm² 
Contrast   Diff. weighted images  On 
MTC  Off Trace weighted images  On 
Magn. preparation  None Average ADC maps  On 
Fat suppr.  Fat sat. Individual ADC maps  On 
Extra Fat Suppr.  on FA maps  On 
Saturation Mode  standard Mosaic On 
Averaging mode  Long term Tensor  On 
Reconstruction  Magnitude Noise level  40 
Delay in TR  0 ms Diff. directions  270 (14 B0) 
Multiple series  Off Sequence   
Resolution   Introduction  Off 
Base resolution 146 Bandwidth  1426 Hz/Px 
Phase resolution 100% Optimization  None 
Phase partial Fourier  6/8 Free echo spacing  On 
Interpolation  Off Echo spacing  0.89 ms 
PAT mode  GRAPPA EPI factor  118 
Accel. factor PE 2 RF pulse type  Normal 
Ref. lines PE 30 Gradient mode  Fast* 
Matrix Coil Mode  Auto (Triple) Add. FFT Scale Factor  1.0 
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B1 IMAGE ACQUISITION 
TA 03:00 Matrix Coil Mode  Auto (Triple) 
Voxel size 4.0×4.0×4.0 mm  Reference scan mode  Separate 
Slabs  1 Image Filter  Off 
Position  L3.0 A18.5 F41.4 Distortion Corr.  Off 
Orientation  Transversal Prescan Normalize  Off 
Phase enc. dir.  R >> L Normalize  Off 
Rotation  90.00 deg B1 filter  Off 
Phase oversampling  0% Raw filter  Off 
Slice oversampling  0% Elliptical filter  Off 
Slices per slab 48 Coil Combine Mode  Sum of Squares 
FoV read  256 mm Auto Coil Select  Default 
FoV phase 75.00% Shim mode  Standard 
Slice thickness  4.0 mm Adjust with body coil  Off 
TR  500.00 ms Assume Silicone  Off 
TE 1  39.06 ms ? Ref. amplitude 1H  0.000 V 
TE 2  19.53 ms Adjustment Tolerance  Auto 
Concatenations  1 Sequence   
Filter  None Dimension  3D 
Coil elements  HEA;HEP Contrasts  2 
Contrast   Bandwidth  2298 Hz/Px 
Fat suppr.  Fat sat. RF spoiling  Off 
Reconstruction  Magnitude Refoc. Corr  6.0 [%] 
Measurements  11 Scale s. gradient  15.0 [%] 
Resolution   Mixing time  33800 [us] 
Base resolution  64 Max refoc. angle  230 [deg] 
Phase resolution  100% Dec refoc. angle  10 [deg] 
Slice resolution  100% Flip angle for ref scans 230 [deg] 
Phase partial Fourier  Off Dur per 5 degrees  140 [us] 
PAT mode  GRAPPA BWT SE/STE factor  6 [us] 
Accel. factor PE  2 No dummy scans  0 
Ref. lines PE  48 RF spoil incr.  50.0 [deg] 
Accel. factor 3D  2 Crushers permutation  On 
Ref. lines 3D  48 Optimized RF duration  On 
 237 
 
GRADIENT FIELD MAPPING ACQUISITION 
TA 02:14 Resolution   
Voxel size 3.0×3.0×2.0 mm Base resolution  64 
Slices  64 Phase resolution  100% 
Dist. factor  50% Phase partial Fourier  Off 
Position  L3.0 A9.2 F41.4 Interpolation  Off 
Orientation  Transversal Matrix Coil Mode  Auto (CP) 
Phase enc. dir.  R >> L Image Filter  Off 
Rotation  90.00 deg Distortion Corr.  Off 
Phase oversampling  0% Prescan Normalize  Off 
FoV read  192 mm Normalize  Off 
FoV phase  100.00% B1 filter  Off 
Slice thickness  2.0 mm Raw filter  Off 
TR  1020 ms Elliptical filter  Off 
TE 1  10.00 ms Shim mode  Standard 
TE 2  12.46 ms Adjust with body coil  Off 
Averages  1 Assume Silicone  Off 
Concatenations  1 ? Ref. amplitude 1H  0.000 V 
Filter  None Adjustment Tolerance  Auto 
Coil elements  HEA;HEP Sequence   
Contrast   Introduction  On 
MTC  Off Dimension  2D 
Flip angle  90 deg Asymmetric echo  Off 
Fat suppr.  None Contrasts  2 
Averaging mode  Long term Bandwidth  260 Hz/Px 
Reconstruction  Magn./Phase Flow comp.  Yes 
Measurements  1 RF pulse type  Normal 
Multiple series  Off Gradient mode  Fast 
    RF spoiling  On 
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MT IMAGE ACQUISITION 
TA 07:00 Ref. lines PE  18 
Voxel size 1.0×1.0×1.0 mm Accel. factor 3D  1 
Slabs  1 Matrix Coil Mode  Auto (Triple) 
Position  L3.4 A24.0 F52.3 Reference scan mode  Integrated 
Orientation  Sagittal Image Filter  Off 
Phase enc. dir.  A >> P Distortion Corr.  Off 
Rotation  0.00 deg Prescan Normalize  Off 
Slice oversampling  0.00% Normalize  Off 
Slices per slab  176 B1 filter  Off 
FoV read  256 mm Raw filter  Off 
FoV phase  93.80% Elliptical filter  Off 
Slice thickness  1.00 mm Shim mode  Standard 
TR  24.50 ms Adjust with body coil  Off 
TE 1 2.34 ms Assume Silicone  Off 
TE 2 4.68 ms ? Ref. amplitude 1H  0.000 V 
TE 3 7.02 ms Adjustment Tolerance  Auto 
TE 4 9.36 ms Sequence   
TE 5 11.70 ms Dimension 3D 
TE 6 14.04 ms Contrasts  6 
Concatenations  1 Bandwidth  465 Hz/Px 
Filter  None RF spoiling  On 
Coil elements  HEA;HEP MT repetition factor  1 
Contrast   FA Gaussian  220 [deg] 
MTC  On Duration Gaussian  4000 [us] 
Flip angle  6 deg Off-resonance Gaussian] 2000 [Hz 
Reconstruction  Magn./Phase Flat Top MT spoiler  1000 [us] 
Resolution   Dur. Prew. Ramp  150 [us] 
Base resolution  256 Dur. Prew. Flat  600 [us] 
Phase resolution  100% Dur. RO Ramp  80 [us] 
Slice resolution  100% RF spoil incr.  137.0 [deg] 
Phase partial Fourier  Off RF excitation  Sinc (non-sel.) 
Slice partial Fourier  6/8 Rec: fixed duration  30 [us] 
PAT mode  GRAPPA Sinc: fixed duration  160 [us] 
Accel. factor PE  2 BWT of sinc  6 [int] 
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PROTON DENSITY IMAGE ACQUISITION 
TA 07:00 Accel. factor PE  2 
Voxel size 1.0×1.0×1.0 mm Ref. lines PE  18 
Slabs  1 Accel. factor 3D  1 
Position  L3.4 A24.0 F52.3 Matrix Coil Mode  Auto (Triple) 
Orientation  Sagittal Reference scan mode  Integrated 
Phase enc. dir.  A >> P Image Filter  Off 
Rotation  0.00 deg Distortion Corr.  Off 
Slice oversampling  0.00% Prescan Normalize  Off 
Slices per slab  176 Normalize  Off 
FoV read  256 mm B1 filter  Off 
FoV phase  93.80% Raw filter  Off 
Slice thickness  1.00 mm Elliptical filter  Off 
TR  24.50 ms Shim mode  Standard 
TE 1 2.34 ms Adjust with body coil  Off 
TE 2 4.68 ms Assume Silicone  Off 
TE 3 7.02 ms ? Ref. amplitude 1H  0.000 V 
TE 4 9.36 ms Adjustment Tolerance  Auto 
TE 5 11.70 ms Sequence   
TE 6 14.04 ms Dimension 3D 
TE 7 16.38 ms Contrasts  8 
TE 8 18.72 ms Bandwidth  465 Hz/Px 
Concatenations  1 RF spoiling  On 
Filter  None MT repetition factor  1 
Coil elements  HEA;HEP FA Gaussian  220 [deg] 
Contrast   Duration Gaussian  4000 [us] 
MTC  Off Off-resonance Gaussian  2000 [Hz] 
Flip angle  6 deg Flat Top MT spoiler  1000 [us] 
Reconstruction  Magn./Phase Dur. Prew. Ramp  150 [us] 
Resolution   Dur. Prew. Flat  600 [us] 
Base resolution  256 Dur. RO Ramp  80 [us] 
Phase resolution  100% RF spoil incr.  137.0 [deg] 
Slice resolution  100% RF excitation  Sinc (non-sel.) 
Phase partial Fourier  Off Rec: fixed duration  30 [us] 
Slice partial Fourier  6/8 Sinc: fixed duration  160 [us] 
PAT mode  GRAPPA BWT of sinc  6 [int] 
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T1 IMAGE ACQUISITION 
TA 07:00 Accel. factor PE  2 
Voxel size 1.0×1.0×1.0 mm Ref. lines PE  18 
Routine   Accel. factor 3D  1 
Slabs  1 Matrix Coil Mode  Auto (Triple) 
Position  L3.4 A24.0 F52.3 Reference scan mode  Integrated 
Orientation Sagittal Image Filter  Off 
Phase enc. dir.  A >> P Distortion Corr.  Off 
Rotation  0.00 deg Prescan Normalize  Off 
Slice oversampling  0.00% Normalize  Off 
Slices per slab  176 B1 filter  Off 
FoV read  256 mm Raw filter  Off 
FoV phase  93.80% Elliptical filter  Off 
Slice thickness  1.00 mm Shim mode  Standard 
TR 24.50 ms Adjust with body coil  Off 
TE 1 2.34 ms Assume Silicone  Off 
TE 2 4.68 ms ? Ref. amplitude 1H  0.000 V 
TE 3  7.02 ms Adjustment Tolerance  Auto 
TE 4  9.36 ms Sequence   
TE 5 11.70 ms Dimension  3D 
TE 6  14.04 ms Contrasts 8 
TE 7  16.38 ms Bandwidth  465 Hz/Px 
TE 8  18.72 ms RF spoiling  On 
Concatenations  1 MT repetition factor  1 
Filter  None FA Gaussian 220 [deg] 
Coil elements  HEA;HEP Duration Gaussian  4000 [us] 
Contrast   Off-resonance Gaussian  2000 [Hz] 
MTC  Off Flat Top MT spoiler  1000 [us] 
Flip angle  21 deg Dur. Prew. Ramp  150 [us] 
Reconstruction  Magn./Phase Dur. Prew. Flat  600 [us] 
Resolution   Dur. RO Ramp  80 [us] 
Base resolution 256 RF spoil incr.  137.0 [deg] 
Phase resolution  100% RF excitation  Sinc (non-sel.) 
Slice resolution  100% Rec: fixed duration  100 [us] 
Phase partial Fourier  Off Sinc: fixed duration  580 [us] 
Slice partial Fourier  6/8 BWT of sinc  6 [int] 
PAT mode  GRAPPA     
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RESTING STATE FMRI ACQUISITION 
TA 08:01 Adjustment Tolerance  Auto 
Voxel size 3.0×3.0×2.5 mm GLM Statistics  Off 
Slices  45 Dynamic t-maps  Off 
Dist. factor  20% Starting ignore meas  0 
Position L4.0 A11.8 F30.3 Ignore after transition  0 
Orientation  T > C-8.2 > S-1.5 Model transition states  On 
Phase enc. dir.  P >> A Temp. highpass filter  On 
Rotation  -180.00 deg Threshold  4 
Phase oversampling  0% Paradigm size  5 
FoV read  192 mm Meas[1]  Baseline 
FoV phase  100.00% Meas[2]  Baseline 
Slice thickness  2.5 mm Meas[3]  Baseline 
TR  60.0 ms Meas[4]  Baseline 
TE 1  30.00 ms Meas[5]  Active 
TE 2  30.00 ms Motion correction  On 
TE 3  30.00 ms Interpolation  3D-K-space 
Concatenations  1 Spatial filter  Off 
Filter  None Sequence   
Coil elements  HEA;HEP Dimension  2D 
Contrast   Contrasts  1 
Flip angle  90.0 deg Bandwidth  2298 Hz/Px 
Fat suppr.  Fat sat. Output Data Type  Image Data 
Reconstruction  Magnitude Trigger Output  Cogent 
Measurements  3 Phase Correction Mode  Point/Point 
Pause after meas. 1  0.000 s Read Gradient Normal 
Pause after meas. 2  0.000 s Phase Gradient  Normal 
Resolution   Phase FoV  Normal 
Base resolution  64 PE direction  Positive 
Phase resolution  100% RO Waveform  Trapezoidal 
PAT mode  None Refoc. Corr  2.0 [%] 
Matrix Coil Mode  Auto (CP) Multi-echo full FOV  Off 
Image Filter  Off FatSat FA  130 [deg] 
Distortion Corr.  Off X-Shim 1  0.0 [mT/m*ms] 
Prescan Normalize  Off X-Shim 2  0.0 [mT/m*ms] 
Normalize  Off X-Shim 3  0.0 [mT/m*ms] 
B1 filter  Off Y-Shim 1 0.0 [mT/m*ms] 
Raw filter  Off Y-Shim 2 0.0 [mT/m*ms] 
Elliptical filter  Off Y-Shim 3  0.0 [mT/m*ms] 
Shim mode  Standard Z-Shim 1  0.0 [mT/m*ms] 
Adjust with body coil  Off Z-Shim 2  0.0 [mT/m*ms] 
Assume Silicone  Off Z-Shim 3  0.0 [mT/m*ms] 
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ALTERNATIVE RESTING STATE FMRI (LOW SAR)  
TA 06:53 Adjustment Tolerance  Auto 
Voxel size 3.0×3.0×2.5 mm GLM Statistics  Off 
Slices  45 Dynamic t-maps  Off 
Dist. factor  20% Starting ignore meas  0 
Position  L4.0 A11.8 F30.3 Ignore after transition  0 
Orientation  T > C-8.2 > S-1.5 Model transition states  On 
Phase enc. dir.  A >> P Temp. highpass filter  On 
Rotation  0.00 deg Threshold  4 
Phase oversampling  0% Paradigm size  5 
FoV read  192 mm Meas[1]  Baseline 
FoV phase  100.00% Meas[2]  Baseline 
Slice thickness  2.5 mm Meas[3] Baseline 
TR  60.0 ms Meas[4] Baseline 
TE 1  30.00 ms Meas[5]  Active 
TE 2  30.00 ms Motion correction On 
TE 3  30.00 ms Interpolation  3D-K-space 
Concatenations  1 Spatial filter  Off 
Filter  None Sequence   
Coil elements  HEA;HEP Dimension  2D 
Contrast   Contrasts  1 
Flip angle  90.0 deg Bandwidth  2298 Hz/Px 
Fat suppr.  Fat sat. Output Data Type  Image Data 
Reconstruction  Magnitude Trigger Output  Cogent 
Measurements  153 Phase Correction Mode  Point/Point 
Pause after meas.  0.000 s Read Gradient  Normal 
Resolution   Phase Gradient  Normal 
Base resolution  64 Phase FoV  Normal 
Phase resolution  100% PE direction  Positive 
PAT mode  None RO Waveform  Trapezoidal 
Matrix Coil Mode  Auto (CP) Refoc. Corr  2.0 [%] 
Image Filter  Off Multi-echo full FOV  Off 
Distortion Corr.  Off FatSat FA  130 [deg] 
Prescan Normalize Off X-Shim 1  0.0 [mT/m*ms] 
Normalize Off X-Shim 2  0.0 [mT/m*ms] 
B1 filter Off X-Shim 3  0.0 [mT/m*ms] 
Raw filter Off Y-Shim 1 0.0 [mT/m*ms] 
Elliptical filter Off Y-Shim 2 0.0 [mT/m*ms] 
Shim mode  Standard Y-Shim 3 0.0 [mT/m*ms] 
Adjust with body coil  Off Z-Shim 1 0.0 [mT/m*ms] 
Assume Silicone  Off Z-Shim 2 0.0 [mT/m*ms] 
Ref. amplitude 1H  0.000 V Z-Shim 3  0.0 [mT/m*ms] 
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The National Hospital for Neurology and Neurosurgery 
Queen Square 
LONDON  
WC1N 3BG 
 
 
Telephone 0207837 3611 
Fax 020 7278 5616 
 
 
 
The National Hospital for Neurology and Neurosurgery is part of UCL Hospitals NHS Trust which also 
includes the Eastman Dental Hospital, Elizabeth Garrett Anderson and Obstetric Hospital, The Heart 
Hospital, Hospital for Tropical Diseases, The Middlesex Hospital and University College Hospital. 
 
 
 
  
 
 
 
 
Introduction 
You are being invited to take part in a research study. Before you decide, it is important for you to 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Ask us if there is anything that 
is not clear or if you would like more information.   
 
What is the purpose of the study? 
The basal ganglia are a collection of structures deep within the brain. They play a critical role in 
mediating normal movements, and also are involved in the regulation of memory, impulsivity and 
behaviour. Normally the communication between these structures is highly organised, but can become 
disrupted in certain movement, behavioural or psychiatric disorders such as Parkinson’s disease, 
Dystonia and Tourette’s syndrome. Diffusion Tensor Imaging (DTI) is a Magnetic Resonance 
Imaging (MRI) technique that allows researchers to trace the connections between different brain 
structures. We are seeking to better map the connections between the basal ganglia and the rest of the 
brain.  
 
You are about to undergo a surgical operation to implant a deep brain stimulator into certain structures 
of the basal ganglia, or to create a surgical lesion to disrupt brain connections between these 
structures. The exact site depends on the reason you are having the surgery. We want to examine our 
results with the clinical effect of the treatment you are going to receive. As a normal part of this 
procedure, you will have MRI scans both before and during the surgery. We will combine our results 
with these scans in an attempt to understand which parts of the brain are affected by the treatment. 
The hope is this will lead to a better understanding of normal basal ganglia function, how your disease 
affects it and allows us to develop more accurate ways of targeting these structures in the future. 
 
The proposed study is outlined in detail over the next few pages. In summary, we will: 
1) Perform an extra MRI scan before your operation that will allow us to map the connections 
from the area affected by the surgery. 
2) Perform questionnaires both before and after the treatment to examine for changes in mood 
and impulsivity 
3) Document carefully the effect of the treatment following surgery. 
4) Look for a link between the changes seen due to the treatment, and the connections identified 
using the specialised MRI scan. 
5)  
CONFIDENTIAL 
Information for surgical patients (version 3.0-08 February 2016 ) 
Basal Ganglia Connectivity 
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Do I have to take part? 
We have approached you because you are going to undergo a functional neurosurgery procedure that 
involves the implantation of a deep brain stimulator or the creation of a surgical brain lesion. We will 
be asking everyone due to undergo this procedure over the next 18 months. If you do decide to take 
part you will be given this information sheet to keep and be asked to sign a consent form, which you 
will also be given to keep. Your participation in this trial is entirely voluntary. Even if you decide to 
take part you are still free to withdraw at any time and without giving a reason. A decision to 
withdraw at any time, or a decision not to take part, will not affect the standard of care you receive. 
 
What is involved in the study?   
 
1. A 35-minute, DTI scan prior to your operation to allow us to map the white matter 
connections. This will be timed to occur at the same time you attend for other routine pre-
operative investigations. In some selected patients, a longer and more detailed scan will be 
done. 
2. Following surgery, you will undergo a series of routine clinical tests and questionnaires, which 
will take approximately 20 minutes to complete. This is the standard practice after this type of 
surgery, and we will collect copies of this data.  
3. The normal procedure when the deep brain stimulator is switched on is to test each electrode 
contact in turn, and carefully document the response you have – During this the clinical 
researcher (Mr Akram) will also be present, to document these results. 
4. Whilst you are still in hospital, between 2-5 days after the stimulator settings have been set, it 
is routine to repeat some of the earlier questionnaires which will take around 20 minutes to 
complete – We will collect copies of this data 
5. If you are having an ablative surgical procedure (surgical lesioning), you will be invited to 
have a post-operative scan, identical to the pre-operative one, 6 months after surgery. This 
scan will be used to examine the changes in the brain connections following the surgical 
procedure. 
 
Diffusion Tensor Imaging (DTI) 
As noted above, you will undergo a special type of MRI scan called diffusion tensor imaging (DTI). 
This is a specialised scan that allows us to map the connections between different areas of the brain. 
You will lie on a couch inside the scanner, with your head in a specially designed headrest, which is 
cushioned for comfort. Inside the scanner there are speakers, an intercom so that you can speak to us 
and a screen on which a film can be shown. The scanner makes a loud clicking noise so we will give 
you earplugs to wear. The scan can be stopped at any time.  
 
Is it safe? 
To be eligible for the surgical procedure you are about to have, you have already been assessed for 
MRI compatibility, and have probably had MRI scans in the past. The DTI scan is a form of MRI and 
hence poses no additional risk. 
 
 
 
The researcher (Mr Akram) is legally obliged to recheck your compatibility for MRI prior to any 
scanning for safety purposes. Please inform us if any of the following apply to you: 
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• You have a pacemaker 
• You have an implanted medication pump 
• You have a metal plate in the skull or metal objects inside the eye or skull (for example 
after brain surgery or an accident)  
• You have any tattoos anywhere except the ankle and foot.  
 
MRI is a painless and safe technique, which can obtain detailed pictures of the brain. As the name 
implies it uses magnetic fields to generate the pictures and unlike X-ray techniques there is no 
ionising radiation used. As long as people with any magnetic metal implants are excluded (see above), 
there are no known risks.  
 
What would happen to the information about me that is collected? Who would have access to it? 
All information which is collected about you during the course of the research will be kept strictly 
confidential.   Any information about you which leaves the hospital / institute will have your name 
and address, date of birth and all identifiable information (including patient/hospital/NHS number) 
removed so that you cannot be recognised from it. The information held would include a brief 
summary of your symptoms and of your medical history and the results of the assessment outlined 
above. The ‘data controllers’ (i.e. the organisations collecting, storing, handling and processing the 
information) would be the National Hospital for Neurology and Neurosurgery and the Institute of 
Neurology. As principal investigator, Mr Ludvic Zrinzo would be responsible by law for the safety 
and security of this information.  Your medical records may be inspected by competent authorities and 
properly authorized persons, but if any information is released this will be done in coded form with 
your name removed from the records so that your confidentiality is strictly maintained. The 
information collected about you may also be shown to authorised people from the UK Regulatory 
Authority (the Medicines and Healthcare Products Regulatory Authority) and Research Ethics 
Committee; this is to ensure that the study is carried out to the highest possible scientific standards.  
All will have a duty of confidentiality to you as a research participant. The results of the study will be 
stored on a secured computer database for a minimum of 20 years. 
 
It is important that your GP is aware that you are taking part in a research project.  With your 
permission, your GP would therefore be informed by letter on a strictly confidential basis. 
 
What will happen if the findings may affect me personally? 
The tests used in this study are currently research tools only and of uncertain significance. 
Potentially, unusually high levels of impulsivity may be found on the questionnaires. If this occurs 
then your doctors (Dr Foltynie/Dr Limousin) would be informed and any further formal 
assessments arranged as required. 
Who is organising and funding the research? 
This project is being organised by the Institute of Neurology, in conjunction with the National 
Hospital for Neurology and Neurosurgery. The costs of research (including researchers’ salaries and 
equipment) are being paid by a grant from the Brain Research Trust (BRT). 
 
How do you find us? 
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We are close to Russell Square tube station, on the Piccadilly line. We can reimburse travel expenses 
for you and a companion, so keep any receipts you have to enable us to do this as quickly as possible. 
 
What happens if something goes wrong? 
 
If you have a concern or complaint about any aspect of this study, you should initially speak to the 
researcher (Mr Akram, telephone-07709093929 or to Mr Ludvic Zrinzo telephone 0203 108 0026) 
who will do their best to answer your questions. Any complaint about the way you have been dealt 
with during the study or any possible harm you might suffer will be addressed as far as possible. 
 
If you remain unhappy and wish to complain formally, you can do this through the NHS Complaints 
Procedure. If you are harmed by taking part in this research project, there are no special compensation 
arrangements. If you are harmed due to someone’s negligence, then you may have grounds for taking 
legal action but you may have to pay the legal costs. Regardless of this, if you wish to complain, or 
have any concerns about this study, the normal National Health Service complaints mechanism should 
be available to you. At this hospital the person to contact would be: 
 
 
   Ms Jennifer Fraser 
   Complaints Coordinator, Box 52 
   National Hospital for Neurology and Neurosurgery 
   Queen Square, London WC1N 3BG     
Tel: 0207 829 8765 
 
Further information 
If you would like to volunteer or would like to know more about the study, please contact: 
 
 
Mr Harith Akram 
 
The Unit of Functional Neurosurgery  - Institute of Neurology 
33 Queen Square 
London 
WC1N 3BG 
 
Telephone: 02031080034 
 
For out of hours contact please call Mr Harith Akram on 07709093929 
 
 
 
Thank you for taking the time to read this information sheet 
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The National Hospital for Neurology and Neurosurgery 
Queen Square 
LONDON  
WC1N 3BG 
 
 
Telephone 0207837 3611 
Fax 020 7278 5616 
 
 
 
The National Hospital for Neurology and Neurosurgery is part of UCL Hospitals NHS Trust which also 
includes the Eastman Dental Hospital, Elizabeth Garrett Anderson and Obstetric Hospital, The Heart 
Hospital, Hospital for Tropical Diseases, The Middlesex Hospital and University College Hospital. 
Patient Identification Number for this Study:  …………….. 
Consent Form Version Number and Date:  ……………….. 
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